[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"fda-warning-letters-search:[\"Pentax of America Inc\",\"\",\"\",\"\",\"\",1]":3,"fda-latest-sync-dates":123},{"warningLetters":4,"total":122},[5,32,53,78,100],{"id":6,"raw":7,"subject":12,"body_html":14,"body_text":15,"firm_name":16,"letter_id":17,"created_at":18,"fei_number":19,"letter_url":20,"updated_at":21,"action_type":22,"case_status":23,"posted_date":24,"marcs_cms_no":25,"product_type":26,"closeout_date":19,"issuing_office":11,"recipient_name":27,"body_fetched_at":28,"delivery_method":29,"recipient_title":19,"reference_number":30,"action_taken_date":31,"medical_device_id":19,"response_letter_date":19},139,[8,9,10,11,12,13,13,13],"\u003Ctime datetime=\"2026-05-26T13:20:00Z\">05\u002F26\u002F2026\u003C\u002Ftime>\n","\u003Ctime datetime=\"2026-05-14T04:00:00Z\">05\u002F14\u002F2026\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fgc-america-inc-727602-05142026\">GC America, Inc.\u003C\u002Fa>","Center for Drug Evaluation and Research (CDER)","CGMP\u002FFinished Pharmaceuticals\u002FAdulterated","","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Email Return Receipt Requested\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>320-26-76\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n                          \u003Cbr>Over-the-Counter Drugs\n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Joseph T. Talanges\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>President &amp; Chief Operating Officer \u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>GC America, Inc.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>3737 West 127th Street\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Alsip\u003C\u002Fspan>, \u003Cspan>IL\u003C\u002Fspan> \u003Cspan>60803\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n  \u003Cdiv>\n    \u003Cdiv>Secondary Issuing Offices\u003C\u002Fdiv>\n          \u003Cdiv>\n              \u003Cdiv>    \u003Cbr>\n    \n     \n        \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n    \n    \n    \n    \n\u003C\u002Fdiv>\n              \u003C\u002Fdiv>\n      \u003C\u002Fdiv>\n\n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>May 14, 2026\u003C\u002Fp>\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>&nbsp;\u003C\u002Fp>\u003Cp>Dear Mr. Talanges:\u003C\u002Fp>\u003Cp>The United States Food and Drug Administration (FDA) inspected your drug manufacturing facility, GC America, Inc., FEI 1410097, at 3737 West 127th Street, Alsip, Illinois, from November 3 to 7, 2025.\u003C\u002Fp>\u003Cp>This warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\u003C\u002Fp>\u003Cp>Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\u003Cp>We reviewed your November 21, 2025, response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence.\u003C\u002Fp>\u003Cp>During our inspection, our investigator observed specific violations including, but not limited to, the following.\u003C\u002Fp>\u003Cp>\u003Cstrong>1. Your firm failed to test samples of each component for identity and conformity with all appropriate written specifications for purity, strength, and quality (21 CFR 211.84(d)(1) and 211.84(d)(2)).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your firm manufactures OTC drug products, including those for \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Your firm failed to ensure components were suitable for use in manufacturing your drug products.\u003C\u002Fp>\u003Cp>\u003Cstrong>(b)(4)\u003C\u002Fstrong> \u003Cem>Used as a Component in Drug Products\u003C\u002Fem>\u003C\u002Fp>\u003Cp>You did not adequately demonstrate your \u003Cstrong>(b)(4)\u003C\u002Fstrong>, at a minimum, meets specifications in the United States Pharmacopeia (USP) \u003Cstrong>(b)(4)\u003C\u002Fstrong> monograph. For example, your \u003Cstrong>(b)(4)\u003C\u002Fstrong> system records show that you only performed \u003Cstrong>(b)(4)\u003C\u002Fstrong> testing. However, the USP monograph requires additional testing for chemical purity and microbial quality. We also noted you failed to establish a procedure describing \u003Cstrong>(b)(4) \u003C\u002Fstrong>sampling requirements and acceptance criteria. According to your management, you manufactured approximately \u003Cstrong>(b)(4)\u003C\u002Fstrong> finished drug batches with inadequately tested \u003Cstrong>(b)(4)\u003C\u002Fstrong> from 2023 through 2025.\u003C\u002Fp>\u003Cp>\u003Cem>Products Containing Ingredients at Risk for \u003C\u002Fem>\u003Cstrong>(b)(4) \u003C\u002Fstrong>\u003Cem>Contamination\u003C\u002Fem>\u003C\u002Fp>\u003Cp>You also state in your correspondence to the agency that you do not conduct identity testing on each shipment of each lot of your incoming components at high risk of \u003Cstrong>(b)(4)\u003C\u002Fstrong> contamination before using them to manufacture your drug products. This includes, but is not limited to, testing \u003Cstrong>(b)(4)\u003C\u002Fstrong> to determine its appropriate identity prior to use in manufacturing your drug products.\u003C\u002Fp>\u003Cp>Identity testing for \u003Cstrong>(b)(4)\u003C\u002Fstrong> and certain other high-risk drug components includes a USP limit test to ensure the component meets the relevant safety limits for \u003Cstrong>(b)(4)\u003C\u002Fstrong> levels. Because you did not perform identity testing on each shipment of each lot using the USP identification test that detects these hazardous impurities, you failed to assure the acceptability of these components for use in the manufacture of your drug products.\u003C\u002Fp>\u003Cp>The use of ingredients contaminated with \u003Cstrong>(b)(4)\u003C\u002Fstrong> has resulted in various lethal poisoning incidents in humans worldwide. See FDA’s guidance document \u003Cstrong>(b)(4).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>In your response, you acknowledge you do not perform all testing of \u003Cstrong>(b)(4)\u003C\u002Fstrong> per USP, and you commit to sending a sample of your \u003Cstrong>(b)(4)\u003C\u002Fstrong> to a third-party testing laboratory. You also commit to conducting a risk assessment of your deficient \u003Cstrong>(b)(4)\u003C\u002Fstrong> testing on drug products released from 2023 to 2025 and to establishing a \u003Cstrong>(b)(4)\u003C\u002Fstrong> testing SOP.\u003C\u002Fp>\u003Cp>Your response is inadequate. You do not provide a detailed procedure explaining how you will assess your \u003Cstrong>(b)(4)\u003C\u002Fstrong> against compendial requirements. You also lack a comprehensive review of your material system, including supplier evaluations, to ensure the quality of all materials is consistently acceptable.\u003C\u002Fp>\u003Cp>Without adequate testing, you do not have scientific evidence that components conform to appropriate specifications prior to use in the manufacture of your drug products. As a manufacturer, you have a responsibility to adequately sample, test, and examine drug components before use in production to assure quality.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cp>• A procedure for your \u003Cstrong>(b)(4)\u003C\u002Fstrong> system monitoring that specifies routine microbial testing of \u003Cstrong>(b)(4)\u003C\u002Fstrong> to ensure its acceptability for use in each batch of drug products produced by your firm.\u003C\u002Fp>\u003Cp>• The current action\u002Falert limits for total counts and objectionable organisms used for your \u003Cstrong>(b)(4)\u003C\u002Fstrong> system. Ensure that the total count limits for your \u003Cstrong>(b)(4)\u003C\u002Fstrong> are appropriately stringent in view of the intended use of each of the products produced by your firm.\u003C\u002Fp>\u003Cp>• A procedure governing your program for ongoing control, maintenance, and monitoring that ensures the remediated system consistently produces \u003Cstrong>(b)(4)\u003C\u002Fstrong> that meets \u003Cstrong>(b)(4)\u003C\u002Fstrong> USP monograph specifications and appropriate microbial limits.\u003C\u002Fp>\u003Cp>• A comprehensive, independent review of your material system, including but not limited to:\u003Cbr>o evaluating all suppliers of materials (components, containers, and closures) to determine if they are reliable and appropriately qualified\u003Cbr>o an assessment of all materials to determine whether they are consistently of acceptable quality\u003Cbr>o a review to ensure assigned expiration or retest dates are appropriate (supported by data)\u003Cbr>o adequacy of the supplier qualification program, and its selection, qualification, and disqualification provisions\u003C\u002Fp>\u003Cp>• Based on a thorough review, provide a summary of your systems corrective actions and preventive actions (CAPA) to remediate the vendor qualification program and prevent use of unsuitable components, containers and closures.\u003C\u002Fp>\u003Cp>• Your \u003Cstrong>(b)(4)\u003C\u002Fstrong> system qualification report.\u003C\u002Fp>\u003Cp>• The chemical and microbiological quality control specifications you use to test and release each incoming lot of components for use in manufacturing, including high risk drug components.\u003C\u002Fp>\u003Cp>• A description of how you will test each component lot for conformity with all appropriate specifications for identity, strength, quality, and purity. If you intend to accept any results from your supplier’s certificates of analysis instead of testing each component lot for strength, quality, and purity, specify how you will robustly establish the reliability of your supplier’s results through initial validation as well as periodic re-validation. In addition, include a commitment to always conduct at least one specific identity test for each incoming component lot. In the case of \u003Cstrong>(b)(4)\u003C\u002Fstrong>, and certain additional high-risk components we note that this includes the performance of \u003Cstrong>(b)(4)\u003C\u002Fstrong> of the USP monograph.\u003C\u002Fp>\u003Cp>• A summary of your program for qualifying and overseeing contract facilities that test the drug products you manufacture.\u003C\u002Fp>\u003Cp>• A commitment to provide \u003Cstrong>(b)(4)\u003C\u002Fstrong> test results, no later than 30 calendar days from the date of this letter, from testing retains for all lots of high-risk drug components used in the manufacture of drug products. Alternatively, if a retain of a component lot is unavailable, perform retain sample testing of all implicated finished drug product batches for the presence of \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003Cbr>\u003Cbr>• A full risk assessment for drug products that are within expiry which contain any ingredient at risk for \u003Cstrong>(b)(4)\u003C\u002Fstrong> contamination (including, but not limited to, \u003Cstrong>(b)(4)\u003C\u002Fstrong>). Take prompt and appropriate actions to determine the safety of all lots of the component(s) and any related drug product that could contain \u003Cstrong>(b)(4)\u003C\u002Fstrong>, including customer notifications and product recalls for any contaminated lots. Identify additional appropriate CAPA that secure supply chains in the future, including, but not limited to, ensuring that all incoming raw material lots are from fully qualified manufacturers and free from unsafe impurities. Detail these actions in your response to this letter.\u003C\u002Fp>\u003Cp>\u003Cstrong>2. Your firm failed to establish and follow a written testing program designed to assess the stability characteristics of drug products and to test an adequate number of batches of each drug product to determine appropriate storage conditions and expiration dates (21 CFR 211.166(a) and 211.166(b)).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your firm failed to establish a stability program with adequate data from long-term or accelerated storage conditions, demonstrating that drug products remain acceptable throughout the labeled expiry period. For example, the only stability data provided for \u003Cstrong>(b)(4)\u003C\u002Fstrong> consisted of a single batch tested for \u003Cstrong>(b)(4)\u003C\u002Fstrong> at \u003Cstrong>(b)(4)\u003C\u002Fstrong> degrees Celsius with no controlled humidity condition. Furthermore, you have no ongoing stability studies for any drugs currently manufactured.\u003C\u002Fp>\u003Cp>Without an appropriate stability program, you lack adequate scientific evidence to demonstrate your drug products meet established specifications and retain their quality attributes through your labeled expiry.\u003C\u002Fp>\u003Cp>See FDA’s guidance document \u003Cem>Q1A(R2) Stability Testing of New Drug Substances and Products\u003C\u002Fem> to help you meet the CGMP requirements for stability testing at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71707\u002Fdownload.\u003C\u002Fp>\u003Cp>In your response, you acknowledge you do not have an appropriate written testing program to assess the stability characteristics of your drugs. You also state you will test expired reserve samples and perform a risk assessment for distributing drugs without adequate stability data. You also commit to initiating ongoing stability testing and modifying your procedures to include updated stability instructions.\u003C\u002Fp>\u003Cp>Your response is inadequate. You lack analytical data to show your drugs maintain their quality attributes throughout their shelf life. You also fail to provide updated procedures and training records indicating you have implemented an adequate stability program.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cp>• A comprehensive, independent assessment and CAPA plan to ensure the adequacy of your stability program. Your remediated program should include, but not be limited to:\u003Cbr>o Stability indicating methods\u003Cbr>o Stability studies for each drug product in its marketed container-closure system before distribution is permitted\u003Cbr>o an ongoing program in which representative batches of each product are added each year to the program to determine if the shelf-life claim remains valid\u003Cbr>o detailed definition of the specific attributes to be tested at each station (timepoint)\u003Cbr>o all procedures that describe these and other elements of your remediated stability program\u003C\u002Fp>\u003Cp>\u003Cstrong>3. Your firm failed to establish adequate written responsibilities and procedures applicable to the quality control unit (21 CFR 211.22(d)).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your quality unit (QU) did not adequately oversee your drug manufacturing operations. For example, your QU failed to ensure adequate control of your analytical data. Our investigator documented an uncontrolled password for the \u003Cstrong>(b)(4)\u003C\u002Fstrong> meter affixed to a laptop by a sticker used for processing \u003Cstrong>(b)(4)\u003C\u002Fstrong> meter test results. In addition, the data from the \u003Cstrong>(b)(4)\u003C\u002Fstrong> meter is automatically deleted when the laptop is shutdown, so no records were available to show that your QU reviewed this data. Furthermore, you were unable to provide audit trails or an SOP describing oversight and retention requirements of electronic records. The lack of proper electronic record controls undermines the reliability and integrity of your laboratory data (21 CFR 211.68(b)).\u003C\u002Fp>\u003Cp>Your QU also failed to perform annual product reviews of your drug products since our previous inspection in 2018. Furthermore, no written procedures for this requirement were available (21 CFR 211.180(e)).\u003C\u002Fp>\u003Cp>In your response, you acknowledge you did not exercise appropriate controls to ensure authorized access to electronic records. Also, you commit to removing shared passwords, creating a data integrity policy, and implementing an annual product review procedure.\u003C\u002Fp>\u003Cp>Your response is inadequate. You do not provide updated procedures and training records to demonstrate you have corrected your data control deficiencies. You also lack product quality assessments.\u003C\u002Fp>\u003Cp>Your quality system does not adequately ensure the accuracy and integrity of data to support the safety, effectiveness, and quality of the drugs you manufacture. See FDA’s guidance document \u003Cem>Data Integrity and Compliance with Drug CGMP: Questions and Answers\u003C\u002Fem> for guidance on establishing and following CGMP compliant data integrity practices at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F119267\u002Fdownload.\u003C\u002Fp>\u003Cp>We strongly recommend that you retain a qualified consultant to assist in your remediation. In response to this letter, provide:\u003C\u002Fp>\u003Cp>• A comprehensive investigation into the extent of the inaccuracies in data records and reporting including results of the data review for drugs distributed in the United States. Include a detailed description of the scope and root causes of your data integrity lapses.\u003C\u002Fp>\u003Cp>• A current risk assessment of the potential effects of the observed failures on the quality of your drugs. Your assessment should include analyses of the risks to patients caused by the release of drugs affected by a lapse of data integrity and analyses of the risks posed by ongoing operations.\u003Cbr>\u003Cbr>• A management strategy for your firm that includes the details of your global corrective action and preventive action plan. The detailed corrective action plan should describe how you intend to ensure the reliability and completeness of all data generated by your firm including microbiological and analytical data, manufacturing records, and all data submitted to FDA.\u003C\u002Fp>\u003Cp>• A comprehensive assessment and remediation plan to ensure your QU is given the authority and resources to effectively function. The assessment should also include, but not be limited to:\u003Cbr>o A determination of whether procedures used by your firm are robust and appropriate\u003Cbr>o Provisions for QU oversight throughout your operations to evaluate adherence to appropriate practices\u003Cbr>o A complete and final review of each batch and its related information before the QU disposition decision\u003Cbr>o Oversight and approval of investigations and discharging of all other QU duties to ensure identity, strength, quality, and purity of all products.\u003C\u002Fp>\u003Cp>• A complete assessment of documentation systems used throughout your manufacturing and laboratory operations to determine where documentation practices are insufficient. Include a detailed CAPA plan that comprehensively remediates your firm’s documentation practices to ensure you retain attributable, legible, complete, original, accurate, contemporaneous records throughout your operation.\u003C\u002Fp>\u003Cp>\u003Cstrong>CGMP Consultant Recommended\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Based upon the nature of the violations we identified at your firm, you should engage a qualified consultant as set forth in 21 CFR 211.34 to assist your firm in meeting CGMP requirements.\u003C\u002Fp>\u003Cp>Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\u003C\u002Fp>\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\u003C\u002Fp>\u003Cp>Correct any violations promptly. Failure to promptly and adequately address this matter may result in regulatory or legal action without further notice including, without limitation, seizure and injunction. Unresolved violations may also prevent other Federal agencies from awarding contracts.\u003C\u002Fp>\u003Cp>Failure to address violations may also cause FDA to withhold issuance of export certificates. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to address any violations.\u003Cbr>\u003Cbr>This letter notifies you of our findings and provides you with an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\u003C\u002Fp>\u003Cp>Send your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 1410097 and ATTN: Matthew Jensen.\u003C\u002Fp>\u003Cp>\u003Cbr>Sincerely,\u003Cbr>Kennerly K. Chapman -S\u003Cbr>Francis Godwin\u003Cbr>Director\u003Cbr>Digitally signed by Kennerly K. Chapman -S\u003Cbr>Date: 2026.05.14 15:58:58 -04'00'\u003Cbr>Office of Manufacturing Quality Office of Compliance\u003Cbr>Center for Drug Evaluation and Research\u003Cbr>&nbsp;\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Email Return Receipt Requested\n\nReference #:\n\n320-26-76\n\nProduct:\n\nDrugs\n\nOver-the-Counter Drugs\n\nRecipient:\n\nRecipient Name\n\nMr. Joseph T. Talanges\n\nRecipient Title\n\nPresident & Chief Operating Officer\n\nGC America, Inc.\n\n3737 West 127th Street\n\nAlsip, IL 60803\n\nUnited States\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nSecondary Issuing Offices\n\nUnited States\n\nMay 14, 2026\nWARNING LETTER\n\nDear Mr. Talanges:\nThe United States Food and Drug Administration (FDA) inspected your drug manufacturing facility, GC America, Inc., FEI 1410097, at 3737 West 127th Street, Alsip, Illinois, from November 3 to 7, 2025.\nThis warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\nBecause your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 351(a)(2)(B).\nWe reviewed your November 21, 2025, response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence.\nDuring our inspection, our investigator observed specific violations including, but not limited to, the following.\n1. Your firm failed to test samples of each component for identity and conformity with all appropriate written specifications for purity, strength, and quality (21 CFR 211.84(d)(1) and 211.84(d)(2)).\nYour firm manufactures OTC drug products, including those for (b)(4). Your firm failed to ensure components were suitable for use in manufacturing your drug products.\n(b)(4) Used as a Component in Drug Products\nYou did not adequately demonstrate your (b)(4), at a minimum, meets specifications in the United States Pharmacopeia (USP) (b)(4) monograph. For example, your (b)(4) system records show that you only performed (b)(4) testing. However, the USP monograph requires additional testing for chemical purity and microbial quality. We also noted you failed to establish a procedure describing (b)(4) sampling requirements and acceptance criteria. According to your management, you manufactured approximately (b)(4) finished drug batches with inadequately tested (b)(4) from 2023 through 2025.\nProducts Containing Ingredients at Risk for (b)(4) Contamination\nYou also state in your correspondence to the agency that you do not conduct identity testing on each shipment of each lot of your incoming components at high risk of (b)(4) contamination before using them to manufacture your drug products. This includes, but is not limited to, testing (b)(4) to determine its appropriate identity prior to use in manufacturing your drug products.\nIdentity testing for (b)(4) and certain other high-risk drug components includes a USP limit test to ensure the component meets the relevant safety limits for (b)(4) levels. Because you did not perform identity testing on each shipment of each lot using the USP identification test that detects these hazardous impurities, you failed to assure the acceptability of these components for use in the manufacture of your drug products.\nThe use of ingredients contaminated with (b)(4) has resulted in various lethal poisoning incidents in humans worldwide. See FDA’s guidance document (b)(4).\nIn your response, you acknowledge you do not perform all testing of (b)(4) per USP, and you commit to sending a sample of your (b)(4) to a third-party testing laboratory. You also commit to conducting a risk assessment of your deficient (b)(4) testing on drug products released from 2023 to 2025 and to establishing a (b)(4) testing SOP.\nYour response is inadequate. You do not provide a detailed procedure explaining how you will assess your (b)(4) against compendial requirements. You also lack a comprehensive review of your material system, including supplier evaluations, to ensure the quality of all materials is consistently acceptable.\nWithout adequate testing, you do not have scientific evidence that components conform to appropriate specifications prior to use in the manufacture of your drug products. As a manufacturer, you have a responsibility to adequately sample, test, and examine drug components before use in production to assure quality.\nIn response to this letter, provide:\n• A procedure for your (b)(4) system monitoring that specifies routine microbial testing of (b)(4) to ensure its acceptability for use in each batch of drug products produced by your firm.\n• The current action\u002Falert limits for total counts and objectionable organisms used for your (b)(4) system. Ensure that the total count limits for your (b)(4) are appropriately stringent in view of the intended use of each of the products produced by your firm.\n• A procedure governing your program for ongoing control, maintenance, and monitoring that ensures the remediated system consistently produces (b)(4) that meets (b)(4) USP monograph specifications and appropriate microbial limits.\n• A comprehensive, independent review of your material system, including but not limited to:\no evaluating all suppliers of materials (components, containers, and closures) to determine if they are reliable and appropriately qualified\no an assessment of all materials to determine whether they are consistently of acceptable quality\no a review to ensure assigned expiration or retest dates are appropriate (supported by data)\no adequacy of the supplier qualification program, and its selection, qualification, and disqualification provisions\n• Based on a thorough review, provide a summary of your systems corrective actions and preventive actions (CAPA) to remediate the vendor qualification program and prevent use of unsuitable components, containers and closures.\n• Your (b)(4) system qualification report.\n• The chemical and microbiological quality control specifications you use to test and release each incoming lot of components for use in manufacturing, including high risk drug components.\n• A description of how you will test each component lot for conformity with all appropriate specifications for identity, strength, quality, and purity. If you intend to accept any results from your supplier’s certificates of analysis instead of testing each component lot for strength, quality, and purity, specify how you will robustly establish the reliability of your supplier’s results through initial validation as well as periodic re-validation. In addition, include a commitment to always conduct at least one specific identity test for each incoming component lot. In the case of (b)(4), and certain additional high-risk components we note that this includes the performance of (b)(4) of the USP monograph.\n• A summary of your program for qualifying and overseeing contract facilities that test the drug products you manufacture.\n• A commitment to provide (b)(4) test results, no later than 30 calendar days from the date of this letter, from testing retains for all lots of high-risk drug components used in the manufacture of drug products. Alternatively, if a retain of a component lot is unavailable, perform retain sample testing of all implicated finished drug product batches for the presence of (b)(4).\n\n• A full risk assessment for drug products that are within expiry which contain any ingredient at risk for (b)(4) contamination (including, but not limited to, (b)(4)). Take prompt and appropriate actions to determine the safety of all lots of the component(s) and any related drug product that could contain (b)(4), including customer notifications and product recalls for any contaminated lots. Identify additional appropriate CAPA that secure supply chains in the future, including, but not limited to, ensuring that all incoming raw material lots are from fully qualified manufacturers and free from unsafe impurities. Detail these actions in your response to this letter.\n2. Your firm failed to establish and follow a written testing program designed to assess the stability characteristics of drug products and to test an adequate number of batches of each drug product to determine appropriate storage conditions and expiration dates (21 CFR 211.166(a) and 211.166(b)).\nYour firm failed to establish a stability program with adequate data from long-term or accelerated storage conditions, demonstrating that drug products remain acceptable throughout the labeled expiry period. For example, the only stability data provided for (b)(4) consisted of a single batch tested for (b)(4) at (b)(4) degrees Celsius with no controlled humidity condition. Furthermore, you have no ongoing stability studies for any drugs currently manufactured.\nWithout an appropriate stability program, you lack adequate scientific evidence to demonstrate your drug products meet established specifications and retain their quality attributes through your labeled expiry.\nSee FDA’s guidance document Q1A(R2) Stability Testing of New Drug Substances and Products to help you meet the CGMP requirements for stability testing at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71707\u002Fdownload.\nIn your response, you acknowledge you do not have an appropriate written testing program to assess the stability characteristics of your drugs. You also state you will test expired reserve samples and perform a risk assessment for distributing drugs without adequate stability data. You also commit to initiating ongoing stability testing and modifying your procedures to include updated stability instructions.\nYour response is inadequate. You lack analytical data to show your drugs maintain their quality attributes throughout their shelf life. You also fail to provide updated procedures and training records indicating you have implemented an adequate stability program.\nIn response to this letter, provide:\n• A comprehensive, independent assessment and CAPA plan to ensure the adequacy of your stability program. Your remediated program should include, but not be limited to:\no Stability indicating methods\no Stability studies for each drug product in its marketed container-closure system before distribution is permitted\no an ongoing program in which representative batches of each product are added each year to the program to determine if the shelf-life claim remains valid\no detailed definition of the specific attributes to be tested at each station (timepoint)\no all procedures that describe these and other elements of your remediated stability program\n3. Your firm failed to establish adequate written responsibilities and procedures applicable to the quality control unit (21 CFR 211.22(d)).\nYour quality unit (QU) did not adequately oversee your drug manufacturing operations. For example, your QU failed to ensure adequate control of your analytical data. Our investigator documented an uncontrolled password for the (b)(4) meter affixed to a laptop by a sticker used for processing (b)(4) meter test results. In addition, the data from the (b)(4) meter is automatically deleted when the laptop is shutdown, so no records were available to show that your QU reviewed this data. Furthermore, you were unable to provide audit trails or an SOP describing oversight and retention requirements of electronic records. The lack of proper electronic record controls undermines the reliability and integrity of your laboratory data (21 CFR 211.68(b)).\nYour QU also failed to perform annual product reviews of your drug products since our previous inspection in 2018. Furthermore, no written procedures for this requirement were available (21 CFR 211.180(e)).\nIn your response, you acknowledge you did not exercise appropriate controls to ensure authorized access to electronic records. Also, you commit to removing shared passwords, creating a data integrity policy, and implementing an annual product review procedure.\nYour response is inadequate. You do not provide updated procedures and training records to demonstrate you have corrected your data control deficiencies. You also lack product quality assessments.\nYour quality system does not adequately ensure the accuracy and integrity of data to support the safety, effectiveness, and quality of the drugs you manufacture. See FDA’s guidance document Data Integrity and Compliance with Drug CGMP: Questions and Answers for guidance on establishing and following CGMP compliant data integrity practices at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F119267\u002Fdownload.\nWe strongly recommend that you retain a qualified consultant to assist in your remediation. In response to this letter, provide:\n• A comprehensive investigation into the extent of the inaccuracies in data records and reporting including results of the data review for drugs distributed in the United States. Include a detailed description of the scope and root causes of your data integrity lapses.\n• A current risk assessment of the potential effects of the observed failures on the quality of your drugs. Your assessment should include analyses of the risks to patients caused by the release of drugs affected by a lapse of data integrity and analyses of the risks posed by ongoing operations.\n\n• A management strategy for your firm that includes the details of your global corrective action and preventive action plan. The detailed corrective action plan should describe how you intend to ensure the reliability and completeness of all data generated by your firm including microbiological and analytical data, manufacturing records, and all data submitted to FDA.\n• A comprehensive assessment and remediation plan to ensure your QU is given the authority and resources to effectively function. The assessment should also include, but not be limited to:\no A determination of whether procedures used by your firm are robust and appropriate\no Provisions for QU oversight throughout your operations to evaluate adherence to appropriate practices\no A complete and final review of each batch and its related information before the QU disposition decision\no Oversight and approval of investigations and discharging of all other QU duties to ensure identity, strength, quality, and purity of all products.\n• A complete assessment of documentation systems used throughout your manufacturing and laboratory operations to determine where documentation practices are insufficient. Include a detailed CAPA plan that comprehensively remediates your firm’s documentation practices to ensure you retain attributable, legible, complete, original, accurate, contemporaneous records throughout your operation.\nCGMP Consultant Recommended\nBased upon the nature of the violations we identified at your firm, you should engage a qualified consultant as set forth in 21 CFR 211.34 to assist your firm in meeting CGMP requirements.\nYour use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\nConclusion\nThe violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\nCorrect any violations promptly. Failure to promptly and adequately address this matter may result in regulatory or legal action without further notice including, without limitation, seizure and injunction. Unresolved violations may also prevent other Federal agencies from awarding contracts.\nFailure to address violations may also cause FDA to withhold issuance of export certificates. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to address any violations.\n\nThis letter notifies you of our findings and provides you with an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\nSend your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 1410097 and ATTN: Matthew Jensen.\n\nSincerely,\nKennerly K. Chapman -S\nFrancis Godwin\nDirector\nDigitally signed by Kennerly K. Chapman -S\nDate: 2026.05.14 15:58:58 -04'00'\nOffice of Manufacturing Quality Office of Compliance\nCenter for Drug Evaluation and Research","GC America, Inc.","gc-america-inc-727602-05142026","2026-08-18T06:42:28.498414+00:00",null,"https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fgc-america-inc-727602-05142026","2026-10-26T08:08:44.827832+00:00","Warning Letter","Issued","2026-05-26","727602","Drugs Over-the-Counter Drugs","Mr. Joseph T. Talanges","2026-08-19T04:39:48.869+00:00","Via Email Return Receipt Requested","320-26-76","2026-05-14",{"id":33,"raw":34,"subject":12,"body_html":39,"body_text":40,"firm_name":41,"letter_id":42,"created_at":43,"fei_number":19,"letter_url":44,"updated_at":45,"action_type":22,"case_status":23,"posted_date":46,"marcs_cms_no":47,"product_type":48,"closeout_date":19,"issuing_office":38,"recipient_name":49,"body_fetched_at":50,"delivery_method":51,"recipient_title":19,"reference_number":19,"action_taken_date":52,"medical_device_id":19,"response_letter_date":19},2632,[35,36,37,38,12,13,13,13],"\u003Ctime datetime=\"2022-06-07T13:20:00Z\">06\u002F07\u002F2022\u003C\u002Ftime>\n","\u003Ctime datetime=\"2022-05-23T04:00:00Z\">05\u002F23\u002F2022\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Faire-master-america-inc-622546-05232022\">Aire-Master of America, Inc.\u003C\u002Fa>","Division of Pharmaceutical Quality Operations III","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>UPS\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Walter R. Heinle\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>President\u002FCOO\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Aire-Master of America, Inc.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>1821 N. State Highway CC\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Nixa\u003C\u002Fspan>, \u003Cspan>MO\u003C\u002Fspan> \u003Cspan>65714-8015\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Division of Pharmaceutical Quality Operations III\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>May 23, 2022\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003Cbr>\nCase #622546\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Heinle:\u003C\u002Fp>\n\n\u003Cp>The U.S. Food and Drug Administration (FDA) inspected your drug manufacturing facility, Aire-Master of America, Inc., FEI 3002764676, at 1821 N. State Highway CC, Nixa Missouri, from October 5 to October 19, 2021\u003C\u002Fp>\n\n\u003Cp>This warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\u003C\u002Fp>\n\n\u003Cp>Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\n\n\u003Cp>In addition, Aire-Master Foaming Hand Sanitizer (2 and 64 fl oz) and Aire-Master Foaming Hand Sanitizer with Aloe are unapproved new drugs introduced or delivered for introduction into interstate commerce in violation of section 505(a) of the FD&amp;C Act, 21 U.S.C. 355(a), and are misbranded under sections 502(ee) of the FD&amp;C Act, 21 U.S.C. 352(ee). Introduction or delivery for introduction of such products into interstate commerce is prohibited under sections 301(d) and (a) of the FD&amp;C Act, 21 U.S.C. 331(d) and (a). These violations are described in more detail below.\u003C\u002Fp>\n\n\u003Cp>We reviewed your November 4, 2022, response to our Form FDA 483 in detail.\u003C\u002Fp>\n\n\u003Cp>Your response is inadequate because it did not provide sufficient detail or evidence of corrective actions to bring your operations into compliance with CGMP.\u003C\u002Fp>\n\n\u003Cp>During our inspection, our investigators observed specific violations including, but not limited to, the following.\u003Cbr>\n\u003Cbr>\n\u003Cstrong>1. Your firm failed to establish laboratory controls that include scientifically sound and appropriate specifications, standards, sampling plans, and test procedures designed to assure that components, drug product containers, closures, in-process materials, labeling, and drug products conform to appropriate standards of identity, strength, quality, and purity (21 CFR 211.160(b)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your laboratory sampling plans and testing methods were not scientifically sound. You collected non-representative samples of your water system. Water from your water system is used in the formulation of your topical over-the-counter (OTC) drug products. Specifically, your water system monitoring procedure provided during the inspection did not discuss the number, location, or frequency of samples to collect. You told our investigator that you typically take a sample from your water system \u003Cstrong>(b)(4)\u003C\u002Fstrong> from a single location near the \u003Cstrong>(b)(4)\u003C\u002Fstrong> component. The sampling frequency and locations, which did not include sampling from any point of use, were not appropriate to provide substantive data to promptly detect system variability.\u003C\u002Fp>\n\n\u003Cp>Furthermore, your microbiological testing used for water analysis was deficient. You have not shown your test methods were adequate for determining the quality of the water in view of its intended use in your drug products. Furthermore, you lacked appropriate limits, routine testing, or validated methods for detecting the presence of \u003Cem>B. cepacia\u003C\u002Fem> in your water system. Your microbiological testing is insufficient to assure that your water system is suitable for its intended use.\u003C\u002Fp>\n\n\u003Cp>Additionally, FDA analysis of samples collected from your water system recovered too-numerous-to-count results for multiple total microbial count tests.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide the following:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>A comprehensive, independent assessment of your water system design, control, and maintenance.\u003C\u002Fli>\n\t\u003Cli>A thorough remediation plan to install and operate a suitable water system. Include a robust ongoing control, maintenance, and monitoring program to ensure the remediated system design consistently produces water adhering to \u003Cstrong>(b)(4)\u003C\u002Fstrong> Water, USP monograph specifications and appropriate microbial limits.\u003C\u002Fli>\n\t\u003Cli>A detailed risk assessment addressing the potential effects of the observed water system failures on the quality of all drug product lots currently in U.S. distribution or within expiry. Specify actions that you will take in response to the risk assessment, such as customer notifications and product recalls.\u003C\u002Fli>\n\t\u003Cli>A procedure governing your program for ongoing control, maintenance, and monitoring that ensures the remediated system consistently produces water that meets \u003Cstrong>(b)(4)\u003C\u002Fstrong> Water, USP monograph specifications and appropriate microbial limits.\u003C\u002Fli>\n\t\u003Cli>A procedure for your water system monitoring that specifies routine microbial testing of \u003Cstrong>(b)(4)\u003C\u002Fstrong> water to ensure its acceptability for use in each batch of drug products produced by your firm.\u003C\u002Fli>\n\t\u003Cli>A diagram of your water system and its components. Include a list of all water system point-of-uses (POUs), their locations, and frequency of testing.\u003C\u002Fli>\n\t\u003Cli>The current action\u002Falert limits for total counts and objectionable organisms used for your \u003Cstrong>(b)(4)\u003C\u002Fstrong> Water system. Ensure that the total count limits for your \u003Cstrong>(b)(4)\u003C\u002Fstrong> water are appropriately stringent in view of the intended use of each of the products produced by your firm.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>\u003Cstrong>2. Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your quality unit (QU) failed to conduct an adequate investigation into a complaint received for a “fishy” odor in your Foaming Waterless Hand Sanitizer\u003Csup>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> lot #713588. Your investigation stated that you “checked inventory in the warehouse and noticed the smell that the customer complained of. Inventory was then taken out of stock.” You determined to rework some of the old product into a new batch “to lessen the smell of the product in question.”\u003C\u002Fp>\n\n\u003Cp>Our investigator collected a certificate of analysis (COA) showing “alcohol\u002Fno fragrance” as the specification for this drug product. As this complaint described a foul odor in distributed drug product, your QU should have performed a thorough investigation into this complaint as per 21 CFR 211.198. Instead, your production management performed a very limited investigation. The resolution for this complaint was to ensure employees “purge the \u003Cstrong>(b)(4)\u003C\u002Fstrong> tank before filling the vat with \u003Cstrong>(b)(4)\u003C\u002Fstrong> water.” While the investigation indicated that the \u003Cstrong>(b)(4)\u003C\u002Fstrong> water was the source of the odor, you failed to address why your formulation water had a foul odor. Additionally, your investigation lacked meaningful corrective action and preventive action (CAPA) to prevent recurrence.\u003C\u002Fp>\n\n\u003Cp>Inadequate investigations can lead to unidentified root causes, ineffective CAPA, and recurring problems that compromise the ability to produce safe and effective products.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide the following:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>A comprehensive, independent assessment of your overall system for investigating deviations, discrepancies, complaints, out-of-specification (OOS) results, and failures. Provide a detailed action plan to remediate this system. Your action plan should include, but not be limited to, significant improvements in investigation competencies, scope determination, root cause evaluation, CAPA effectiveness, quality unit oversight, and written procedures. Address how your firm will ensure all phases of investigations are appropriately conducted.\u003C\u002Fli>\n\t\u003Cli>An independent assessment and remediation plan for your CAPA program. Provide a report that evaluates whether the program includes effective root cause analysis, ensures CAPA effectiveness, analyzes investigations trends, improves the CAPA program when needed, implements final quality unit decisions, and is fully supported by executive management.\u003C\u002Fli>\n\t\u003Cli>A comprehensive assessment and remediation plan to ensure your QU is given the authority and resources to effectively function. The assessment should also include, but not be limited to:\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>&nbsp; &nbsp; o A determination of whether procedures used by your firm are robust and appropriate\u003Cbr>\n&nbsp; &nbsp; o Provisions for QU oversight throughout your operations to evaluate adherence to appropriate practices\u003Cbr>\n&nbsp; &nbsp; o A complete and final review of each batch and its related information before the QU disposition decision\u003Cbr>\n&nbsp; &nbsp; o Oversight and approval of investigations and discharging of all other QU duties to ensure identity, strength, quality, and purity of all products\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>3. Your firm failed to conduct, for each batch of drug product, appropriate laboratory testing, as necessary, required to be free of objectionable microorganisms (21 CFR 211.165(b)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your firm released finished drug products without adequate testing for critical microbial attributes (e.g., total count, absence of objectionable microorganisms). Without testing each batch prior to release, you did not have scientific evidence that all drug product batches were free of microbial contamination that is objectionable in view of its intended use.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide the following:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>A list of chemical and microbial specifications, including test methods, used to analyze each lot of your drug products before a lot disposition decision.\u003C\u002Fli>\n\t\u003Cli>An action plan and timelines for conducting full chemical and microbiological testing of retain samples to determine the quality of all batches of drug product distributed to the United States that are within expiry as of the date of this letter.\u003C\u002Fli>\n\t\u003Cli>A summary of all results obtained from testing retain samples from each batch. If such testing reveals substandard quality drug products, take rapid corrective actions, such as notifying customers and product recalls.\u003C\u002Fli>\n\t\u003Cli>A comprehensive, independent assessment of your laboratory practices, procedures, methods, equipment, documentation, and analyst competencies. Based on this review, provide a detailed plan to remediate and evaluate the effectiveness of your laboratory system.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>\u003Cstrong>4. Your firm failed to clean, maintain, and, as appropriate for the nature of the drug, sanitize and\u002For sterilize equipment and utensils at appropriate intervals to prevent malfunctions or contamination that would alter the safety, identity, strength, quality, or purity of the drug product beyond the official or other established requirements (21 CFR 211.67(a)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>You failed to demonstrate that your cleaning and disinfection practices are adequate to remove contaminants from shared equipment used to manufacture household cleaners as well as your topical OTC drug products. Although you did not validate your equipment cleaning methods, you continued to manufacture your topical OTC drug products using the same equipment that you use to manufacture numerous cleaners in your facility, including \u003Cstrong>(b)(4)\u003C\u002Fstrong> Bathroom Cleaner.\u003C\u002Fp>\n\n\u003Cp>This cleaner is labeled as, “CAUTION: IRRITANT” and “For Sensitive skin, please wear household rubber gloves.”\u003Cbr>\n\u003Cbr>\nIt is unacceptable as a matter of CGMP to continue manufacturing drugs using the same equipment that you use to manufacture industrial-grade cleaning products. Moreover, the potential toxicity of these products increases the hazard if a cross-contamination or material mixup deviation occurs.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide the following:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>A comprehensive, independent retrospective assessment of your cleaning effectiveness to evaluate the scope of cross-contamination hazards. Include the identity of residues, other manufacturing equipment that may have been improperly cleaned, and an assessment whether cross-contaminated products may have been released for distribution. The assessment should identify any inadequacies of cleaning procedures and practices, and encompass each piece of manufacturing equipment used to manufacture more than one product.\u003C\u002Fli>\n\t\u003Cli>A CAPA plan, based on the retrospective assessment of your cleaning and disinfection program, that includes appropriate remediations to your cleaning and disinfection processes and practices, and timelines for completion. Provide a detailed summary of vulnerabilities in your process for lifecycle management of equipment cleaning and disinfection. Describe improvements to your cleaning and disinfection program, including enhancements to cleaning effectiveness; segregation of pharmaceutical from non-pharmaceutical manufacturing; improved ongoing verification of proper cleaning and disinfection execution for all products and equipment; and all other needed remediations.\u003C\u002Fli>\n\t\u003Cli>Appropriate improvements to your cleaning validation program, with special emphasis on incorporating conditions identified as worst case in your drug manufacturing operation. This should include but not be limited to identification and evaluation of all worst-case:\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>&nbsp; &nbsp; o drugs with higher toxicities\u003Cbr>\n&nbsp; &nbsp; o drugs with higher drug potencies\u003Cbr>\n&nbsp; &nbsp; o drugs of lower solubility in their cleaning solvents\u003Cbr>\n&nbsp; &nbsp; o drugs with characteristics that make them difficult to clean\u003Cbr>\n&nbsp; &nbsp; o swabbing locations for areas that are most difficult to clean\u003Cbr>\n&nbsp; &nbsp; o maximum hold times before cleaning\u003C\u002Fp>\n\n\u003Cp>In addition, describe the steps that must be taken in your change management system before introduction of new manufacturing equipment or a new product.\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>A summary of updated standard operating procedure (SOPs) that ensure an appropriate program is in place for verification and validation of cleaning procedures for products, processes, and equipment.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>\u003Cstrong>5. Your firm failed to conduct at least one test to verify the identity of each component of a drug product (21 CFR 211.84(d)(1)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>You lacked appropriate identity testing for your incoming components used to manufacture your drug products. For example, your firm did not ensure that at least one specific identity test was conducted for each lot of your drug product components citric acid and carbomer. Additionally, your identity test methods for glycerin, and ethyl alcohol components are insufficient as they were not adequate to detect the toxic chemicals diethylene glycol and methanol, respectively.\u003C\u002Fp>\n\n\u003Cp>By not adequately analyzing each incoming lot of components for identity, you failed to ensure your incoming components are of appropriate quality to use in the manufacture of drug products.\u003C\u002Fp>\n\n\u003Cp>You manufacture multiple drugs that contain glycerin. The use of glycerin contaminated with DEG has resulted in various lethal poisoning incidents in humans worldwide.\u003C\u002Fp>\n\n\u003Cp>See FDA’s guidance document \u003Cem>Testing of Glycerin for Diethylene Glycol\u003C\u002Fem> to help you meet the CGMP requirements when manufacturing drugs containing glycerin at \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Ftesting-glycerin-diethylene-glycol\">https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Ftesting-glycerin-diethylene-glycol\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>You also manufacture multiple drugs that contain ethanol. The use of ethanol contaminated with methanol has resulted in various lethal poisoning incidents in humans worldwide.\u003C\u002Fp>\n\n\u003Cp>See FDA’s guidance document Policy for Testing of Alcohol (Ethanol) and Isopropyl Alcohol for Methanol, Including During the Public Health Emergency (COVID-19) to help you meet the CGMP requirements when manufacturing drugs containing ethanol at \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fpolicy-testing-alcohol-ethanol-and-isopropyl-alcohol-methanol-including-during-public-health\">https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fpolicy-testing-alcohol-ethanol-and-isopropyl-alcohol-methanol-including-during-public-health\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide the following:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>The chemical and microbiological quality control specifications you use to test and release each incoming lot of component for use in manufacturing.\u003C\u002Fli>\n\t\u003Cli>A description of how you will test each component lot for conformity with all appropriate specifications for identity, strength, quality, and purity. If you intend to accept any results from your supplier’s COA instead of testing each component lot for strength, quality, and purity, specify how you will robustly establish the reliability of your supplier’s results through initial validation as well as periodic re-validation. In addition, include a commitment to always conduct at least one specific identity test for each incoming component lot.\u003C\u002Fli>\n\t\u003Cli>A summary of results obtained from testing all components to evaluate the reliability of the COA from each component manufacturer. Include your SOP that describes this COA validation program.\u003C\u002Fli>\n\t\u003Cli>A summary of your program for qualifying and overseeing contract facilities that test the drug products you manufacture.\u003C\u002Fli>\n\t\u003Cli>Results of tests for diethylene glycol (DEG) and ethylene glycol (EG) in retain samples of all glycerin lots used to manufacture your drug products.\u003C\u002Fli>\n\t\u003Cli>A full risk assessment for drug products that contain glycerin and are within expiry in the U.S. market. Take prompt corrective actions and preventive actions, and detail your future actions to ensure appropriate selection of your suppliers, ongoing scrutiny of their supply chain, and appropriate incoming lot controls.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>\u003Cstrong>Unapproved New Drug and Misbranding Violations\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Examples of claims observed on the Aire-Master Foaming Hand Sanitizer (2 and 64 fl oz) and AireMaster Foaming Hand Sanitizer with Aloe labels that provide evidence of the intended uses\u003Csup>\u003Cem>\u003Cstrong>2&nbsp;\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup>(as defined in 21 CFR 201.128) of the product include, but may not be limited to, the following:\u003C\u002Fp>\n\n\u003Cp>“\u003Cstrong>Drug Facts . . . Active Ingredient\u003C\u002Fstrong> . . . Ethanol 62% . . . \u003Cstrong>Purpose\u003C\u002Fstrong> . . . Antiseptic. . . \u003Cstrong>Uses\u003C\u002Fstrong> . . . Handwash to help reduce bacteria that potentially can cause disease. . . \u003Cstrong>Directions\u003C\u002Fstrong> . . . Dispense an adequate amount in your palm to cover all surfaces of hands completely · Rub hands together until dry · Does not require rinsing. . .” [from your Aire-Master Foaming Hand Sanitizer label]\u003C\u002Fp>\n\n\u003Cp>“\u003Cstrong>Drug Facts . . . Active Ingredient\u003C\u002Fstrong> . . . Ethanol 62% . . . \u003Cstrong>Purpose\u003C\u002Fstrong> . . . Antiseptic. . . \u003Cstrong>Uses\u003C\u002Fstrong> . . . Handwash to help reduce bacteria that potentially can cause disease. . . \u003Cstrong>Directions\u003C\u002Fstrong> . . . Dispense an adequate amount in your palm to cover all surfaces of hands completely · Rub hands together until dry · Does not require rinsing. . .” [from your Aire-Master Foaming Hand Sanitizer with Aloe label]\u003C\u002Fp>\n\n\u003Cp>These topical antiseptic products are “new drugs” within the meaning of section 201(p) of the FD&amp;C Act, 21 U.S.C. 321(p), because they are not generally recognized as safe and effective (GRASE) for use under the conditions prescribed, recommended, or suggested in their labeling. New drugs may not be introduced or delivered for introduction into interstate commerce without prior approval from FDA, as described in section 505(a) of the FD&amp;C Act, 21 U.S.C. 355(a), unless they are lawfully marketed under section 505G of the FD&amp;C Act (which is not the case for this product, as further described below) or other exceptions not applicable here. No FDA-approved application pursuant to section 505 of the FD&amp;C Act, 21 U.S.C. 355, is in effect for these drug products, nor are we aware of any adequate and well-controlled clinical studies in the published literature that support a determination that your AireMaster Foaming Hand Sanitizer (2 and 64 fl oz) and Aire-Master Foaming Hand Sanitizer with Aloe products are GRASE for use under the conditions suggested, recommended, or prescribed in their labeling. Accordingly, these products are unapproved new drugs marketed in violation of sections 505(a) and 301(d) of the FD&amp;C Act, 21 U.S.C 355(a) and 331(d).\u003C\u002Fp>\n\n\u003Cp>We note that over-the-counter (OTC) topical antiseptic products had been the subject of rulemaking under the Agency’s OTC Drug Review. In particular, such products were addressed in a tentative final monograph (TFM) entitled “Topical Antimicrobial Drug Products for Over-the-Counter Human Use; Tentative Final Monograph for Health-Care Antiseptic Drug Products,” Proposed Rule, 59 FR 31402 (June 17, 1994) (1994 TFM), as further amended by “Safety and Effectiveness of Consumer Antiseptics; Topical Antimicrobial Drug Products for Over-the-Counter Human Use; Proposed Amendment of the Tentative Final Monograph; Reopening of Administrative Record,” Proposed Rule, 81 FR 42912 (June 30, 2016)(Consumer Antiseptic Rubs Proposed Rule). Over the course of these rulemakings, three active ingredients (benzalkonium chloride, ethyl alcohol (ethanol), and isopropyl alcohol) were classified as Category III for use in consumer antiseptic rub products, meaning that additional safety and effectiveness data are needed to support a determination that a drug product containing one of these active ingredients would be GRASE for use as a consumer antiseptic rub. Additionally, OTC consumer antiseptic washes were addressed in “Safety and Effectiveness of Consumer Antiseptics; Topical Antimicrobial Drug Products for Over-the-Counter Human Use,” Proposed Rule, 78 FR 76444 (December 17, 2013) (Consumer Antiseptic Washes Proposed Rule) and “OTC Safety and Effectiveness of Topical Antimicrobial Drug Products for Over-the-Counter Human Use,” Final Rule, 81 FR 61106 (September 6, 2016). We note that ethyl alcohol is not one of the active ingredients that was classified as Category III for use as an active ingredient in a consumer antiseptic wash. Under the Consumer Antiseptic Washes rulemaking, ethyl alcohol was determined to be ineligible for evaluation under the OTC Drug Review for use as an active ingredient in consumer antiseptic washes.\u003C\u002Fp>\n\n\u003Cp>Section 505G of the FD&amp;C Act addresses nonprescription drugs marketed without an approved application. Under section 505G(a)(3) of the FD&amp;C Act, drugs that were classified as Category III for safety or effectiveness in a TFM that is the most recently applicable proposal or determination for such drug issued under 21 CFR Part 330 – and that were not classified as Category II for safety or effectiveness – are not required to have an approved application under section 505 in order to be marketed, as long as they are in conformity with the relevant conditions of use outlined in the applicable TFM, including the active ingredient, and comply with all other applicable requirements.\u003C\u002Fp>\n\n\u003Cp>However, Aire-Master Foaming Hand Sanitizer (2 and 64 fl oz) and Aire-Master Foaming Hand Sanitizer with Aloe do not conform to the 1994 TFM, as further amended by the 2016 Consumer Antiseptic Rubs Proposed Rule [and the 2013 Consumer Antiseptic Washes Proposed Rule], nor any other TFM, proposed rule, or final rule, and do not meet the conditions under section 505G(a)(3) of the FD&amp;C Act for marketing without an approved application under section 505.\u003C\u002Fp>\n\n\u003Cp>As previously noted, statements on each of the product labels for Aire-Master Foaming Hand Sanitizer (2 and 64 fl oz) and Aire-Master Foaming Hand Sanitizer with Aloe suggest that these products are intended to be both consumer antiseptic washes and consumer antiseptic rubs. However, ethyl alcohol (in any concentration) is not an active ingredient permitted for use in consumer antiseptic hand washes under the 1994 TFM.\u003C\u002Fp>\n\n\u003Cp>Lastly, these products are misbranded under section 502(ee) of the FD&amp;C Act, 21 U.S.C. 352(ee), because Aire-Master Foaming Hand Sanitizer (2 and 64 fl oz) and Aire-Master Foaming Hand Sanitizer with Aloe are nonprescription drug(s) subject to section 505G of the FD&amp;C Act, 21 U.S.C. 355h, but do not comply with the requirements for marketing under that section and are not the subject of an application approved under section 505 of the FD&amp;C Act, 21 U.S.C. 355.\u003C\u002Fp>\n\n\u003Cp>The introduction or delivery for introduction of a misbranded drug into interstate commerce is prohibited under section 301(a) of the FD&amp;C Act, 21 U.S.C. 331(a).\u003C\u002Fp>\n\n\u003Cp>Additionally, we note that under 21 CFR 201.61(a), “[t]he principal display panel of an over-the-counter drug in package form shall bear as one of its principal features, a statement of identity of the commodity.” Under section 505G(a)(3) of the FD&amp;C Act and the 1994 TFM, the statement of identity for health-care antiseptic drug products, a category that included consumer antiseptic rub drug products, must contain “the established name of the drug, if any” (59 FR 31442). Currently, there is no established name for consumer antiseptic rub drug products that have the active ingredient ethyl alcohol and are formulated as a gel. However, we recommend that you include the active ingredient’s name, such as “alcohol gel,” as appropriate, as part of the statement of identity that appears on the principal display panel for all of your product labels.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>CGMP Consultant Recommended\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Based upon the nature of the violations we identified at your firm, we strongly recommend engaging a consultant to assist your firm in meeting CGMP requirements. Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Objectionable Organisms\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>For further information regarding the significance of \u003Cem>B. cepacia \u003C\u002Fem>complex and other objectionable contamination of non-sterile, water-based drug products, see FDA’s advisory notice posted on July 7, 2021, at \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002FDrugs\u002FDrugSafety\u002Fucm559508.htm\">https:\u002F\u002Fwww.fda.gov\u002FDrugs\u002FDrugSafety\u002Fucm559508.htm\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\u003C\u002Fp>\n\n\u003Cp>Correct any violations promptly. Failure to promptly and adequately address this matter may result in regulatory or legal action without further notice including, without limitation, seizure and injunction. Unresolved violations may also prevent other Federal agencies from awarding contracts.\u003C\u002Fp>\n\n\u003Cp>Failure to address violations may also cause FDA to withhold issuance of Export Certificates. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to address any violations.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\u003C\u002Fp>\n\n\u003Cp>Your written notification should refer to the Warning Letter Number above (622546). Please address your reply via email to: ORAPHARM3_RESPONSES@fda.hhs.gov\u003C\u002Fp>\n\n\u003Cp>Attention: Nicholas F. Lyons, Director of Compliance\u003Cbr>\nU.S. Food and Drug Administration\u003Cbr>\nDivision of Pharmaceutical Quality Operations III\u003C\u002Fp>\n\n\u003Cp>If you have questions regarding the contents of this letter, please contact Nicholas F. Lyons, Director of Compliance at (312) 596-4220.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Jeffrey D. Meng\u003Cbr>\nProgram Division Director\u003Cbr>\nDivision of Pharmaceutical Quality Operations III\u003C\u002Fp>\n\n\u003Cp>__________________________________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> Due to an increased demand for alcohol-based hand sanitizers during the COVID-19 pandemic, FDA published the Guidance for Industry: Temporary Policy for Preparation of Certain Alcohol-Based Hand Sanitizer Products During the Public Health Emergency (COVID-19) on March 19, 2020, and subsequently updated the guidance several times. The guidance was withdrawn effective December 31, 2021 (86 Fed Reg at 56960). This guidance communicated the Agency’s temporary policy that we did not intend to take action against firms for CGMP violations under section 501(a)(2)(B) of the FD&amp;C Act if such firms prepared alcohol-based hand sanitizers for consumer use (or for use as a health care personnel hand rub) during the public health emergency, provided certain circumstances described in the guidance are present. These circumstances included preparation of hand sanitizer products using only the ingredients and formulas set forth in the guidance. A review of the formulations of the drug products indicates that such products were not prepared consistent with FDA’s temporary policy set forth in the guidance. Because Aire-Master of America’s hand sanitizer drug products were not consistent with the formulations described in these guidances, they did not fall within any temporary Agency policy not to take action against firms manufacturing hand sanitizer drug products for violations of section 505 of the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> We note that your Aire-Master Foaming Hand Sanitizer Foaming Hand Sanitizer (2 and 64 fl oz) and Aire-Master Foaming Hand Sanitizer with Aloe, drug products’ labeling contains conflicting information regarding whether they should be used as consumer antiseptic rub\u002Fconsumer antiseptic wash or consumer antiseptic rub. The term “hand sanitizer” generally refers to consumer antiseptic rubs, and the Drug Facts Label of your product both indicates that the product is to be used for handwashing (presumably with water) and suggests that it should be used without water (i.e., “[a]pply liberal amount into hand” and “rub to dryness with attention to area around nails and between fingers”). These products, however, do not conform to the requirements for either a consumer antiseptic rub or a consumer antiseptic wash, as further described below.\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nUPS\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nMr. Walter R. Heinle\n\nRecipient Title\n\nPresident\u002FCOO\n\nAire-Master of America, Inc.\n\n1821 N. State Highway CC\n\nNixa, MO 65714-8015\n\nUnited States\n\nIssuing Office:\n\nDivision of Pharmaceutical Quality Operations III\n\nUnited States\n\nMay 23, 2022\n\nWARNING LETTER\n\nCase #622546\n\nDear Mr. Heinle:\n\nThe U.S. Food and Drug Administration (FDA) inspected your drug manufacturing facility, Aire-Master of America, Inc., FEI 3002764676, at 1821 N. State Highway CC, Nixa Missouri, from October 5 to October 19, 2021\n\nThis warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\n\nBecause your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 351(a)(2)(B).\n\nIn addition, Aire-Master Foaming Hand Sanitizer (2 and 64 fl oz) and Aire-Master Foaming Hand Sanitizer with Aloe are unapproved new drugs introduced or delivered for introduction into interstate commerce in violation of section 505(a) of the FD&C Act, 21 U.S.C. 355(a), and are misbranded under sections 502(ee) of the FD&C Act, 21 U.S.C. 352(ee). Introduction or delivery for introduction of such products into interstate commerce is prohibited under sections 301(d) and (a) of the FD&C Act, 21 U.S.C. 331(d) and (a). These violations are described in more detail below.\n\nWe reviewed your November 4, 2022, response to our Form FDA 483 in detail.\n\nYour response is inadequate because it did not provide sufficient detail or evidence of corrective actions to bring your operations into compliance with CGMP.\n\nDuring our inspection, our investigators observed specific violations including, but not limited to, the following.\n\n1. Your firm failed to establish laboratory controls that include scientifically sound and appropriate specifications, standards, sampling plans, and test procedures designed to assure that components, drug product containers, closures, in-process materials, labeling, and drug products conform to appropriate standards of identity, strength, quality, and purity (21 CFR 211.160(b)).\n\nYour laboratory sampling plans and testing methods were not scientifically sound. You collected non-representative samples of your water system. Water from your water system is used in the formulation of your topical over-the-counter (OTC) drug products. Specifically, your water system monitoring procedure provided during the inspection did not discuss the number, location, or frequency of samples to collect. You told our investigator that you typically take a sample from your water system (b)(4) from a single location near the (b)(4) component. The sampling frequency and locations, which did not include sampling from any point of use, were not appropriate to provide substantive data to promptly detect system variability.\n\nFurthermore, your microbiological testing used for water analysis was deficient. You have not shown your test methods were adequate for determining the quality of the water in view of its intended use in your drug products. Furthermore, you lacked appropriate limits, routine testing, or validated methods for detecting the presence of B. cepacia in your water system. Your microbiological testing is insufficient to assure that your water system is suitable for its intended use.\n\nAdditionally, FDA analysis of samples collected from your water system recovered too-numerous-to-count results for multiple total microbial count tests.\n\nIn response to this letter, provide the following:\n\nA comprehensive, independent assessment of your water system design, control, and maintenance.\n\nA thorough remediation plan to install and operate a suitable water system. Include a robust ongoing control, maintenance, and monitoring program to ensure the remediated system design consistently produces water adhering to (b)(4) Water, USP monograph specifications and appropriate microbial limits.\n\nA detailed risk assessment addressing the potential effects of the observed water system failures on the quality of all drug product lots currently in U.S. distribution or within expiry. Specify actions that you will take in response to the risk assessment, such as customer notifications and product recalls.\n\nA procedure governing your program for ongoing control, maintenance, and monitoring that ensures the remediated system consistently produces water that meets (b)(4) Water, USP monograph specifications and appropriate microbial limits.\n\nA procedure for your water system monitoring that specifies routine microbial testing of (b)(4) water to ensure its acceptability for use in each batch of drug products produced by your firm.\n\nA diagram of your water system and its components. Include a list of all water system point-of-uses (POUs), their locations, and frequency of testing.\n\nThe current action\u002Falert limits for total counts and objectionable organisms used for your (b)(4) Water system. Ensure that the total count limits for your (b)(4) water are appropriately stringent in view of the intended use of each of the products produced by your firm.\n\n2. Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192).\n\nYour quality unit (QU) failed to conduct an adequate investigation into a complaint received for a “fishy” odor in your Foaming Waterless Hand Sanitizer1 lot #713588. Your investigation stated that you “checked inventory in the warehouse and noticed the smell that the customer complained of. Inventory was then taken out of stock.” You determined to rework some of the old product into a new batch “to lessen the smell of the product in question.”\n\nOur investigator collected a certificate of analysis (COA) showing “alcohol\u002Fno fragrance” as the specification for this drug product. As this complaint described a foul odor in distributed drug product, your QU should have performed a thorough investigation into this complaint as per 21 CFR 211.198. Instead, your production management performed a very limited investigation. The resolution for this complaint was to ensure employees “purge the (b)(4) tank before filling the vat with (b)(4) water.” While the investigation indicated that the (b)(4) water was the source of the odor, you failed to address why your formulation water had a foul odor. Additionally, your investigation lacked meaningful corrective action and preventive action (CAPA) to prevent recurrence.\n\nInadequate investigations can lead to unidentified root causes, ineffective CAPA, and recurring problems that compromise the ability to produce safe and effective products.\n\nIn response to this letter, provide the following:\n\nA comprehensive, independent assessment of your overall system for investigating deviations, discrepancies, complaints, out-of-specification (OOS) results, and failures. Provide a detailed action plan to remediate this system. Your action plan should include, but not be limited to, significant improvements in investigation competencies, scope determination, root cause evaluation, CAPA effectiveness, quality unit oversight, and written procedures. Address how your firm will ensure all phases of investigations are appropriately conducted.\n\nAn independent assessment and remediation plan for your CAPA program. Provide a report that evaluates whether the program includes effective root cause analysis, ensures CAPA effectiveness, analyzes investigations trends, improves the CAPA program when needed, implements final quality unit decisions, and is fully supported by executive management.\n\nA comprehensive assessment and remediation plan to ensure your QU is given the authority and resources to effectively function. The assessment should also include, but not be limited to:\n\no A determination of whether procedures used by your firm are robust and appropriate\n\no Provisions for QU oversight throughout your operations to evaluate adherence to appropriate practices\n\no A complete and final review of each batch and its related information before the QU disposition decision\n\no Oversight and approval of investigations and discharging of all other QU duties to ensure identity, strength, quality, and purity of all products\n\n3. Your firm failed to conduct, for each batch of drug product, appropriate laboratory testing, as necessary, required to be free of objectionable microorganisms (21 CFR 211.165(b)).\n\nYour firm released finished drug products without adequate testing for critical microbial attributes (e.g., total count, absence of objectionable microorganisms). Without testing each batch prior to release, you did not have scientific evidence that all drug product batches were free of microbial contamination that is objectionable in view of its intended use.\n\nIn response to this letter, provide the following:\n\nA list of chemical and microbial specifications, including test methods, used to analyze each lot of your drug products before a lot disposition decision.\n\nAn action plan and timelines for conducting full chemical and microbiological testing of retain samples to determine the quality of all batches of drug product distributed to the United States that are within expiry as of the date of this letter.\n\nA summary of all results obtained from testing retain samples from each batch. If such testing reveals substandard quality drug products, take rapid corrective actions, such as notifying customers and product recalls.\n\nA comprehensive, independent assessment of your laboratory practices, procedures, methods, equipment, documentation, and analyst competencies. Based on this review, provide a detailed plan to remediate and evaluate the effectiveness of your laboratory system.\n\n4. Your firm failed to clean, maintain, and, as appropriate for the nature of the drug, sanitize and\u002For sterilize equipment and utensils at appropriate intervals to prevent malfunctions or contamination that would alter the safety, identity, strength, quality, or purity of the drug product beyond the official or other established requirements (21 CFR 211.67(a)).\n\nYou failed to demonstrate that your cleaning and disinfection practices are adequate to remove contaminants from shared equipment used to manufacture household cleaners as well as your topical OTC drug products. Although you did not validate your equipment cleaning methods, you continued to manufacture your topical OTC drug products using the same equipment that you use to manufacture numerous cleaners in your facility, including (b)(4) Bathroom Cleaner.\n\nThis cleaner is labeled as, “CAUTION: IRRITANT” and “For Sensitive skin, please wear household rubber gloves.”\n\nIt is unacceptable as a matter of CGMP to continue manufacturing drugs using the same equipment that you use to manufacture industrial-grade cleaning products. Moreover, the potential toxicity of these products increases the hazard if a cross-contamination or material mixup deviation occurs.\n\nIn response to this letter, provide the following:\n\nA comprehensive, independent retrospective assessment of your cleaning effectiveness to evaluate the scope of cross-contamination hazards. Include the identity of residues, other manufacturing equipment that may have been improperly cleaned, and an assessment whether cross-contaminated products may have been released for distribution. The assessment should identify any inadequacies of cleaning procedures and practices, and encompass each piece of manufacturing equipment used to manufacture more than one product.\n\nA CAPA plan, based on the retrospective assessment of your cleaning and disinfection program, that includes appropriate remediations to your cleaning and disinfection processes and practices, and timelines for completion. Provide a detailed summary of vulnerabilities in your process for lifecycle management of equipment cleaning and disinfection. Describe improvements to your cleaning and disinfection program, including enhancements to cleaning effectiveness; segregation of pharmaceutical from non-pharmaceutical manufacturing; improved ongoing verification of proper cleaning and disinfection execution for all products and equipment; and all other needed remediations.\n\nAppropriate improvements to your cleaning validation program, with special emphasis on incorporating conditions identified as worst case in your drug manufacturing operation. This should include but not be limited to identification and evaluation of all worst-case:\n\no drugs with higher toxicities\n\no drugs with higher drug potencies\n\no drugs of lower solubility in their cleaning solvents\n\no drugs with characteristics that make them difficult to clean\n\no swabbing locations for areas that are most difficult to clean\n\no maximum hold times before cleaning\n\nIn addition, describe the steps that must be taken in your change management system before introduction of new manufacturing equipment or a new product.\n\nA summary of updated standard operating procedure (SOPs) that ensure an appropriate program is in place for verification and validation of cleaning procedures for products, processes, and equipment.\n\n5. Your firm failed to conduct at least one test to verify the identity of each component of a drug product (21 CFR 211.84(d)(1)).\n\nYou lacked appropriate identity testing for your incoming components used to manufacture your drug products. For example, your firm did not ensure that at least one specific identity test was conducted for each lot of your drug product components citric acid and carbomer. Additionally, your identity test methods for glycerin, and ethyl alcohol components are insufficient as they were not adequate to detect the toxic chemicals diethylene glycol and methanol, respectively.\n\nBy not adequately analyzing each incoming lot of components for identity, you failed to ensure your incoming components are of appropriate quality to use in the manufacture of drug products.\n\nYou manufacture multiple drugs that contain glycerin. The use of glycerin contaminated with DEG has resulted in various lethal poisoning incidents in humans worldwide.\n\nSee FDA’s guidance document Testing of Glycerin for Diethylene Glycol to help you meet the CGMP requirements when manufacturing drugs containing glycerin at https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Ftesting-glycerin-diethylene-glycol.\n\nYou also manufacture multiple drugs that contain ethanol. The use of ethanol contaminated with methanol has resulted in various lethal poisoning incidents in humans worldwide.\n\nSee FDA’s guidance document Policy for Testing of Alcohol (Ethanol) and Isopropyl Alcohol for Methanol, Including During the Public Health Emergency (COVID-19) to help you meet the CGMP requirements when manufacturing drugs containing ethanol at https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fpolicy-testing-alcohol-ethanol-and-isopropyl-alcohol-methanol-including-during-public-health.\n\nIn response to this letter, provide the following:\n\nThe chemical and microbiological quality control specifications you use to test and release each incoming lot of component for use in manufacturing.\n\nA description of how you will test each component lot for conformity with all appropriate specifications for identity, strength, quality, and purity. If you intend to accept any results from your supplier’s COA instead of testing each component lot for strength, quality, and purity, specify how you will robustly establish the reliability of your supplier’s results through initial validation as well as periodic re-validation. In addition, include a commitment to always conduct at least one specific identity test for each incoming component lot.\n\nA summary of results obtained from testing all components to evaluate the reliability of the COA from each component manufacturer. Include your SOP that describes this COA validation program.\n\nA summary of your program for qualifying and overseeing contract facilities that test the drug products you manufacture.\n\nResults of tests for diethylene glycol (DEG) and ethylene glycol (EG) in retain samples of all glycerin lots used to manufacture your drug products.\n\nA full risk assessment for drug products that contain glycerin and are within expiry in the U.S. market. Take prompt corrective actions and preventive actions, and detail your future actions to ensure appropriate selection of your suppliers, ongoing scrutiny of their supply chain, and appropriate incoming lot controls.\n\nUnapproved New Drug and Misbranding Violations\n\nExamples of claims observed on the Aire-Master Foaming Hand Sanitizer (2 and 64 fl oz) and AireMaster Foaming Hand Sanitizer with Aloe labels that provide evidence of the intended uses2 (as defined in 21 CFR 201.128) of the product include, but may not be limited to, the following:\n\n“Drug Facts . . . Active Ingredient . . . Ethanol 62% . . . Purpose . . . Antiseptic. . . Uses . . . Handwash to help reduce bacteria that potentially can cause disease. . . Directions . . . Dispense an adequate amount in your palm to cover all surfaces of hands completely · Rub hands together until dry · Does not require rinsing. . .” [from your Aire-Master Foaming Hand Sanitizer label]\n\n“Drug Facts . . . Active Ingredient . . . Ethanol 62% . . . Purpose . . . Antiseptic. . . Uses . . . Handwash to help reduce bacteria that potentially can cause disease. . . Directions . . . Dispense an adequate amount in your palm to cover all surfaces of hands completely · Rub hands together until dry · Does not require rinsing. . .” [from your Aire-Master Foaming Hand Sanitizer with Aloe label]\n\nThese topical antiseptic products are “new drugs” within the meaning of section 201(p) of the FD&C Act, 21 U.S.C. 321(p), because they are not generally recognized as safe and effective (GRASE) for use under the conditions prescribed, recommended, or suggested in their labeling. New drugs may not be introduced or delivered for introduction into interstate commerce without prior approval from FDA, as described in section 505(a) of the FD&C Act, 21 U.S.C. 355(a), unless they are lawfully marketed under section 505G of the FD&C Act (which is not the case for this product, as further described below) or other exceptions not applicable here. No FDA-approved application pursuant to section 505 of the FD&C Act, 21 U.S.C. 355, is in effect for these drug products, nor are we aware of any adequate and well-controlled clinical studies in the published literature that support a determination that your AireMaster Foaming Hand Sanitizer (2 and 64 fl oz) and Aire-Master Foaming Hand Sanitizer with Aloe products are GRASE for use under the conditions suggested, recommended, or prescribed in their labeling. Accordingly, these products are unapproved new drugs marketed in violation of sections 505(a) and 301(d) of the FD&C Act, 21 U.S.C 355(a) and 331(d).\n\nWe note that over-the-counter (OTC) topical antiseptic products had been the subject of rulemaking under the Agency’s OTC Drug Review. In particular, such products were addressed in a tentative final monograph (TFM) entitled “Topical Antimicrobial Drug Products for Over-the-Counter Human Use; Tentative Final Monograph for Health-Care Antiseptic Drug Products,” Proposed Rule, 59 FR 31402 (June 17, 1994) (1994 TFM), as further amended by “Safety and Effectiveness of Consumer Antiseptics; Topical Antimicrobial Drug Products for Over-the-Counter Human Use; Proposed Amendment of the Tentative Final Monograph; Reopening of Administrative Record,” Proposed Rule, 81 FR 42912 (June 30, 2016)(Consumer Antiseptic Rubs Proposed Rule). Over the course of these rulemakings, three active ingredients (benzalkonium chloride, ethyl alcohol (ethanol), and isopropyl alcohol) were classified as Category III for use in consumer antiseptic rub products, meaning that additional safety and effectiveness data are needed to support a determination that a drug product containing one of these active ingredients would be GRASE for use as a consumer antiseptic rub. Additionally, OTC consumer antiseptic washes were addressed in “Safety and Effectiveness of Consumer Antiseptics; Topical Antimicrobial Drug Products for Over-the-Counter Human Use,” Proposed Rule, 78 FR 76444 (December 17, 2013) (Consumer Antiseptic Washes Proposed Rule) and “OTC Safety and Effectiveness of Topical Antimicrobial Drug Products for Over-the-Counter Human Use,” Final Rule, 81 FR 61106 (September 6, 2016). We note that ethyl alcohol is not one of the active ingredients that was classified as Category III for use as an active ingredient in a consumer antiseptic wash. Under the Consumer Antiseptic Washes rulemaking, ethyl alcohol was determined to be ineligible for evaluation under the OTC Drug Review for use as an active ingredient in consumer antiseptic washes.\n\nSection 505G of the FD&C Act addresses nonprescription drugs marketed without an approved application. Under section 505G(a)(3) of the FD&C Act, drugs that were classified as Category III for safety or effectiveness in a TFM that is the most recently applicable proposal or determination for such drug issued under 21 CFR Part 330 – and that were not classified as Category II for safety or effectiveness – are not required to have an approved application under section 505 in order to be marketed, as long as they are in conformity with the relevant conditions of use outlined in the applicable TFM, including the active ingredient, and comply with all other applicable requirements.\n\nHowever, Aire-Master Foaming Hand Sanitizer (2 and 64 fl oz) and Aire-Master Foaming Hand Sanitizer with Aloe do not conform to the 1994 TFM, as further amended by the 2016 Consumer Antiseptic Rubs Proposed Rule [and the 2013 Consumer Antiseptic Washes Proposed Rule], nor any other TFM, proposed rule, or final rule, and do not meet the conditions under section 505G(a)(3) of the FD&C Act for marketing without an approved application under section 505.\n\nAs previously noted, statements on each of the product labels for Aire-Master Foaming Hand Sanitizer (2 and 64 fl oz) and Aire-Master Foaming Hand Sanitizer with Aloe suggest that these products are intended to be both consumer antiseptic washes and consumer antiseptic rubs. However, ethyl alcohol (in any concentration) is not an active ingredient permitted for use in consumer antiseptic hand washes under the 1994 TFM.\n\nLastly, these products are misbranded under section 502(ee) of the FD&C Act, 21 U.S.C. 352(ee), because Aire-Master Foaming Hand Sanitizer (2 and 64 fl oz) and Aire-Master Foaming Hand Sanitizer with Aloe are nonprescription drug(s) subject to section 505G of the FD&C Act, 21 U.S.C. 355h, but do not comply with the requirements for marketing under that section and are not the subject of an application approved under section 505 of the FD&C Act, 21 U.S.C. 355.\n\nThe introduction or delivery for introduction of a misbranded drug into interstate commerce is prohibited under section 301(a) of the FD&C Act, 21 U.S.C. 331(a).\n\nAdditionally, we note that under 21 CFR 201.61(a), “[t]he principal display panel of an over-the-counter drug in package form shall bear as one of its principal features, a statement of identity of the commodity.” Under section 505G(a)(3) of the FD&C Act and the 1994 TFM, the statement of identity for health-care antiseptic drug products, a category that included consumer antiseptic rub drug products, must contain “the established name of the drug, if any” (59 FR 31442). Currently, there is no established name for consumer antiseptic rub drug products that have the active ingredient ethyl alcohol and are formulated as a gel. However, we recommend that you include the active ingredient’s name, such as “alcohol gel,” as appropriate, as part of the statement of identity that appears on the principal display panel for all of your product labels.\n\nCGMP Consultant Recommended\n\nBased upon the nature of the violations we identified at your firm, we strongly recommend engaging a consultant to assist your firm in meeting CGMP requirements. Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\n\nObjectionable Organisms\n\nFor further information regarding the significance of B. cepacia complex and other objectionable contamination of non-sterile, water-based drug products, see FDA’s advisory notice posted on July 7, 2021, at https:\u002F\u002Fwww.fda.gov\u002FDrugs\u002FDrugSafety\u002Fucm559508.htm.\n\nConclusion\n\nThe violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\n\nCorrect any violations promptly. Failure to promptly and adequately address this matter may result in regulatory or legal action without further notice including, without limitation, seizure and injunction. Unresolved violations may also prevent other Federal agencies from awarding contracts.\n\nFailure to address violations may also cause FDA to withhold issuance of Export Certificates. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to address any violations.\n\nThis letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\n\nYour written notification should refer to the Warning Letter Number above (622546). Please address your reply via email to: ORAPHARM3_RESPONSES@fda.hhs.gov\n\nAttention: Nicholas F. Lyons, Director of Compliance\n\nU.S. Food and Drug Administration\n\nDivision of Pharmaceutical Quality Operations III\n\nIf you have questions regarding the contents of this letter, please contact Nicholas F. Lyons, Director of Compliance at (312) 596-4220.\n\nSincerely,\n\n\u002FS\u002F\n\nJeffrey D. Meng\n\nProgram Division Director\n\nDivision of Pharmaceutical Quality Operations III\n\n__________________________________\n\n1 Due to an increased demand for alcohol-based hand sanitizers during the COVID-19 pandemic, FDA published the Guidance for Industry: Temporary Policy for Preparation of Certain Alcohol-Based Hand Sanitizer Products During the Public Health Emergency (COVID-19) on March 19, 2020, and subsequently updated the guidance several times. The guidance was withdrawn effective December 31, 2021 (86 Fed Reg at 56960). This guidance communicated the Agency’s temporary policy that we did not intend to take action against firms for CGMP violations under section 501(a)(2)(B) of the FD&C Act if such firms prepared alcohol-based hand sanitizers for consumer use (or for use as a health care personnel hand rub) during the public health emergency, provided certain circumstances described in the guidance are present. These circumstances included preparation of hand sanitizer products using only the ingredients and formulas set forth in the guidance. A review of the formulations of the drug products indicates that such products were not prepared consistent with FDA’s temporary policy set forth in the guidance. Because Aire-Master of America’s hand sanitizer drug products were not consistent with the formulations described in these guidances, they did not fall within any temporary Agency policy not to take action against firms manufacturing hand sanitizer drug products for violations of section 505 of the FD&C Act.\n\n2 We note that your Aire-Master Foaming Hand Sanitizer Foaming Hand Sanitizer (2 and 64 fl oz) and Aire-Master Foaming Hand Sanitizer with Aloe, drug products’ labeling contains conflicting information regarding whether they should be used as consumer antiseptic rub\u002Fconsumer antiseptic wash or consumer antiseptic rub. The term “hand sanitizer” generally refers to consumer antiseptic rubs, and the Drug Facts Label of your product both indicates that the product is to be used for handwashing (presumably with water) and suggests that it should be used without water (i.e., “[a]pply liberal amount into hand” and “rub to dryness with attention to area around nails and between fingers”). These products, however, do not conform to the requirements for either a consumer antiseptic rub or a consumer antiseptic wash, as further described below.","Aire-Master of America, Inc.","aire-master-america-inc-622546-05232022","2026-08-18T06:42:29.262718+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Faire-master-america-inc-622546-05232022","2026-10-26T08:07:51.568165+00:00","2022-06-07","622546","Drugs","Mr. Walter R. Heinle","2026-08-20T01:50:22.912+00:00","UPS","2022-05-23",{"id":54,"raw":55,"subject":60,"body_html":62,"body_text":63,"firm_name":64,"letter_id":65,"created_at":66,"fei_number":19,"letter_url":67,"updated_at":68,"action_type":22,"case_status":69,"posted_date":70,"marcs_cms_no":71,"product_type":72,"closeout_date":73,"issuing_office":59,"recipient_name":74,"body_fetched_at":75,"delivery_method":76,"recipient_title":19,"reference_number":19,"action_taken_date":77,"medical_device_id":19,"response_letter_date":19},1138,[56,57,58,59,60,13,61,13],"\u003Ctime datetime=\"2024-12-10T14:20:00Z\">12\u002F10\u002F2024\u003C\u002Ftime>\n","\u003Ctime datetime=\"2024-11-22T05:00:00Z\">11\u002F22\u002F2024\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fmid-america-pet-food-llc-681516-11222024\">Mid America Pet Food LLC\u003C\u002Fa>","Center for Veterinary Medicine","CGMP\u002FFood for Animals\u002FPrepared, Packed or Held Under Insanitary Conditions\u002FAdulterated","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fmid-america-pet-food-llc-681516-08212025\">\u003Ctime datetime=\"2025-08-28T04:00:00Z\">08\u002F28\u002F2025\u003C\u002Ftime>\n\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Animal &amp; Veterinary\u003Cbr>Food &amp; Beverages                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Jeff Caswell\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Chief Executive Officer \u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Mid America Pet Food LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>2024 N. Frontage Road\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Mount Pleasant\u003C\u002Fspan>, \u003Cspan>TX\u003C\u002Fspan> \u003Cspan>75455-6474\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Veterinary Medicine\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003Cbr>\u003Cstrong>CMS# 681516\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>November 22, 2024\u003C\u002Fp>\u003Cp>Dear Mr. Caswell:\u003C\u002Fp>\u003Cp>The U.S. Food and Drug Administration (FDA) inspected your pet food manufacturing facility located at 2024 N. Frontage Road, Mount Pleasant, Texas from November 2, 2023, through December 18, 2023. FDA also conducted a subsequent inspection from January 23, 2024, through February 9, 2024, at this facility. We received your responses dated January 10, 2024; March 4, 2024; and July 10, 2024, to the FDA 483 Inspectional Observations. FDA conducted the 2023 inspection in response to your voluntary Class I recalls initiated on September 3, 2023, expanded on October 30, 2023, and further expanded on November 9, 2023, to include all your dog and cat food with best by dates before October 31, because they had the potential to be contaminated with \u003Cem>Salmonella\u003C\u002Fem>. In addition, FDA conducted the 2023 inspection as part of an investigation, along with the Centers for Disease Control (CDC) and state and local partners, into a multi-state foodborne illness outbreak of \u003Cem>Salmonella\u003C\u002Fem> Kiambu implicated in human illnesses through epidemiological traceback.\u003Cem>\u003Cstrong>\u003Csup>1\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> A total of seven people from seven states were infected with the outbreak strain from January 14, 2023 to August 19, 2023, and one person was hospitalized. Six of the affected people were children under one year of age. \u003Cem>Salmonella\u003C\u002Fem> can affect animals eating the products, and there is risk to humans from handling contaminated pet products and utensils that came into contact with the affected pet products. Children, the elderly, and individuals with compromised immune systems may be at greater risk for Salmonella infection.\u003C\u002Fp>\u003Cp>These illnesses were linked by whole genome sequencing to dog food manufactured at your facility in 2023 through a sample of Victor Super Premium Dog Food Classic Hi-Pro Plus (lot 1000016385; Best By 4\u002F30\u002F24) collected by the South Carolina Department of Agriculture on August 15, 2023, which you recalled on September 3, 2023. On October 30, 2023, you expanded your initial recall to include Victor Super Premium Dog Food, Select Beef Meal &amp; Brown Rice Formula with best by dates of June 12, 2024 (5 lbs. lot 1000016890; 15 lbs. lot 1000016891; and 40 lbs. lot 1000016892). On November 9, 2023, you expanded your recall to include all products with best by dates before October 31, 2024, because your testing revealed the presence of \u003Cem>Salmonella\u003C\u002Fem> Kiambu in a lot for which you reported receiving a consumer complaint involving human illness. Based on analytical results, FDA considers the Victor Super Premium Dog Food Classic Hi-Pro Plus (lot 1000016385; Best By 4\u002F30\u002F24)lot to be adulterated in that it bears or contains a poisonous or deleterious substance which may render it injurious to health.\u003Cem>\u003Cstrong>\u003Csup>2\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fp>\u003Cp>FDA collected environmental samples (i.e., swabs) from surfaces in your manufacturing facility during this inspection and a subsequent inspection, conducted from January 23, 2024, through February 9, 2024, in response to a consumer complaint. Analysis of these samples using whole genome sequencing revealed that three of the Salmonella-positive environmental swabs collected in the post-process area of your facility during the 2024 inspection are closely related to seven Salmonella-positive environmental swabs collected in the pre-process areas of your facility during the 2023 inspection, indicating that your facility may have three resident strains of Salmonella: Salmonella Rissen, Salmonella Minnesota, and Salmonella Mbandaka.\u003C\u002Fp>\u003Cp>During these inspections FDA Investigators found evidence of significant violations of the Current Good Manufacturing Practice, Hazard Analysis, and Risk-Based Preventive Controls for Food for Animals requirements in Title 21, Code of Federal Regulations, Part 507 (21 CFR Part 507), which cause your products to be adulterated in that they were prepared, packed, or held under insanitary conditions whereby they may have become contaminated with filth, or whereby they may have been rendered injurious to health.\u003Cem>\u003Cstrong>\u003Csup>3\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> Additionally, the introduction or delivery for introduction into interstate commerce of any food that is adulterated is a prohibited act.\u003Cem>\u003Cstrong>\u003Csup>4\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> Furthermore, the failure of the owner, operator, or agent in charge of a covered facility to comply with the preventive controls provisions of 21 CFR 507 (located in subparts A, C, D, E, and F of Part 507) is a prohibited act.\u003Cem>\u003Cstrong>\u003Csup>5\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> You may find the FD&amp;C Act and FDA’s regulations through links on the FDA’s website at www.fda.gov.\u003C\u002Fp>\u003Cp>At the conclusion of our inspections on December 18, 2023, and February 9, 2024, you were issued two separate Forms FDA 483, Inspectional Observations. We received your written responses to these observations dated January 10, 2024, March 4, 2024, and July 10, 2024, and address your corrective actions below, in relation to each of the noted violations.\u003C\u002Fp>\u003Cp>\u003Cstrong>Hazard Analysis and Risk-Based Preventive Controls Requirements\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your animal food facility is subject to the hazard analysis and risk-based preventive controls requirements found in 21 CFR Part 507, subparts A, C, D, E, and F. During the inspection of your facility, the FDA Investigators obtained evidence of significant violations of these requirements, which included:\u003C\u002Fp>\u003Cp>1. You did not identify and implement a preventive control to provide assurances that any hazards requiring a preventive control will be significantly minimized or prevented, as required by 21 CFR 507.34(a)(1).\u003C\u002Fp>\u003Cp>Specifically, your hazard analysis determined the hazard of Salmonella requires preventive controls and identified sanitation and process controls to control the hazard of Salmonella in your finished pet food.\u003C\u002Fp>\u003Cp>A. Your Food Safety Plan dated January 9, 2024, documents your sanitation control for Salmonella spp. in post-extrusion processing environments by removing residual material on post-extruder surfaces and applying sanitizer in accordance with the sanitizer label. However, you failed to adequately implement your sanitation control.\u003C\u002Fp>\u003Cp>i. You use \u003Cstrong>(b)(4)\u003C\u002Fstrong> as a sanitizer for food-contact equipment and utensils. Your “\u003Cstrong>(b)(4)\u003C\u002Fstrong> Procedure” (SOP 1500) standard operating procedure (SOP), dated December 5, 2023, documents, “Surfaces must remain thoroughly wetted for \u003Cstrong>(b)(4)\u003C\u002Fstrong> followed by adequate draining and air drying . . . [a]llow the identified surface to air dry before the manufacturing process can resume, or the identified surface is reintroduced for use.” Furthermore, the label for \u003Cstrong>(b)(4)\u003C\u002Fstrong> documents “treated surfaces must remain wet for at least \u003Cstrong>(b)(4)\u003C\u002Fstrong> followed by adequate draining and air drying” for food-processing equipment and food-contact surfaces. On January 30, 2024, FDA Investigators observed an employee designated to the post-extrusion area cleaning food-contact equipment who used \u003Cstrong>(b)(4)\u003C\u002Fstrong> to sanitize the equipment and then immediately dried the surface of the equipment with a paper towel. During this cleaning, the equipment made direct contact with the employee’s clothing which was visibly soiled with apparent dog food.\u003C\u002Fp>\u003Cp>ii. Your “Housekeeping Procedure” (CGMP 2800),” dated February 2, 2022, documents that the sanitation lead employee write their initials on sanitation records to document their inspection and review of sanitation activities on the Master Cleaning Schedule. Your Master Cleaning Schedule, “Housekeeping #5” for December 2023 does not document \u003Cstrong>(b)(4)\u003C\u002Fstrong> cleaning for the discharge hoppers located in the packaging area for the entire month of December 20\u003Ca>23.\u003C\u002Fa>\u003C\u002Fp>\u003Cp>In addition, there were multiple instances of other equipment and areas where you did not document sanitation activities in accordance with your Master Cleaning Schedule in April 2023, May 2023, June 2023, September 2023, December 2023, and January 2024.\u003C\u002Fp>\u003Cp>iii. On January 26, 2024, FDA Investigators observed visible debris on food-contact surfaces of equipment such as brushes, brooms, and squeegees after cleaning and sanitizing of equipment was performed by your third-party sanitation service. In addition, you could not produce any sanitation records for July and August of 2023 and your records for April 2023 and May 2023 were incomplete. Your lack of complete records in addition to the ineffective cleaning observed by Investigators demonstrates your failure to implement your sanitation preventive control.\u003C\u002Fp>\u003Cp>B. Your Food Safety Plan dated January 9, 2024, documents “CGMP controls” to minimize the hazard of \u003Cem>Salmonella\u003C\u002Fem> spp. in post-extrusion processing environments.\u003C\u002Fp>\u003Cp>i. On January 23, 2024, FDA Investigators observed rainwater entering your facility through the roof while you were manufacturing multiple lots of dog food. FDA Investigators observed standing water and soaked absorbent pads in staging, production, and finished product areas, including in post-process areas such as the dryer room and packaging areas. Your manufacturing facility must be constructed in a manner such does not become a source of potential contamination to your animal food.\u003C\u002Fp>\u003Cp>C. Your Food Safety Plan dated January 9, 2024, documents your process control for \u003Cem>Salmonella\u003C\u002Fem> spp. at the Storage of Liquid Bulk Ingredients step for chicken fat is to \u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\u003Cp>i. You did not document the \u003Cstrong>(b)(4)\u003C\u002Fstrong> process control applied to your chicken fat prior to January 13, 2024, which demonstrates you did not effectively implement your process control. Your \u003Cstrong>(b)(4)\u003C\u002Fstrong> Log (SOP-5800F-\u003Cstrong>(b)(4)\u003C\u002Fstrong>), documents that from January 13 through February 4, 2024, you did not routinely \u003Cstrong>(b)(4)\u003C\u002Fstrong> in accordance with the validation study you provided for this process. The target \u003Cstrong>(b)(4)\u003C\u002Fstrong> listed as a parameter in on the \u003Cstrong>(b)(4)\u003C\u002Fstrong> Log is \u003Cstrong>(b)(4)\u003C\u002Fstrong>, and your records document that you \u003Cstrong>(b)(4)\u003C\u002Fstrong> to \u003Cstrong>(b)(4)\u003C\u002Fstrong> of \u003Cstrong>(b)(4)\u003C\u002Fstrong> truckloads of fat received from January 13 through February 4, 2024.\u003C\u002Fp>\u003Cp>ii. You did not document that the \u003Cstrong>(b)(4)\u003C\u002Fstrong> process control of \u003Cstrong>(b)(4)\u003C\u002Fstrong> was applied to your chicken fat until January 29, 2024. You produced approximately \u003Cstrong>(b)(4)\u003C\u002Fstrong> pounds of Victor Brand Dog Food using this fat from January 13, 2024, to January 28, 2024.\u003C\u002Fp>\u003Cp>\u003Cu>Evaluation of your response:\u003C\u002Fu>\u003Cbr>A. Your response dated January 10, 2024, documents that you updated your Master Sanitation schedule, updated sanitation standard operating procedures, and provided training to your employees. In addition, your response provided a timeline of the steps you took in response to the recalls, which included hiring a consultant and voluntarily closing your facility in November 2023 to perform deep cleaning and implement corrections. However, you did not provide records that document your new sanitation programs are implemented and we were unable to evaluate your corrections. In addition, FDA Investigators observed sanitation deficiencies persisted through the January to February 2024 inspection. Your response dated March 4, 2024, stated, “our programs have been, and are, effective for controlling \u003Cem>Salmonella\u003C\u002Fem> contamination both in finished product, as well as within the facility.” However, sampling conducted by FDA Investigators and by your employees as part of your finished product and environmental testing indicates \u003Cem>Salmonella\u003C\u002Fem> continued to persist in your facility. For example, FDA Investigators found \u003Cem>Salmonella\u003C\u002Fem> in 40 of 100 environmental swabs taken November 2, 2023, of which 17 positive swabs were from the extrusion or post-extrusion areas. In addition, FDA Investigators collected additional environmental swabs from the extrusion and post-extrusion areas on January 25, 2024, three of which were positive for \u003Cem>Salmonella\u003C\u002Fem> and genetically related to seven swabs collected during FDA’s 2023 inspection. Finally, you provided copies of your updated Master Sanitation Schedule, sanitation standard operating procedures, training records, and limited sanitation records (December 22, 2023, and January 4 and 31, 2024) in your response dated March 4, 2024. We are unable to fully evaluate your corrections from these limited records and will verify the status of your corrections during the next inspection. We encourage you to provide us with documentation of implementation of your corrections in follow-up correspondence.\u003C\u002Fp>\u003Cp>B. Your response dated July 10, 2024, provided invoices from a roofing company including roof repairs and installing a \u003Cstrong>(b)(4)\u003C\u002Fstrong>. We will verify the status of these corrective actions during the next inspection.\u003C\u002Fp>\u003Cp>C. Your response dated March 4, 2024, stated that since January 13, 2024, you have updated your procedure and now \u003Cstrong>(b)(4)\u003C\u002Fstrong> to each new truckload of chicken fat you receive. After \u003Cstrong>(b)(4)\u003C\u002Fstrong>, you stated you \u003Cstrong>(b)(4)\u003C\u002Fstrong>. You stated in your response that you are installing \u003Cstrong>(b)(4)\u003C\u002Fstrong> that will \u003Cstrong>(b)(4)\u003C\u002Fstrong>, have retrained employees, and provided temperature monitoring documents during the FDA inspection. However, you did not demonstrate that your \u003Cstrong>(b)(4)\u003C\u002Fstrong> is appropriately calculated to \u003Cstrong>(b)(4)\u003C\u002Fstrong> required to achieve a \u003Cstrong>(b)(4)\u003C\u002Fstrong> reduction of \u003Cem>Salmonella\u003C\u002Fem> in accordance with the validation study you provided. The target concentration listed as a parameter in on the \u003Cstrong>(b)(4)\u003C\u002Fstrong> Log is \u003Cstrong>(b)(4)\u003C\u002Fstrong>, and your records document that you \u003Cstrong>(b)(4)\u003C\u002Fstrong> to \u003Cstrong>(b)(4)\u003C\u002Fstrong> of \u003Cstrong>(b)(4)\u003C\u002Fstrong> truckloads of chicken fat received from January 13 through February 4, 2024. Therefore, we are unable to fully evaluate your corrections and will verify the status of your corrections during the next inspection. We encourage you to provide us with documentation of implementation of your corrections in follow-up correspondence.\u003C\u002Fp>\u003Cp>2. You did not take appropriate corrective action when a preventive control, combination of preventive controls, or the food safety plan as a whole was found to be ineffective, as required by 21 CFR 507.42(b)(1)(ii), in order to identify and correct the problem, reduce the likelihood that the problem will recur, evaluate all affected animal food for safety, and when appropriate, reanalyze the food safety plan as required by 507.42(b)(2).\u003C\u002Fp>\u003Cp>A. Specifically, your Food Safety Plan, dated January 9, 2024, documents your sanitation control for \u003Cem>Salmonella\u003C\u002Fem> spp. in post-extrusion processing environments requires environmental monitoring. Your “Environmental Monitoring Program,” (EMP) (SOP-3525), dated November 22, 2023, documents “[s]ince all finished products are tested using \u003Cstrong>(b)(4)\u003C\u002Fstrong> sampling and testing for \u003Cem>Salmonella\u003C\u002Fem>, the EMP will not include Zone \u003Cstrong>(b)(4)\u003C\u002Fstrong> pathogen testing. It is generally accepted that finished product pathogen testing substitute [sic] for Zone \u003Cstrong>(b)(4)\u003C\u002Fstrong> pathogen testing.” Seventeen of the finished product lots you collected between the dates of December 20, 2023, and January 29, 2024, were positive for \u003Cem>Salmonella\u003C\u002Fem>. Ten of these \u003Cem>Salmonella\u003C\u002Fem>-positive samples were collected after you ceased manufacturing to conduct intensive cleaning and sanitation operations from December 23 through 25, 2023. In addition, you collected one additional \u003Cem>Salmonella\u003C\u002Fem>-positive sample on January 29, 2024, after you ceased manufacturing to conduct intensive cleaning and sanitation operations from January 10, 2024, to January 12, 2024.\u003C\u002Fp>\u003Cp>Finished product testing is the only verification procedure of effective implementation for the following of your preventive controls: \u003Cstrong>(b)(4)\u003C\u002Fstrong> process control, zone \u003Cstrong>(b)(4)\u003C\u002Fstrong> sanitation control, and extruder \u003Cstrong>(b)(4)\u003C\u002Fstrong> process control. You could not provide Investigators documentation demonstrating you conducted any root cause analyses to determine which of your preventive controls may have failed when samples from your finished product tested positive for \u003Cem>Salmonella\u003C\u002Fem> spp. Furthermore, you did not assess the food safety impact the affected finished product lots may have had on shared equipment prior to distributing subsequent lots made on the shared equipment in interstate commerce.\u003C\u002Fp>\u003Cp>B. Your “Environmental Monitoring Program (EMP)” SOP, (SOP-3525), dated November 22, 2023, documents you will “assess the impact of the [\u003Cem>Salmonella\u003C\u002Fem>] positive on the finished products (for zone \u003Cstrong>(b)(4)\u003C\u002Fstrong> positives only)” and collect a minimum of \u003Cstrong>(b)(4)\u003C\u002Fstrong> “vector swabs” before and after sanitation, \u003Cstrong>(b)(4)\u003C\u002Fstrong> of which will be the original positive site. However, you failed to collect the required minimum \u003Cstrong>(b)(4)\u003C\u002Fstrong> “vector swabs” before and after sanitation (including the original Salmonella positive site), and assess the impact of Salmonella positive environmental positives on the finished product on the following occasions:\u003C\u002Fp>\u003Cp>i. On December 21, 2023, you received \u003Cem>Salmonella\u003C\u002Fem>-positive environmental sampling results for sample “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” from a swab you collected on December 17, 2023, from “\u003Cstrong>(b)(4)\u003C\u002Fstrong> Dryer Zone \u003Cstrong>(b)(4)\u003C\u002Fstrong> South west \u003Cstrong>(b)(4)\u003C\u002Fstrong> door.” Your environmental monitoring program SOP documents that you will collect a minimum of \u003Cstrong>(b)(4)\u003C\u002Fstrong> “vector swabs” before and after sanitation, \u003Cstrong>(b)(4)\u003C\u002Fstrong> of which will be the original positive site. However, you only collected \u003Cstrong>(b)(4)\u003C\u002Fstrong> “vector swabs”, none of which included the original positive site. In addition, you did not assess the food safety impact on any of the finished product lots you manufactured between December 17, 2023, and December 21, 2023, when you conducted cleaning and re-testing of the environment in accordance with your environmental monitoring program SOP. Products manufactured during this time were released to interstate commerce.\u003C\u002Fp>\u003Cp>ii. On December 26, 2023, you received \u003Cem>Salmonella\u003C\u002Fem>-positive environmental sampling results for sample “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” from a swab you collected on December 21, 2023, from the zone \u003Cstrong>(b)(4)\u003C\u002Fstrong> above \u003Cstrong>(b)(4)\u003C\u002Fstrong> leading to \u003Cstrong>(b)(4)\u003C\u002Fstrong> underneath \u003Cstrong>(b)(4)\u003C\u002Fstrong> equipment and repair sign on \u003Cstrong>(b)(4)\u003C\u002Fstrong> dryer.” Your environmental monitoring program SOP documents that you will collect a minimum \u003Cstrong>(b)(4)\u003C\u002Fstrong> “vector swabs” before and after sanitation, \u003Cstrong>(b)(4)\u003C\u002Fstrong> of which will be the original positive site. However, you only collected \u003Cstrong>(b)(4)\u003C\u002Fstrong> “vector swabs”, none of which included the original positive site. In addition, you did not assess the food safety impact on any of the finished product lots you manufactured between December 21, 2023, and December 23, 2023, after which you ceased operations through December 26, 2023. Products manufactured during this time were released to interstate commerce.\u003C\u002Fp>\u003Cp>\u003Cu>Evaluation of your response:\u003C\u002Fu>\u003Cbr>Your response dated March 4, 2024, stated that you believe your programs are effective for controlling \u003Cem>Salmonella\u003C\u002Fem> both in the manufacturing environment and in finished product. Additionally, you provided documentation of your sanitation activities for the dates following the Salmonella-positive environmental and product samples and stated that you have updated your procedures to require a root cause analysis for each positive event and would supplement your response with updated root cause analyses with an expected completion in four to eight weeks. Your response dated July 10, 2024, included copies of examples of your facility’s corrective actions when \u003Cem>Salmonella\u003C\u002Fem> is found through your environmental monitoring program. However, your root cause analysis does not consider how you will reduce the likelihood the problem will recur. Additionally, we cannot evaluate your investigation into possibly affected animal food due to illegible documents regarding product testing. Therefore, we are unable to fully evaluate your corrections and will verify the status of your corrections during the next inspection. We encourage you to provide us with documentation of implementation of your corrections in follow-up correspondence.\u003C\u002Fp>\u003Cp>\u003Cu>Conclusion\u003C\u002Fu>\u003Cbr>This letter is not intended to be an all-inclusive statement of violations that may exist at your facility or in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law and FDA regulations.\u003C\u002Fp>\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. You should take prompt action to correct the violations cited in this letter. Failure to adequately address this matter may lead to legal action, including, without limitation, seizure, and injunction.\u003C\u002Fp>\u003Cp>For more information about FDA’s current thinking on the requirements of 21 CFR Part 507, see:\u003C\u002Fp>\u003Cul>\u003Cli>Guidance for Industry #235: “Current Good Manufacturing Practice Requirements for Food for Animals”, \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F97464\u002Fdownload\">https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F97464\u002Fdownload\u003C\u002Fa>\u003C\u002Fli>\u003Cli>Guidance for Industry #245: “Hazard Analysis and Risk-Based Preventive Controls for Food for Animals”, \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F110477\u002Fdownload\">https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F110477\u002Fdownload\u003C\u002Fa>\u003C\u002Fli>\u003Cli>Draft Guidance for Industry #246: “Hazard Analysis and Risk-Based Preventive Controls for Food for Animals: Supply Chain Program”, \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F113923\u002Fdownload\">https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F113923\u002Fdownload\u003C\u002Fa>\u003C\u002Fli>\u003C\u002Ful>\u003Cp>Within fifteen working days of receipt of this letter, please notify this office in writing of the specific steps you have taken to correct any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective action within fifteen working days, state the reason for the delay and the time within which you will complete the correction. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\u003Cp>In the interest of administrative efficiency, fiscal responsibility, and environmental awareness, the Food &amp; Drug Administration, Center for Veterinary Medicine, Office of Surveillance and Compliance is encouraging electronic submission of correspondence. In support of our efforts, we offer facilities the opportunity to submit all correspondence in electronic format up to 100 megabytes. Files greater than 100 megabytes may be submitted as smaller files in separate emails. There is no need to provide a back-up hard copy of any documentation you submit electronically. If you submit electronic correspondence, please ensure that the facility name, establishment identifier (FEI), and inspection location are included in the correspondence. An electronic acknowledgement will be issued upon receipt of your email. Please direct your electronic correspondence to CVMAnimalFoodCompliance@fda.hhs.gov and copy Compliance Officer Jessica Nanini (jessica.nanini@fda.hhs.gov). Including both email addresses will ensure your correspondence is routed as quickly as possible to the appropriate Agency personnel.\u003C\u002Fp>\u003Cp>If you are unable to submit your correspondence electronically, please direct it to the attention of Compliance Officer Jessica D. Nanini at the following address:\u003C\u002Fp>\u003Cp>United States Food &amp; Drug Administration\u003Cbr>Center for Veterinary Medicine\u003Cbr>Office of Surveillance and Compliance\u003Cbr>MPN 2, Room E436\u003Cbr>12225 Wilkins Avenue\u003Cbr>Rockville, Maryland 20852\u003C\u002Fp>\u003Cp>If you have questions regarding this letter, please contact Compliance Officer Jessica D. Nanini by telephone at (443) 280-1276, or by email at jessica.nanini@fda.hhs.gov.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Isaac K. Carney\u003Cbr>Director, Division of Food Compliance\u003Cbr>Office of Surveillance and Compliance\u003Cbr>Center for Veterinary Medicine\u003C\u002Fp>\u003Cp>Cc:\u003Cbr>Mary Sasser, Program Director\u003Cbr>Office of the Texas State Chemist\u003Cbr>445 Agronomy Road\u003Cbr>College Station, Texas 77843\u003C\u002Fp>\u003Cp>Lorey Bell Grady, Feed Safety Program Manager\u003Cbr>South Carolina Department of Agriculture\u003Cbr>123 Ballard Court\u003Cbr>West Columbia, South Carolina 29172\u003C\u002Fp>\u003Cp>____________________\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> Centers for Disease Control and Prevention, Investigation Details Salmonella Outbreak Linked to Dry Dog Food, https:\u002F\u002Fwww.cdc.gov\u002Fsalmonella\u002Foutbreaks\u002Fdog-food-10-23\u002Finvestigation.html\u003Cbr>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> See section 402(a)(1) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) [21 U.S.C. § 342(a)(1)].\u003Cbr>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem> See section 402(a)(4) of the FD&amp;C Act [21 U.S.C. § 342(a)(4)] and 21 CFR 507.1(a)(1)(ii).\u003Cbr>\u003Cem>\u003Cstrong>4\u003C\u002Fstrong>\u003C\u002Fem> See section 301(a) of the FD&amp;C Act [21 U.S.C. § 331(a)].\u003Cbr>\u003Cem>\u003Cstrong>5\u003C\u002Fstrong>\u003C\u002Fem> See section 301(uu) of the FD&amp;C Act [21 U.S.C. § 331(uu)].&nbsp;\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA Electronic Mail\n\nProduct:\n\nAnimal & Veterinary\nFood & Beverages\n\nRecipient:\n\nRecipient Name\n\nJeff Caswell\n\nRecipient Title\n\nChief Executive Officer\n\nMid America Pet Food LLC\n\n2024 N. Frontage Road\n\nMount Pleasant, TX 75455-6474\n\nUnited States\n\nIssuing Office:\n\nCenter for Veterinary Medicine\n\nUnited States\n\nWARNING LETTER\nCMS# 681516\nNovember 22, 2024\nDear Mr. Caswell:\nThe U.S. Food and Drug Administration (FDA) inspected your pet food manufacturing facility located at 2024 N. Frontage Road, Mount Pleasant, Texas from November 2, 2023, through December 18, 2023. FDA also conducted a subsequent inspection from January 23, 2024, through February 9, 2024, at this facility. We received your responses dated January 10, 2024; March 4, 2024; and July 10, 2024, to the FDA 483 Inspectional Observations. FDA conducted the 2023 inspection in response to your voluntary Class I recalls initiated on September 3, 2023, expanded on October 30, 2023, and further expanded on November 9, 2023, to include all your dog and cat food with best by dates before October 31, because they had the potential to be contaminated with Salmonella. In addition, FDA conducted the 2023 inspection as part of an investigation, along with the Centers for Disease Control (CDC) and state and local partners, into a multi-state foodborne illness outbreak of Salmonella Kiambu implicated in human illnesses through epidemiological traceback.1 A total of seven people from seven states were infected with the outbreak strain from January 14, 2023 to August 19, 2023, and one person was hospitalized. Six of the affected people were children under one year of age. Salmonella can affect animals eating the products, and there is risk to humans from handling contaminated pet products and utensils that came into contact with the affected pet products. Children, the elderly, and individuals with compromised immune systems may be at greater risk for Salmonella infection.\nThese illnesses were linked by whole genome sequencing to dog food manufactured at your facility in 2023 through a sample of Victor Super Premium Dog Food Classic Hi-Pro Plus (lot 1000016385; Best By 4\u002F30\u002F24) collected by the South Carolina Department of Agriculture on August 15, 2023, which you recalled on September 3, 2023. On October 30, 2023, you expanded your initial recall to include Victor Super Premium Dog Food, Select Beef Meal & Brown Rice Formula with best by dates of June 12, 2024 (5 lbs. lot 1000016890; 15 lbs. lot 1000016891; and 40 lbs. lot 1000016892). On November 9, 2023, you expanded your recall to include all products with best by dates before October 31, 2024, because your testing revealed the presence of Salmonella Kiambu in a lot for which you reported receiving a consumer complaint involving human illness. Based on analytical results, FDA considers the Victor Super Premium Dog Food Classic Hi-Pro Plus (lot 1000016385; Best By 4\u002F30\u002F24)lot to be adulterated in that it bears or contains a poisonous or deleterious substance which may render it injurious to health.2\nFDA collected environmental samples (i.e., swabs) from surfaces in your manufacturing facility during this inspection and a subsequent inspection, conducted from January 23, 2024, through February 9, 2024, in response to a consumer complaint. Analysis of these samples using whole genome sequencing revealed that three of the Salmonella-positive environmental swabs collected in the post-process area of your facility during the 2024 inspection are closely related to seven Salmonella-positive environmental swabs collected in the pre-process areas of your facility during the 2023 inspection, indicating that your facility may have three resident strains of Salmonella: Salmonella Rissen, Salmonella Minnesota, and Salmonella Mbandaka.\nDuring these inspections FDA Investigators found evidence of significant violations of the Current Good Manufacturing Practice, Hazard Analysis, and Risk-Based Preventive Controls for Food for Animals requirements in Title 21, Code of Federal Regulations, Part 507 (21 CFR Part 507), which cause your products to be adulterated in that they were prepared, packed, or held under insanitary conditions whereby they may have become contaminated with filth, or whereby they may have been rendered injurious to health.3 Additionally, the introduction or delivery for introduction into interstate commerce of any food that is adulterated is a prohibited act.4 Furthermore, the failure of the owner, operator, or agent in charge of a covered facility to comply with the preventive controls provisions of 21 CFR 507 (located in subparts A, C, D, E, and F of Part 507) is a prohibited act.5 You may find the FD&C Act and FDA’s regulations through links on the FDA’s website at www.fda.gov.\nAt the conclusion of our inspections on December 18, 2023, and February 9, 2024, you were issued two separate Forms FDA 483, Inspectional Observations. We received your written responses to these observations dated January 10, 2024, March 4, 2024, and July 10, 2024, and address your corrective actions below, in relation to each of the noted violations.\nHazard Analysis and Risk-Based Preventive Controls Requirements\nYour animal food facility is subject to the hazard analysis and risk-based preventive controls requirements found in 21 CFR Part 507, subparts A, C, D, E, and F. During the inspection of your facility, the FDA Investigators obtained evidence of significant violations of these requirements, which included:\n1. You did not identify and implement a preventive control to provide assurances that any hazards requiring a preventive control will be significantly minimized or prevented, as required by 21 CFR 507.34(a)(1).\nSpecifically, your hazard analysis determined the hazard of Salmonella requires preventive controls and identified sanitation and process controls to control the hazard of Salmonella in your finished pet food.\nA. Your Food Safety Plan dated January 9, 2024, documents your sanitation control for Salmonella spp. in post-extrusion processing environments by removing residual material on post-extruder surfaces and applying sanitizer in accordance with the sanitizer label. However, you failed to adequately implement your sanitation control.\ni. You use (b)(4) as a sanitizer for food-contact equipment and utensils. Your “(b)(4) Procedure” (SOP 1500) standard operating procedure (SOP), dated December 5, 2023, documents, “Surfaces must remain thoroughly wetted for (b)(4) followed by adequate draining and air drying . . . [a]llow the identified surface to air dry before the manufacturing process can resume, or the identified surface is reintroduced for use.” Furthermore, the label for (b)(4) documents “treated surfaces must remain wet for at least (b)(4) followed by adequate draining and air drying” for food-processing equipment and food-contact surfaces. On January 30, 2024, FDA Investigators observed an employee designated to the post-extrusion area cleaning food-contact equipment who used (b)(4) to sanitize the equipment and then immediately dried the surface of the equipment with a paper towel. During this cleaning, the equipment made direct contact with the employee’s clothing which was visibly soiled with apparent dog food.\nii. Your “Housekeeping Procedure” (CGMP 2800),” dated February 2, 2022, documents that the sanitation lead employee write their initials on sanitation records to document their inspection and review of sanitation activities on the Master Cleaning Schedule. Your Master Cleaning Schedule, “Housekeeping #5” for December 2023 does not document (b)(4) cleaning for the discharge hoppers located in the packaging area for the entire month of December 2023.\nIn addition, there were multiple instances of other equipment and areas where you did not document sanitation activities in accordance with your Master Cleaning Schedule in April 2023, May 2023, June 2023, September 2023, December 2023, and January 2024.\niii. On January 26, 2024, FDA Investigators observed visible debris on food-contact surfaces of equipment such as brushes, brooms, and squeegees after cleaning and sanitizing of equipment was performed by your third-party sanitation service. In addition, you could not produce any sanitation records for July and August of 2023 and your records for April 2023 and May 2023 were incomplete. Your lack of complete records in addition to the ineffective cleaning observed by Investigators demonstrates your failure to implement your sanitation preventive control.\nB. Your Food Safety Plan dated January 9, 2024, documents “CGMP controls” to minimize the hazard of Salmonella spp. in post-extrusion processing environments.\ni. On January 23, 2024, FDA Investigators observed rainwater entering your facility through the roof while you were manufacturing multiple lots of dog food. FDA Investigators observed standing water and soaked absorbent pads in staging, production, and finished product areas, including in post-process areas such as the dryer room and packaging areas. Your manufacturing facility must be constructed in a manner such does not become a source of potential contamination to your animal food.\nC. Your Food Safety Plan dated January 9, 2024, documents your process control for Salmonella spp. at the Storage of Liquid Bulk Ingredients step for chicken fat is to (b)(4) and (b)(4).\ni. You did not document the (b)(4) process control applied to your chicken fat prior to January 13, 2024, which demonstrates you did not effectively implement your process control. Your (b)(4) Log (SOP-5800F-(b)(4)), documents that from January 13 through February 4, 2024, you did not routinely (b)(4) in accordance with the validation study you provided for this process. The target (b)(4) listed as a parameter in on the (b)(4) Log is (b)(4), and your records document that you (b)(4) to (b)(4) of (b)(4) truckloads of fat received from January 13 through February 4, 2024.\nii. You did not document that the (b)(4) process control of (b)(4) was applied to your chicken fat until January 29, 2024. You produced approximately (b)(4) pounds of Victor Brand Dog Food using this fat from January 13, 2024, to January 28, 2024.\nEvaluation of your response:\nA. Your response dated January 10, 2024, documents that you updated your Master Sanitation schedule, updated sanitation standard operating procedures, and provided training to your employees. In addition, your response provided a timeline of the steps you took in response to the recalls, which included hiring a consultant and voluntarily closing your facility in November 2023 to perform deep cleaning and implement corrections. However, you did not provide records that document your new sanitation programs are implemented and we were unable to evaluate your corrections. In addition, FDA Investigators observed sanitation deficiencies persisted through the January to February 2024 inspection. Your response dated March 4, 2024, stated, “our programs have been, and are, effective for controlling Salmonella contamination both in finished product, as well as within the facility.” However, sampling conducted by FDA Investigators and by your employees as part of your finished product and environmental testing indicates Salmonella continued to persist in your facility. For example, FDA Investigators found Salmonella in 40 of 100 environmental swabs taken November 2, 2023, of which 17 positive swabs were from the extrusion or post-extrusion areas. In addition, FDA Investigators collected additional environmental swabs from the extrusion and post-extrusion areas on January 25, 2024, three of which were positive for Salmonella and genetically related to seven swabs collected during FDA’s 2023 inspection. Finally, you provided copies of your updated Master Sanitation Schedule, sanitation standard operating procedures, training records, and limited sanitation records (December 22, 2023, and January 4 and 31, 2024) in your response dated March 4, 2024. We are unable to fully evaluate your corrections from these limited records and will verify the status of your corrections during the next inspection. We encourage you to provide us with documentation of implementation of your corrections in follow-up correspondence.\nB. Your response dated July 10, 2024, provided invoices from a roofing company including roof repairs and installing a (b)(4). We will verify the status of these corrective actions during the next inspection.\nC. Your response dated March 4, 2024, stated that since January 13, 2024, you have updated your procedure and now (b)(4) to each new truckload of chicken fat you receive. After (b)(4), you stated you (b)(4). You stated in your response that you are installing (b)(4) that will (b)(4), have retrained employees, and provided temperature monitoring documents during the FDA inspection. However, you did not demonstrate that your (b)(4) is appropriately calculated to (b)(4) required to achieve a (b)(4) reduction of Salmonella in accordance with the validation study you provided. The target concentration listed as a parameter in on the (b)(4) Log is (b)(4), and your records document that you (b)(4) to (b)(4) of (b)(4) truckloads of chicken fat received from January 13 through February 4, 2024. Therefore, we are unable to fully evaluate your corrections and will verify the status of your corrections during the next inspection. We encourage you to provide us with documentation of implementation of your corrections in follow-up correspondence.\n2. You did not take appropriate corrective action when a preventive control, combination of preventive controls, or the food safety plan as a whole was found to be ineffective, as required by 21 CFR 507.42(b)(1)(ii), in order to identify and correct the problem, reduce the likelihood that the problem will recur, evaluate all affected animal food for safety, and when appropriate, reanalyze the food safety plan as required by 507.42(b)(2).\nA. Specifically, your Food Safety Plan, dated January 9, 2024, documents your sanitation control for Salmonella spp. in post-extrusion processing environments requires environmental monitoring. Your “Environmental Monitoring Program,” (EMP) (SOP-3525), dated November 22, 2023, documents “[s]ince all finished products are tested using (b)(4) sampling and testing for Salmonella, the EMP will not include Zone (b)(4) pathogen testing. It is generally accepted that finished product pathogen testing substitute [sic] for Zone (b)(4) pathogen testing.” Seventeen of the finished product lots you collected between the dates of December 20, 2023, and January 29, 2024, were positive for Salmonella. Ten of these Salmonella-positive samples were collected after you ceased manufacturing to conduct intensive cleaning and sanitation operations from December 23 through 25, 2023. In addition, you collected one additional Salmonella-positive sample on January 29, 2024, after you ceased manufacturing to conduct intensive cleaning and sanitation operations from January 10, 2024, to January 12, 2024.\nFinished product testing is the only verification procedure of effective implementation for the following of your preventive controls: (b)(4) process control, zone (b)(4) sanitation control, and extruder (b)(4) process control. You could not provide Investigators documentation demonstrating you conducted any root cause analyses to determine which of your preventive controls may have failed when samples from your finished product tested positive for Salmonella spp. Furthermore, you did not assess the food safety impact the affected finished product lots may have had on shared equipment prior to distributing subsequent lots made on the shared equipment in interstate commerce.\nB. Your “Environmental Monitoring Program (EMP)” SOP, (SOP-3525), dated November 22, 2023, documents you will “assess the impact of the [Salmonella] positive on the finished products (for zone (b)(4) positives only)” and collect a minimum of (b)(4) “vector swabs” before and after sanitation, (b)(4) of which will be the original positive site. However, you failed to collect the required minimum (b)(4) “vector swabs” before and after sanitation (including the original Salmonella positive site), and assess the impact of Salmonella positive environmental positives on the finished product on the following occasions:\ni. On December 21, 2023, you received Salmonella-positive environmental sampling results for sample “(b)(4)” from a swab you collected on December 17, 2023, from “(b)(4) Dryer Zone (b)(4) South west (b)(4) door.” Your environmental monitoring program SOP documents that you will collect a minimum of (b)(4) “vector swabs” before and after sanitation, (b)(4) of which will be the original positive site. However, you only collected (b)(4) “vector swabs”, none of which included the original positive site. In addition, you did not assess the food safety impact on any of the finished product lots you manufactured between December 17, 2023, and December 21, 2023, when you conducted cleaning and re-testing of the environment in accordance with your environmental monitoring program SOP. Products manufactured during this time were released to interstate commerce.\nii. On December 26, 2023, you received Salmonella-positive environmental sampling results for sample “(b)(4)” from a swab you collected on December 21, 2023, from the zone (b)(4) above (b)(4) leading to (b)(4) underneath (b)(4) equipment and repair sign on (b)(4) dryer.” Your environmental monitoring program SOP documents that you will collect a minimum (b)(4) “vector swabs” before and after sanitation, (b)(4) of which will be the original positive site. However, you only collected (b)(4) “vector swabs”, none of which included the original positive site. In addition, you did not assess the food safety impact on any of the finished product lots you manufactured between December 21, 2023, and December 23, 2023, after which you ceased operations through December 26, 2023. Products manufactured during this time were released to interstate commerce.\nEvaluation of your response:\nYour response dated March 4, 2024, stated that you believe your programs are effective for controlling Salmonella both in the manufacturing environment and in finished product. Additionally, you provided documentation of your sanitation activities for the dates following the Salmonella-positive environmental and product samples and stated that you have updated your procedures to require a root cause analysis for each positive event and would supplement your response with updated root cause analyses with an expected completion in four to eight weeks. Your response dated July 10, 2024, included copies of examples of your facility’s corrective actions when Salmonella is found through your environmental monitoring program. However, your root cause analysis does not consider how you will reduce the likelihood the problem will recur. Additionally, we cannot evaluate your investigation into possibly affected animal food due to illegible documents regarding product testing. Therefore, we are unable to fully evaluate your corrections and will verify the status of your corrections during the next inspection. We encourage you to provide us with documentation of implementation of your corrections in follow-up correspondence.\nConclusion\nThis letter is not intended to be an all-inclusive statement of violations that may exist at your facility or in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law and FDA regulations.\nThis letter notifies you of our concerns and provides you an opportunity to address them. You should take prompt action to correct the violations cited in this letter. Failure to adequately address this matter may lead to legal action, including, without limitation, seizure, and injunction.\nFor more information about FDA’s current thinking on the requirements of 21 CFR Part 507, see:\nGuidance for Industry #235: “Current Good Manufacturing Practice Requirements for Food for Animals”, https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F97464\u002Fdownload\nGuidance for Industry #245: “Hazard Analysis and Risk-Based Preventive Controls for Food for Animals”, https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F110477\u002Fdownload\nDraft Guidance for Industry #246: “Hazard Analysis and Risk-Based Preventive Controls for Food for Animals: Supply Chain Program”, https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F113923\u002Fdownload\nWithin fifteen working days of receipt of this letter, please notify this office in writing of the specific steps you have taken to correct any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective action within fifteen working days, state the reason for the delay and the time within which you will complete the correction. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration.\nIn the interest of administrative efficiency, fiscal responsibility, and environmental awareness, the Food & Drug Administration, Center for Veterinary Medicine, Office of Surveillance and Compliance is encouraging electronic submission of correspondence. In support of our efforts, we offer facilities the opportunity to submit all correspondence in electronic format up to 100 megabytes. Files greater than 100 megabytes may be submitted as smaller files in separate emails. There is no need to provide a back-up hard copy of any documentation you submit electronically. If you submit electronic correspondence, please ensure that the facility name, establishment identifier (FEI), and inspection location are included in the correspondence. An electronic acknowledgement will be issued upon receipt of your email. Please direct your electronic correspondence to CVMAnimalFoodCompliance@fda.hhs.gov and copy Compliance Officer Jessica Nanini (jessica.nanini@fda.hhs.gov). Including both email addresses will ensure your correspondence is routed as quickly as possible to the appropriate Agency personnel.\nIf you are unable to submit your correspondence electronically, please direct it to the attention of Compliance Officer Jessica D. Nanini at the following address:\nUnited States Food & Drug Administration\nCenter for Veterinary Medicine\nOffice of Surveillance and Compliance\nMPN 2, Room E436\n12225 Wilkins Avenue\nRockville, Maryland 20852\nIf you have questions regarding this letter, please contact Compliance Officer Jessica D. Nanini by telephone at (443) 280-1276, or by email at jessica.nanini@fda.hhs.gov.\nSincerely,\n\u002FS\u002F\nIsaac K. Carney\nDirector, Division of Food Compliance\nOffice of Surveillance and Compliance\nCenter for Veterinary Medicine\nCc:\nMary Sasser, Program Director\nOffice of the Texas State Chemist\n445 Agronomy Road\nCollege Station, Texas 77843\nLorey Bell Grady, Feed Safety Program Manager\nSouth Carolina Department of Agriculture\n123 Ballard Court\nWest Columbia, South Carolina 29172\n____________________\n1 Centers for Disease Control and Prevention, Investigation Details Salmonella Outbreak Linked to Dry Dog Food, https:\u002F\u002Fwww.cdc.gov\u002Fsalmonella\u002Foutbreaks\u002Fdog-food-10-23\u002Finvestigation.html\n2 See section 402(a)(1) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) [21 U.S.C. § 342(a)(1)].\n3 See section 402(a)(4) of the FD&C Act [21 U.S.C. § 342(a)(4)] and 21 CFR 507.1(a)(1)(ii).\n4 See section 301(a) of the FD&C Act [21 U.S.C. § 331(a)].\n5 See section 301(uu) of the FD&C Act [21 U.S.C. § 331(uu)].","Mid America Pet Food LLC","mid-america-pet-food-llc-681516-11222024","2026-08-18T06:42:28.856152+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fmid-america-pet-food-llc-681516-11222024","2026-10-26T08:09:24.969178+00:00","Closed Out","2024-12-10","681516","Animal & VeterinaryFood & Beverages","2025-08-28","Jeff Caswell","2026-08-19T17:39:53.894+00:00","VIA Electronic Mail","2024-11-22",{"id":79,"raw":80,"subject":87,"body_html":88,"body_text":89,"firm_name":90,"letter_id":91,"created_at":92,"fei_number":19,"letter_url":93,"updated_at":94,"action_type":22,"case_status":69,"posted_date":95,"marcs_cms_no":96,"product_type":48,"closeout_date":97,"issuing_office":84,"recipient_name":98,"body_fetched_at":99,"delivery_method":76,"recipient_title":19,"reference_number":19,"action_taken_date":95,"medical_device_id":19,"response_letter_date":19},3572,[81,82,83,84,85,13,86,13],"\u003Ctime datetime=\"2021-01-27T20:45:00Z\">01\u002F27\u002F2021\u003C\u002Ftime>\n","\u003Ctime datetime=\"2021-01-27T05:00:00Z\">01\u002F27\u002F2021\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fprofessional-compounding-centers-america-dba-pcca-597638-01272021\">Professional Compounding Centers of America dba PCCA\u003C\u002Fa>","Center for Drug Evaluation and Research | CDER","CGMP\u002FFinished Pharmaceuticals\u002FAdulterated\u002FMisbranded\u003Cbr \u002F>\r\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fprofessional-compounding-centers-america-dba-pcca-597638-11212023-0\">\u003Ctime datetime=\"2023-12-01T05:00:00Z\">12\u002F01\u002F2023\u003C\u002Ftime>\n\u003C\u002Fa>","CGMP\u002FFinished Pharmaceuticals\u002FAdulterated\u002FMisbranded","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Fabian V. Zaccardo\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Chief Operating Officer\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Professional Compounding Centers of America dba PCCA\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>9901 South Wilcrest Drive\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Houston\u003C\u002Fspan>, \u003Cspan>TX\u003C\u002Fspan> \u003Cspan>77099-5132\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research | CDER\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>Warning Letter 320-21-15\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>\u003Cbr>\nJanuary 27, 2021\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>AMENDED\u003C\u002Fstrong>\u003Cbr>\n(This letter replaces Warning Letter No. 320-21-15 dated January 7, 2021)\u003C\u002Fp>\n\n\u003Cp>\u003Cbr>\nDear Mr. Zaccardo:\u003C\u002Fp>\n\n\u003Cp>The U.S. Food and Drug Administration (FDA) inspected your drug manufacturing facility, Professional Compounding Centers of America, Inc. (PCCA), FEI 1629694, at 9901 South Wilcrest Drive, Houston, Texas from October 22 to 29, 2019.\u003C\u002Fp>\n\n\u003Cp>This warning letter summarizes significant violations, including deviations from current good manufacturing practice (CGMP) for active pharmaceutical ingredients (API). CGMP violations identified at your suppliers caused drugs manufactured by these firms to be adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act). Your receipt in interstate commerce of adulterated drugs and the delivery or proffered delivery thereof, is a violation of section 301(c) of the FD&amp;C Act, 21 U.S.C. 331(c).\u003C\u002Fp>\n\n\u003Cp>Additionally, your glycerin United States Pharmacopeia (USP) product is adulterated under section 501(b) of the FD&amp;C Act, 21 U.S.C. 351(b), for failure to conform to compendial standards for identity, strength, quality, or purity. Your glycerin USP product is also misbranded under section 502(e)(3)(B) and (g) of the FD&amp;C Act because it fails to meet the applicable USP standard of identity. Furthermore, because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your glycerin API is adulterated within the meaning of section 501(a)(2)(B) of FD&amp;C Act, 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\n\n\u003Cp>Finally, your drug products tramadol HCl, fentanyl citrate, buprenorphine HCl and morphine sulfate are misbranded under section 502(a) of the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>We reviewed your November 19, 2019, response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence.\u003C\u002Fp>\n\n\u003Cp>During our inspection, our investigator observed specific violations and deviations including, but not limited to, the following.\u003Cbr>\n\u003Cbr>\n\u003Cstrong>Receipt of Adulterated Drugs\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your receipt in interstate commerce of adulterated drugs (i.e., those listed on an import alert) and the delivery or proffered delivery thereof, is a violation of section 301(c) of the FD&amp;C Act, 21 U.S.C. 331(c).\u003C\u002Fp>\n\n\u003Cp>Our inspection and review of import data revealed your firm received \u003Cstrong>(b)(4)\u003C\u002Fstrong>&nbsp;from \u003Cstrong>(b)(4)\u003C\u002Fstrong>, FEI \u003Cstrong>(b)(4)\u003C\u002Fstrong>, on July 30, 2018. An inspection of \u003Cstrong>(b)(4)\u003C\u002Fstrong>&nbsp;in \u003Cstrong>(b)(4)\u003C\u002Fstrong> revealed significant CGMP deviations including sourcing drugs from a firm that refused an FDA inspection, destruction of batch records in a \u003Cstrong>(b)(4)\u003C\u002Fstrong>, and \u003Cstrong>(b)(4)\u003C\u002Fstrong> on product contact surfaces. As a result of these and other deviations, all drugs manufactured by \u003Cstrong>(b)(4)\u003C\u002Fstrong>, were listed on Import Alert 66-40 (IA 66-40) on \u003Cstrong>(b)(4)\u003C\u002Fstrong>, and the firm was issued a warning letter on \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003Csup>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> All drugs from \u003Cstrong>(b)(4)\u003C\u002Fstrong>. remain listed on IA 66-40 at this time.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Other Drug Suppliers in Your Supply Chain with a History of Non-Compliance\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>We note that an inspection of records at your facility and a review of FDA import data demonstrated that FDA has, in the past, taken regulatory action against at least 23 of your other API suppliers for the manufacture of adulterated drugs under section 501 of the FD&amp;C Act by either listing their drugs on import alert and\u002For issuing them warning letters. Drugs from multiple API suppliers used by PCCA were listed on an import alert, including IA 66-40 for the supplier’s failure to conform to CGMP within the meaning of section 501(a)(2)(B) and Import Alert 99-32 (IA 99-32) for the supplier’s conduct in delaying, denying, or limiting FDA inspections of foreign facilities or providing reasonable access to FDA's inspectional personnel. To understand whether PCCA has received or introduced additional adulterated drugs in interstate commerce, we are therefore requesting information regarding timing of receipt and distribution of drugs from the 23 facilities listed below.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>PCCA suppliers with drugs listed on Import Alert 66-40 for suppliers’ failure to comply with CGMP\u003C\u002Fem>\u003C\u002Fp>\n\n\u003Cp>1. \u003Cstrong>(b)(4)\u003C\u002Fstrong>, FEI \u003Cstrong>(b)(4)\u003C\u002Fstrong>, was issued a warning letter on \u003Cstrong>(b)(4)\u003C\u002Fstrong>, and all drugs from \u003Cstrong>(b)(4)\u003C\u002Fstrong> were listed on IA 66-40 on \u003Cstrong>(b)(4)\u003C\u002Fstrong>, for among other things, the firm’s failure to have procedures for change control, out-of-specification investigations, process deviation investigations, laboratory incidents and failure to validate the manufacturing process. FDA determined that this facility had adequately addressed the deviations and after \u003Cstrong>(b)(4)\u003C\u002Fstrong> the firm’s drugs were removed from IA 66-40. A Warning Letter Close Out (WLCO) letter was issued on \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\n\n\u003Cp>2. Drugs from \u003Cstrong>(b)(4)\u003C\u002Fstrong>, FEI \u003Cstrong>(b)(4)\u003C\u002Fstrong>, were listed on IA 66-40 on \u003Cstrong>(b)(4)\u003C\u002Fstrong>,\u003Csup>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> and the firm was issued a warning letter on \u003Cstrong>(b)(4)\u003C\u002Fstrong>, for among other things, \u003Cstrong>(b)(4)\u003C\u002Fstrong>. FDA determined the firm had adequately addressed the deviations on \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003Csup>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> The firm’s drug products were removed from IA 66-40 on \u003Cstrong>(b)(4)\u003C\u002Fstrong> and a WLCO letter was issued on \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\n\n\u003Cp>3. All drugs from \u003Cstrong>(b)(4)\u003C\u002Fstrong>, FEI \u003Cstrong>(b)(4)\u003C\u002Fstrong>, were listed on IA 66-40 on \u003Cstrong>(b)(4)\u003C\u002Fstrong>, and the firm was issued a warning letter on \u003Cstrong>(b)(4)\u003C\u002Fstrong>, for among other things, manipulating analytical data, including deleting chromatograms and retesting samples into compliance. All drugs from \u003Cstrong>(b)(4)\u003C\u002Fstrong>&nbsp;remain listed on IA 66-40 at this time.\u003C\u002Fp>\n\n\u003Cp>4. All drugs from \u003Cstrong>(b)(4)\u003C\u002Fstrong>, FEI \u003Cstrong>(b)(4)\u003C\u002Fstrong>, were listed on IA 66-40 on \u003Cstrong>(b)(4)\u003C\u002Fstrong>, and the firm was issued a warning letter on \u003Cstrong>(b)(4)\u003C\u002Fstrong>, for among other things, inadequate impurity testing, and lack of audit trails to support CGMP activities. FDA determined that the firm had adequately addressed the deviations on \u003Cstrong>(b)(4)\u003C\u002Fstrong>. A WLCO letter was issued on \u003Cstrong>(b)(4)\u003C\u002Fstrong> and the firm’s drug products were removed from IA 66-40 on \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\n\n\u003Cp>5. All drugs from \u003Cstrong>(b)(4)\u003C\u002Fstrong>, FEI \u003Cstrong>(b)(4)\u003C\u002Fstrong>, were listed on IA 66-40 on \u003Cstrong>(b)(4)\u003C\u002Fstrong>, and the firm was issued a warning letter on \u003Cstrong>(b)(4)\u003C\u002Fstrong>, for among other things, \u003Cstrong>(b)(4)\u003C\u002Fstrong>. All drugs from&nbsp;\u003Cstrong>(b)(4)\u003C\u002Fstrong>&nbsp;remain listed on IA 66-40 at this time.\u003C\u002Fp>\n\n\u003Cp>6. All drugs from \u003Cstrong>(b)(4)\u003C\u002Fstrong>, FEI \u003Cstrong>(b)(4)\u003C\u002Fstrong>, were listed on IA 66-40 on \u003Cstrong>(b)(4)\u003C\u002Fstrong>, and the firm was issued a warning letter on \u003Cstrong>(b)(4)\u003C\u002Fstrong>, for among other things, \u003Cstrong>(b)(4)\u003C\u002Fstrong>. All drugs from \u003Cstrong>(b)(4)\u003C\u002Fstrong>&nbsp;remain listed on IA 66-40 at this time.\u003C\u002Fp>\n\n\u003Cp>7. All drugs from \u003Cstrong>(b)(4)\u003C\u002Fstrong>, FEI \u003Cstrong>(b)(4)\u003C\u002Fstrong>, were listed on IA 66-40 on \u003Cstrong>(b)(4)\u003C\u002Fstrong>, and the firm was issued a warning letter on \u003Cstrong>(b)(4)\u003C\u002Fstrong>, for among other things, a failure to ensure that quality-related complaints are investigated and resolved. All drugs from \u003Cstrong>(b)(4)\u003C\u002Fstrong> remain listed on IA 66-40 at this time.\u003C\u002Fp>\n\n\u003Cp>8. All drugs from \u003Cstrong>(b)(4)\u003C\u002Fstrong>, FEI \u003Cstrong>(b)(4)\u003C\u002Fstrong>, were listed on IA 66-40 on \u003Cstrong>(b)(4)\u003C\u002Fstrong>. All drugs from \u003Cstrong>(b)(4)\u003C\u002Fstrong> remain listed on IA 66-40 at this time.\u003C\u002Fp>\n\n\u003Cp>For manufacturers whose drugs are listed on IA 66-40 for failure to conform to CGMP within the meaning of section 501(a)(2)(B), FDA has evidence that the drugs listed in the import alert appear to be adulterated. You are responsible for ensuring that the drugs you distribute are manufactured in compliance with all relevant CGMP requirements for drugs. Up to date information regarding import alerts can be found at the following FDA website: \u003Ca href=\"https:\u002F\u002Fwww.accessdata.fda.gov\u002Fcms_ia\u002Fialist.html\">https:\u002F\u002Fwww.accessdata.fda.gov\u002Fcms_ia\u002Fialist.html\u003C\u002Fa>\u003C\u002Fp>\n\n\u003Cp>\u003Cem>PCCA suppliers with drugs listed on Import Alert 99-32 for Delaying, Denying, Limiting, or Refusing an FDA Drug Inspection\u003C\u002Fem>\u003C\u002Fp>\n\n\u003Cp>9. All drugs from \u003Cstrong>(b)(4)\u003C\u002Fstrong>, FEI \u003Cstrong>(b)(4)\u003C\u002Fstrong>, were listed on IA 99-32 on \u003Cstrong>(b)(4)\u003C\u002Fstrong>, due to the firm’s denying FDA’s attempt to schedule a pre-announced inspection. All drugs from \u003Cstrong>(b)(4)\u003C\u002Fstrong> remain listed on IA 99-32 at this time.\u003C\u002Fp>\n\n\u003Cp>10. All drugs from \u003Cstrong>(b)(4)\u003C\u002Fstrong>, FEI \u003Cstrong>(b)(4)\u003C\u002Fstrong>, were listed on IA 99-32 on \u003Cstrong>(b)(4)\u003C\u002Fstrong>, due to the firm’s denying FDA’s attempt to schedule a pre-announced inspection. All drugs from \u003Cstrong>(b)(4)\u003C\u002Fstrong> remain listed on IA 99-32 at this time.\u003C\u002Fp>\n\n\u003Cp>11. All drugs from \u003Cstrong>(b)(4)\u003C\u002Fstrong>, FEI \u003Cstrong>(b)(4)\u003C\u002Fstrong>, were listed on IA 99-32 on \u003Cstrong>(b)(4)\u003C\u002Fstrong>, due to the firm’s denying FDA’s attempt to schedule a pre-announced inspection. All drugs from \u003Cstrong>(b)(4)\u003C\u002Fstrong> remain listed on IA 99-32 at this time.\u003C\u002Fp>\n\n\u003Cp>12. All drugs from \u003Cstrong>(b)(4)\u003C\u002Fstrong>, FEI \u003Cstrong>(b)(4)\u003C\u002Fstrong>, were listed on IA 99-32 on \u003Cstrong>(b)(4)\u003C\u002Fstrong>, due to the firm’s delaying and ultimately denying an inspection. All drugs from \u003Cstrong>(b)(4)\u003C\u002Fstrong> remain listed on IA 99-32 at this time.\u003C\u002Fp>\n\n\u003Cp>13. All drugs from \u003Cstrong>(b)(4)\u003C\u002Fstrong>, FEI: \u003Cstrong>(b)(4)\u003C\u002Fstrong>, were listed on IA 99-32 on \u003Cstrong>(b)(4)\u003C\u002Fstrong>, due to the firm’s refusing to accept proposed inspection dates. All drugs from \u003Cstrong>(b)(4)\u003C\u002Fstrong> remain listed on IA 99-32 at this time.\u003C\u002Fp>\n\n\u003Cp>14. All drugs from \u003Cstrong>(b)(4)\u003C\u002Fstrong>, FEI \u003Cstrong>(b)(4)\u003C\u002Fstrong>, were listed on IA 99-32 on \u003Cstrong>(b)(4)\u003C\u002Fstrong>, due to the firm’s denying FDA’s attempt to schedule a pre-announced inspection. All drugs from \u003Cstrong>(b)(4)\u003C\u002Fstrong> remain listed on IA 99-32 at this time.\u003C\u002Fp>\n\n\u003Cp>15. All drugs from \u003Cstrong>(b)(4)\u003C\u002Fstrong>, FEI \u003Cstrong>(b)(4)\u003C\u002Fstrong>, were listed on IA 99-32 on \u003Cstrong>(b)(4)\u003C\u002Fstrong>, due to the firm’s denying FDA’s attempt to schedule a pre-announced inspection. All drugs from \u003Cstrong>(b)(4)\u003C\u002Fstrong> remain listed on IA 99-32 at this time.\u003C\u002Fp>\n\n\u003Cp>16. All drugs from \u003Cstrong>(b)(4)\u003C\u002Fstrong>, FEI \u003Cstrong>(b)(4)\u003C\u002Fstrong>, were listed on IA 99-32 on \u003Cstrong>(b)(4)\u003C\u002Fstrong>, due to the firm’s denying FDA’s attempt to schedule a pre-announced inspection. All drugs from \u003Cstrong>(b)(4)\u003C\u002Fstrong> remain listed on IA 99-32 at this time.\u003C\u002Fp>\n\n\u003Cp>17. All drugs from \u003Cstrong>(b)(4)\u003C\u002Fstrong>, FEI \u003Cstrong>(b)(4)\u003C\u002Fstrong>, were listed on IA 99-32 on \u003Cstrong>(b)(4)\u003C\u002Fstrong>, due to the firm’s delaying and ultimately denying an inspection. All drugs from \u003Cstrong>(b)(4)&nbsp;\u003C\u002Fstrong>remain listed on IA 99-32 at this time.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>PCCA suppliers that received warning letters not otherwise listed above\u003C\u002Fem>\u003C\u002Fp>\n\n\u003Cp>18. \u003Cstrong>(b)(4)\u003C\u002Fstrong>, FEI \u003Cstrong>(b)(4)\u003C\u002Fstrong>, was issued a warning letter on \u003Cstrong>(b)(4)\u003C\u002Fstrong>, for among other things, \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\n\n\u003Cp>19. \u003Cstrong>(b)(4)\u003C\u002Fstrong>, FEI \u003Cstrong>(b)(4)\u003C\u002Fstrong>, was issued a warning letter on \u003Cstrong>(b)(4)\u003C\u002Fstrong>, for among other things, \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Furthermore, buildings used in the production of API were observed to contain \u003Cstrong>(b)(4)\u003C\u002Fstrong>, and \u003Cstrong>(b)(4)\u003C\u002Fstrong> material on the floors. On \u003Cstrong>(b)(4)\u003C\u002Fstrong>, FDA determined that the firm had adequately addressed the deviations contained in that warning letter, and a WLCO letter was issued.\u003C\u002Fp>\n\n\u003Cp>20. \u003Cstrong>(b)(4)\u003C\u002Fstrong>, FEI \u003Cstrong>(b)(4)\u003C\u002Fstrong>, was issued a warning letter on \u003Cstrong>(b)(4)\u003C\u002Fstrong>, for among other things, failure to ensure cleaning practices were adequate to prevent contamination on shared equipment used for API manufacture.\u003C\u002Fp>\n\n\u003Cp>21. \u003Cstrong>(b)(4)\u003C\u002Fstrong>, FEI \u003Cstrong>(b)(4)\u003C\u002Fstrong>, was issued a warning letter on \u003Cstrong>(b)(4)\u003C\u002Fstrong>, for among other things, inadequate investigation of failing test results, and failure to maintain complete data for API tested and distributed to the United States. This warning letter also noted that similar CGMP deficiencies were cited in earlier inspections of the firm, and that the recurring deviations demonstrate that the facility’s oversight and control over the manufacture of drugs is inadequate.\u003C\u002Fp>\n\n\u003Cp>22. \u003Cstrong>(b)(4)\u003C\u002Fstrong>, FEI \u003Cstrong>(b)(4)\u003C\u002Fstrong>, was issued a warning letter on \u003Cstrong>(b)(4)\u003C\u002Fstrong>, for among other things, \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\n\n\u003Cp>23. \u003Cstrong>(b)(4)\u003C\u002Fstrong>, FEI \u003Cstrong>(b)(4)\u003C\u002Fstrong>, was issued a warning letter on \u003Cstrong>(b)(4)\u003C\u002Fstrong>, for among other things, \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide the lot numbers and dates of distribution for all drugs received from each facility listed above. Include the identity of PCCA’s customers who received drugs from the facilities listed above, and whether you distributed the drugs from a listed facility during the time period after the aforementioned warning letters and\u002For import alerts were issued and before a close-out letter was issued and\u002For the firm’s drugs were removed from the import alert. For lots of drug product API received and distributed by PCCA during the relevant time frame, include whether you have notified your customers that they received adulterated drugs from PCCA. If you have not notified any customer who received adulterated drug API from PCCA, notify them, and provide a copy of that notification in your response.\u003C\u002Fp>\n\n\u003Cp>Considering that FDA has found a pattern of drug manufacturers with serious CGMP or other adulteration violations in your supply chain, in response to this letter, also provide a detailed plan to ensure you do not receive or deliver adulterated drugs in interstate commerce, in violation of section 301(c) of the FD&amp;C Act, 21 U.S.C. 331(c). Items in your plan should include a full evaluation of your supplier program, including a plan to audit your suppliers. Furthermore, you should also include a full reconciliation of any drugs from the manufacturers listed above, as well as for all firms or drugs currently on FDA import alerts, to determine if you have any remaining drugs in your possession. Up to date information regarding import alerts can be found at the following FDA website: \u003Ca href=\"https:\u002F\u002Fwww.accessdata.fda.gov\u002Fcms_ia\u002Fialist.html\">https:\u002F\u002Fwww.accessdata.fda.gov\u002Fcms_ia\u002Fialist.html\u003C\u002Fa>\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Adulteration and Misbranding of Glycerin API\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>You repackage glycerin USP and distribute this drug to your customers which include pharmacy compounders. Repackaged glycerin intended as an excipient or other component of a drug product is a drug as defined by section 201(g)(1) the FD&amp;C Act, 21 U.S.C. 321(g)(1). Glycerin is also a drug the name of which is recognized in an official compendium (the USP).\u003Csup>\u003Cem>\u003Cstrong>4\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> A drug with a name recognized in USP–NF must comply with compendial identity standards or be deemed adulterated, misbranded, or both. Sections 501(b) and 502(e)(3)(B) and (g) of the FD&amp;C Act, 21 U.S.C. 351(b), 352(e)(3)(B); see also 21 CFR 299.5(a) and (b). In such cases, the identity is determined by the official tests, procedures and acceptance criteria in the applicable USP-NF monograph. USP-NF General Notices 2.30. Furthermore, in accordance with section 501(a)(2)(B) of the FD&amp;C Act, 21 U.S.C. 351(a)(2)(B), a drug is adulterated “if the methods used in, or the facilities or controls used for, its manufacture, processing, packing, or holding do not conform to or are not operated or administered in conformity with current good manufacturing practice to assure that such drug meets the requirements of this chapter as to safety and has the identity and strength, and meets the quality and purity characteristics, which it purports or is represented to possess.”\u003C\u002Fp>\n\n\u003Cp>FDA compared the testing required in the identification section of the USP monograph for glycerin with PCCA analytical test results, which reference the USP method, and determined the testing for identity of glycerin conducted by PCCA was incomplete and therefore was not adequate to assure that your glycerin conformed to the compendial standards of identity. \u003Cstrong>(b)(4)\u003C\u002Fstrong>. While your \u003Cstrong>(b)(4)\u003C\u002Fstrong> test using \u003Cstrong>(b)(4)\u003C\u002Fstrong> can identify glycerin, it is not an adequate test for detecting DEG and EG in glycerin at USP specified limits. Therefore, you failed to conduct adequate identity testing for glycerin USP and your glycerin drug product is adulterated and misbranded within the meaning of sections 501(b), 501(a)(2)(B), and 502(e)(3)(b) and (g) of the FD&amp;C Act, 21 U.S.C. 351(b), 351(a)(2)(B), and 352(e)(3)(B) and (g), in that you do not have test data to demonstrate its identity meets the standards set forth in an official compendium (the USP) recognized in the FD&amp;C Act. See also 21 CFR 299.5(a) and (b).\u003Csup>\u003Cem>\u003Cstrong>5\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup>\u003C\u002Fp>\n\n\u003Cp>Your response stated that your firm has complied with the regulatory requirement because your firm performed identity testing on each lot prior to release. You further stated that each lot had been previously tested by the manufacturer prior to receipt by your firm. You note that during the initial supplier qualification, you tested the purchased glycerin using a third-party laboratory. You also stated in your response that with your efforts to “know (its) supply chain for glycerin, PCCA is confident that its supply of glycerin is free from DEG contamination.” Moving forward, you committed to requalify your supplier on an \u003Cstrong>(b)(4)\u003C\u002Fstrong> basis. You further stated that you believe that you do not need to test your incoming glycerin for the presence of DEG and EG impurities as it is “superfluous, and simply not required.”\u003C\u002Fp>\n\n\u003Cp>Your response is inadequate because the test you perform for identity on the bulk glycerin that you repackage cannot determine if a batch of glycerin is adulterated with DEG and EG contaminants and does not conform to the identification section of the applicable USP monograph. You cannot ensure the quality and security of the supply chain with regard to DEG and EG adulteration given your current practice because you do not independently verify that the API manufacturer’s reports are reliable through adequate identity testing consistent with the applicable USP monograph upon receipt. Reliability of a supplier is generally established by the receiving entity’s own testing which, when compared to the supplier’s data, shows agreement within the specified limits over a period of time. Periodic monitoring is also generally necessary in order to assure the continued reliability of a supplier’s test results. Relying solely on the manufacturer’s COA is not adequate to comply with applicable requirements as described above. Although, in your response to FDA’s 483, PCCA does commit to re-qualifying its supplier of glycerin on an \u003Cstrong>(b)(4)\u003C\u002Fstrong> basis, it is unclear whether PCCA will verify the API supplier’s COA as part of that \u003Cstrong>(b)(4)\u003C\u002Fstrong> qualification process using an adequate identity test that meets applicable standards.\u003C\u002Fp>\n\n\u003Cp>FDA has received reports about fatal DEG poisoning of consumers who ingested medicinal syrups, such as cough syrup or acetaminophen syrup, that were manufactured with DEG-contaminated glycerin. Historical DEG-related poisonings and fatalities stemmed from multiple violative practices in the glycerin supply chain, including manufacturers not conducting full and adequate identity testing; manufacturers relying on COAs; and COAs, such as those you provide with your glycerin and other drugs, not providing the name of the true manufacturer and thus masking the chain of custody of an adulterated product.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide the following:\u003C\u002Fp>\n\n\u003Cp>• An update regarding implementation of DEG and EG testing for all lots of glycerin.\u003C\u002Fp>\n\n\u003Cp>• A detailed risk assessment for drug products distributed by your firm that contain glycerin and are within expiry in the U.S. market.\u003C\u002Fp>\n\n\u003Cp>• Test reserve samples of all lots of glycerin for DEG and EG with the test method and provide test results.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Misbranding Due to False or Misleading Labeling of Drug Products\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Under section 502(a) of the FD&amp;C Act, a drug is misbranded if its label is “false or misleading in any particular.” Further, 21 CFR 201.1(h)(2) specifies that “The appearance on a drug product label of a person's name without qualification is a representation that the named person is the sole manufacturer of the product. That representation is false and misleading, and the drug product is misbranded under section 502(a) of the [FD&amp;C] act, if the person is not the manufacturer of the product in accordance with this section.”\u003C\u002Fp>\n\n\u003Cp>The labels your firm affixed to the following repackaged\u002Frelabeled API identify PCCA, but do not designate your firm’s role:\u003C\u002Fp>\n\n\u003Cp>• tramadol HCl (lot # C191954);\u003Cbr>\n• fentanyl citrate (lot # C189348);\u003Cbr>\n• buprenorphine HCl (lot # C191213); and,\u003Cbr>\n• morphine sulfate (lot # C192769).\u003C\u002Fp>\n\n\u003Cp>Evidence collected during the inspection of your facility establishes that other firms were involved in the manufacturing of these API. Because these API labels bear only the PCCA name without further qualifications, the labels falsely represent that PCCA is the sole drug manufacturer. Therefore, these repackaged\u002Frelabeled API are misbranded under section 502(a) of the FD&amp;C Act because the labels are false and misleading.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Regulatory Meeting\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Upon submission of your response to this letter, email CDR John W. Diehl, Director, Compliance Branch, FDA\u002FORA\u002FOPQO Division II, at John.Diehl@fda.hhs.gov to schedule a meeting to discuss the adequacy of the corrective actions you proposed to prevent the continued introduction of adulterated and misbranded goods into interstate commerce. Topics of the regulatory meeting will also include supply chain controls and compliance with CGMP.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>The deviations and violations cited in this letter are not intended to be an all-inclusive list of deviations and violations that exist at your facility. You are responsible for investigating and determining the causes of any deviations and violations and for preventing their recurrence or the occurrence of other violations and deviations.\u003C\u002Fp>\n\n\u003Cp>If you are considering an action that is likely to lead to a disruption in the supply of drugs produced at your facility, FDA requests that you contact CDER’s Drug Shortages Staff immediately, at drugshortages@fda.hhs.gov, so that FDA can work with you on the most effective way to bring your operations into compliance with the law. Contacting the Drug Shortages Staff also allows you to meet any obligations you may have to report discontinuances or interruptions in your drug manufacture under 21 U.S.C. 356C(b). This also allows FDA to consider, as soon as possible, what actions, if any, may be needed to avoid shortages and protect the health of patients who depend on your products.\u003Cbr>\nProfessional Compounding Centers of America, Inc., Houston FEI: 1629694 Page 9\u003C\u002Fp>\n\n\u003Cp>Failure to promptly address these deviations and violations may result in legal action without further notice including, without limitation, seizure and injunction. Other Federal agencies may take your compliance history into account when awarding contracts.\u003C\u002Fp>\n\n\u003Cp>Failure to address violations of FD&amp;C Act sections may be cause for FDA to withhold issuance of Export Certificates and may be cause for FDA to withhold approval of new applications or supplements listing your firm as a drug manufacturer. We may re-inspect to verify that you have completed your corrective actions.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done since our inspection to address any deviations and violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot completely address deviations and violations within 15 working days, state your reasons for delay and your schedule for completion.\u003C\u002Fp>\n\n\u003Cp>Please identify your response with FEI 1629694 and Case # 597638. Send your electronic reply to Monica R. Maxwell, Program Division Director, FDA\u002FORA\u002FOPQO Division II at ORAPharm2_Responses@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>If you have any questions concerning the letter, please direct those to CDR Diehl at \u003Cspan>(214) 253-5288\u003Ca>\u003C\u002Fa>\u003C\u002Fspan> or john.diehl@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Alonza Cruse\u003Cbr>\nDirector\u003Cbr>\nOffice of Pharmaceutical Quality Operations\u003Cbr>\nOffice of Medical Products and Tobacco Operations&nbsp;\u003Cbr>\nOffice of Regulatory Affairs\u003C\u002Fp>\n\n\u003Cp>\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Francis Godwin\u003Cbr>\nDirector\u003Cbr>\nOffice of Manufacturing Quality\u003Cbr>\nOffice of Compliance\u003Cbr>\nCenter for Drug Evaluation and Research\u003C\u002Fp>\n\n\u003Cp>___________________________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> Products from \u003Cstrong>(b)(4)\u003C\u002Fstrong>, FEI \u003Cstrong>(b)(4)\u003C\u002Fstrong>, have also been placed on IA 66-40 because that facility ships products manufactured at FEI \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> Certain drugs were carved out due to shortage concerns.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem> Throughout this letter, where applicable, we have provided the date of the memorandum documenting FDA’s internal determination that a firm’s deviations were adequately addressed prior to the final removal of the firm’s products from import alert.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>4\u003C\u002Fstrong>\u003C\u002Fem> USP Glycerin monograph, Document ID: GUID-6A5A5AD2-0762-4830-8E99-D593E5400FF0_4_en-US\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>5\u003C\u002Fstrong>\u003C\u002Fem> See the identity test for glycerin included in the USP Monograph for glycerin, supra note 1\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA Electronic Mail\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nMr. Fabian V. Zaccardo\n\nRecipient Title\n\nChief Operating Officer\n\nProfessional Compounding Centers of America dba PCCA\n\n9901 South Wilcrest Drive\n\nHouston, TX 77099-5132\n\nUnited States\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research | CDER\n\nUnited States\n\nWarning Letter 320-21-15\n\nJanuary 27, 2021\n\nAMENDED\n\n(This letter replaces Warning Letter No. 320-21-15 dated January 7, 2021)\n\nDear Mr. Zaccardo:\n\nThe U.S. Food and Drug Administration (FDA) inspected your drug manufacturing facility, Professional Compounding Centers of America, Inc. (PCCA), FEI 1629694, at 9901 South Wilcrest Drive, Houston, Texas from October 22 to 29, 2019.\n\nThis warning letter summarizes significant violations, including deviations from current good manufacturing practice (CGMP) for active pharmaceutical ingredients (API). CGMP violations identified at your suppliers caused drugs manufactured by these firms to be adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act). Your receipt in interstate commerce of adulterated drugs and the delivery or proffered delivery thereof, is a violation of section 301(c) of the FD&C Act, 21 U.S.C. 331(c).\n\nAdditionally, your glycerin United States Pharmacopeia (USP) product is adulterated under section 501(b) of the FD&C Act, 21 U.S.C. 351(b), for failure to conform to compendial standards for identity, strength, quality, or purity. Your glycerin USP product is also misbranded under section 502(e)(3)(B) and (g) of the FD&C Act because it fails to meet the applicable USP standard of identity. Furthermore, because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your glycerin API is adulterated within the meaning of section 501(a)(2)(B) of FD&C Act, 21 U.S.C. 351(a)(2)(B).\n\nFinally, your drug products tramadol HCl, fentanyl citrate, buprenorphine HCl and morphine sulfate are misbranded under section 502(a) of the FD&C Act.\n\nWe reviewed your November 19, 2019, response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence.\n\nDuring our inspection, our investigator observed specific violations and deviations including, but not limited to, the following.\n\nReceipt of Adulterated Drugs\n\nYour receipt in interstate commerce of adulterated drugs (i.e., those listed on an import alert) and the delivery or proffered delivery thereof, is a violation of section 301(c) of the FD&C Act, 21 U.S.C. 331(c).\n\nOur inspection and review of import data revealed your firm received (b)(4) from (b)(4), FEI (b)(4), on July 30, 2018. An inspection of (b)(4) in (b)(4) revealed significant CGMP deviations including sourcing drugs from a firm that refused an FDA inspection, destruction of batch records in a (b)(4), and (b)(4) on product contact surfaces. As a result of these and other deviations, all drugs manufactured by (b)(4), were listed on Import Alert 66-40 (IA 66-40) on (b)(4), and the firm was issued a warning letter on (b)(4).1 All drugs from (b)(4). remain listed on IA 66-40 at this time.\n\nOther Drug Suppliers in Your Supply Chain with a History of Non-Compliance\n\nWe note that an inspection of records at your facility and a review of FDA import data demonstrated that FDA has, in the past, taken regulatory action against at least 23 of your other API suppliers for the manufacture of adulterated drugs under section 501 of the FD&C Act by either listing their drugs on import alert and\u002For issuing them warning letters. Drugs from multiple API suppliers used by PCCA were listed on an import alert, including IA 66-40 for the supplier’s failure to conform to CGMP within the meaning of section 501(a)(2)(B) and Import Alert 99-32 (IA 99-32) for the supplier’s conduct in delaying, denying, or limiting FDA inspections of foreign facilities or providing reasonable access to FDA's inspectional personnel. To understand whether PCCA has received or introduced additional adulterated drugs in interstate commerce, we are therefore requesting information regarding timing of receipt and distribution of drugs from the 23 facilities listed below.\n\nPCCA suppliers with drugs listed on Import Alert 66-40 for suppliers’ failure to comply with CGMP\n\n1. (b)(4), FEI (b)(4), was issued a warning letter on (b)(4), and all drugs from (b)(4) were listed on IA 66-40 on (b)(4), for among other things, the firm’s failure to have procedures for change control, out-of-specification investigations, process deviation investigations, laboratory incidents and failure to validate the manufacturing process. FDA determined that this facility had adequately addressed the deviations and after (b)(4) the firm’s drugs were removed from IA 66-40. A Warning Letter Close Out (WLCO) letter was issued on (b)(4).\n\n2. Drugs from (b)(4), FEI (b)(4), were listed on IA 66-40 on (b)(4),2 and the firm was issued a warning letter on (b)(4), for among other things, (b)(4). FDA determined the firm had adequately addressed the deviations on (b)(4).3 The firm’s drug products were removed from IA 66-40 on (b)(4) and a WLCO letter was issued on (b)(4).\n\n3. All drugs from (b)(4), FEI (b)(4), were listed on IA 66-40 on (b)(4), and the firm was issued a warning letter on (b)(4), for among other things, manipulating analytical data, including deleting chromatograms and retesting samples into compliance. All drugs from (b)(4) remain listed on IA 66-40 at this time.\n\n4. All drugs from (b)(4), FEI (b)(4), were listed on IA 66-40 on (b)(4), and the firm was issued a warning letter on (b)(4), for among other things, inadequate impurity testing, and lack of audit trails to support CGMP activities. FDA determined that the firm had adequately addressed the deviations on (b)(4). A WLCO letter was issued on (b)(4) and the firm’s drug products were removed from IA 66-40 on (b)(4).\n\n5. All drugs from (b)(4), FEI (b)(4), were listed on IA 66-40 on (b)(4), and the firm was issued a warning letter on (b)(4), for among other things, (b)(4). All drugs from (b)(4) remain listed on IA 66-40 at this time.\n\n6. All drugs from (b)(4), FEI (b)(4), were listed on IA 66-40 on (b)(4), and the firm was issued a warning letter on (b)(4), for among other things, (b)(4). All drugs from (b)(4) remain listed on IA 66-40 at this time.\n\n7. All drugs from (b)(4), FEI (b)(4), were listed on IA 66-40 on (b)(4), and the firm was issued a warning letter on (b)(4), for among other things, a failure to ensure that quality-related complaints are investigated and resolved. All drugs from (b)(4) remain listed on IA 66-40 at this time.\n\n8. All drugs from (b)(4), FEI (b)(4), were listed on IA 66-40 on (b)(4). All drugs from (b)(4) remain listed on IA 66-40 at this time.\n\nFor manufacturers whose drugs are listed on IA 66-40 for failure to conform to CGMP within the meaning of section 501(a)(2)(B), FDA has evidence that the drugs listed in the import alert appear to be adulterated. You are responsible for ensuring that the drugs you distribute are manufactured in compliance with all relevant CGMP requirements for drugs. Up to date information regarding import alerts can be found at the following FDA website: https:\u002F\u002Fwww.accessdata.fda.gov\u002Fcms_ia\u002Fialist.html\n\nPCCA suppliers with drugs listed on Import Alert 99-32 for Delaying, Denying, Limiting, or Refusing an FDA Drug Inspection\n\n9. All drugs from (b)(4), FEI (b)(4), were listed on IA 99-32 on (b)(4), due to the firm’s denying FDA’s attempt to schedule a pre-announced inspection. All drugs from (b)(4) remain listed on IA 99-32 at this time.\n\n10. All drugs from (b)(4), FEI (b)(4), were listed on IA 99-32 on (b)(4), due to the firm’s denying FDA’s attempt to schedule a pre-announced inspection. All drugs from (b)(4) remain listed on IA 99-32 at this time.\n\n11. All drugs from (b)(4), FEI (b)(4), were listed on IA 99-32 on (b)(4), due to the firm’s denying FDA’s attempt to schedule a pre-announced inspection. All drugs from (b)(4) remain listed on IA 99-32 at this time.\n\n12. All drugs from (b)(4), FEI (b)(4), were listed on IA 99-32 on (b)(4), due to the firm’s delaying and ultimately denying an inspection. All drugs from (b)(4) remain listed on IA 99-32 at this time.\n\n13. All drugs from (b)(4), FEI: (b)(4), were listed on IA 99-32 on (b)(4), due to the firm’s refusing to accept proposed inspection dates. All drugs from (b)(4) remain listed on IA 99-32 at this time.\n\n14. All drugs from (b)(4), FEI (b)(4), were listed on IA 99-32 on (b)(4), due to the firm’s denying FDA’s attempt to schedule a pre-announced inspection. All drugs from (b)(4) remain listed on IA 99-32 at this time.\n\n15. All drugs from (b)(4), FEI (b)(4), were listed on IA 99-32 on (b)(4), due to the firm’s denying FDA’s attempt to schedule a pre-announced inspection. All drugs from (b)(4) remain listed on IA 99-32 at this time.\n\n16. All drugs from (b)(4), FEI (b)(4), were listed on IA 99-32 on (b)(4), due to the firm’s denying FDA’s attempt to schedule a pre-announced inspection. All drugs from (b)(4) remain listed on IA 99-32 at this time.\n\n17. All drugs from (b)(4), FEI (b)(4), were listed on IA 99-32 on (b)(4), due to the firm’s delaying and ultimately denying an inspection. All drugs from (b)(4) remain listed on IA 99-32 at this time.\n\nPCCA suppliers that received warning letters not otherwise listed above\n\n18. (b)(4), FEI (b)(4), was issued a warning letter on (b)(4), for among other things, (b)(4).\n\n19. (b)(4), FEI (b)(4), was issued a warning letter on (b)(4), for among other things, (b)(4). Furthermore, buildings used in the production of API were observed to contain (b)(4), and (b)(4) material on the floors. On (b)(4), FDA determined that the firm had adequately addressed the deviations contained in that warning letter, and a WLCO letter was issued.\n\n20. (b)(4), FEI (b)(4), was issued a warning letter on (b)(4), for among other things, failure to ensure cleaning practices were adequate to prevent contamination on shared equipment used for API manufacture.\n\n21. (b)(4), FEI (b)(4), was issued a warning letter on (b)(4), for among other things, inadequate investigation of failing test results, and failure to maintain complete data for API tested and distributed to the United States. This warning letter also noted that similar CGMP deficiencies were cited in earlier inspections of the firm, and that the recurring deviations demonstrate that the facility’s oversight and control over the manufacture of drugs is inadequate.\n\n22. (b)(4), FEI (b)(4), was issued a warning letter on (b)(4), for among other things, (b)(4).\n\n23. (b)(4), FEI (b)(4), was issued a warning letter on (b)(4), for among other things, (b)(4).\n\nIn response to this letter, provide the lot numbers and dates of distribution for all drugs received from each facility listed above. Include the identity of PCCA’s customers who received drugs from the facilities listed above, and whether you distributed the drugs from a listed facility during the time period after the aforementioned warning letters and\u002For import alerts were issued and before a close-out letter was issued and\u002For the firm’s drugs were removed from the import alert. For lots of drug product API received and distributed by PCCA during the relevant time frame, include whether you have notified your customers that they received adulterated drugs from PCCA. If you have not notified any customer who received adulterated drug API from PCCA, notify them, and provide a copy of that notification in your response.\n\nConsidering that FDA has found a pattern of drug manufacturers with serious CGMP or other adulteration violations in your supply chain, in response to this letter, also provide a detailed plan to ensure you do not receive or deliver adulterated drugs in interstate commerce, in violation of section 301(c) of the FD&C Act, 21 U.S.C. 331(c). Items in your plan should include a full evaluation of your supplier program, including a plan to audit your suppliers. Furthermore, you should also include a full reconciliation of any drugs from the manufacturers listed above, as well as for all firms or drugs currently on FDA import alerts, to determine if you have any remaining drugs in your possession. Up to date information regarding import alerts can be found at the following FDA website: https:\u002F\u002Fwww.accessdata.fda.gov\u002Fcms_ia\u002Fialist.html\n\nAdulteration and Misbranding of Glycerin API\n\nYou repackage glycerin USP and distribute this drug to your customers which include pharmacy compounders. Repackaged glycerin intended as an excipient or other component of a drug product is a drug as defined by section 201(g)(1) the FD&C Act, 21 U.S.C. 321(g)(1). Glycerin is also a drug the name of which is recognized in an official compendium (the USP).4 A drug with a name recognized in USP–NF must comply with compendial identity standards or be deemed adulterated, misbranded, or both. Sections 501(b) and 502(e)(3)(B) and (g) of the FD&C Act, 21 U.S.C. 351(b), 352(e)(3)(B); see also 21 CFR 299.5(a) and (b). In such cases, the identity is determined by the official tests, procedures and acceptance criteria in the applicable USP-NF monograph. USP-NF General Notices 2.30. Furthermore, in accordance with section 501(a)(2)(B) of the FD&C Act, 21 U.S.C. 351(a)(2)(B), a drug is adulterated “if the methods used in, or the facilities or controls used for, its manufacture, processing, packing, or holding do not conform to or are not operated or administered in conformity with current good manufacturing practice to assure that such drug meets the requirements of this chapter as to safety and has the identity and strength, and meets the quality and purity characteristics, which it purports or is represented to possess.”\n\nFDA compared the testing required in the identification section of the USP monograph for glycerin with PCCA analytical test results, which reference the USP method, and determined the testing for identity of glycerin conducted by PCCA was incomplete and therefore was not adequate to assure that your glycerin conformed to the compendial standards of identity. (b)(4). While your (b)(4) test using (b)(4) can identify glycerin, it is not an adequate test for detecting DEG and EG in glycerin at USP specified limits. Therefore, you failed to conduct adequate identity testing for glycerin USP and your glycerin drug product is adulterated and misbranded within the meaning of sections 501(b), 501(a)(2)(B), and 502(e)(3)(b) and (g) of the FD&C Act, 21 U.S.C. 351(b), 351(a)(2)(B), and 352(e)(3)(B) and (g), in that you do not have test data to demonstrate its identity meets the standards set forth in an official compendium (the USP) recognized in the FD&C Act. See also 21 CFR 299.5(a) and (b).5\n\nYour response stated that your firm has complied with the regulatory requirement because your firm performed identity testing on each lot prior to release. You further stated that each lot had been previously tested by the manufacturer prior to receipt by your firm. You note that during the initial supplier qualification, you tested the purchased glycerin using a third-party laboratory. You also stated in your response that with your efforts to “know (its) supply chain for glycerin, PCCA is confident that its supply of glycerin is free from DEG contamination.” Moving forward, you committed to requalify your supplier on an (b)(4) basis. You further stated that you believe that you do not need to test your incoming glycerin for the presence of DEG and EG impurities as it is “superfluous, and simply not required.”\n\nYour response is inadequate because the test you perform for identity on the bulk glycerin that you repackage cannot determine if a batch of glycerin is adulterated with DEG and EG contaminants and does not conform to the identification section of the applicable USP monograph. You cannot ensure the quality and security of the supply chain with regard to DEG and EG adulteration given your current practice because you do not independently verify that the API manufacturer’s reports are reliable through adequate identity testing consistent with the applicable USP monograph upon receipt. Reliability of a supplier is generally established by the receiving entity’s own testing which, when compared to the supplier’s data, shows agreement within the specified limits over a period of time. Periodic monitoring is also generally necessary in order to assure the continued reliability of a supplier’s test results. Relying solely on the manufacturer’s COA is not adequate to comply with applicable requirements as described above. Although, in your response to FDA’s 483, PCCA does commit to re-qualifying its supplier of glycerin on an (b)(4) basis, it is unclear whether PCCA will verify the API supplier’s COA as part of that (b)(4) qualification process using an adequate identity test that meets applicable standards.\n\nFDA has received reports about fatal DEG poisoning of consumers who ingested medicinal syrups, such as cough syrup or acetaminophen syrup, that were manufactured with DEG-contaminated glycerin. Historical DEG-related poisonings and fatalities stemmed from multiple violative practices in the glycerin supply chain, including manufacturers not conducting full and adequate identity testing; manufacturers relying on COAs; and COAs, such as those you provide with your glycerin and other drugs, not providing the name of the true manufacturer and thus masking the chain of custody of an adulterated product.\n\nIn response to this letter, provide the following:\n\n• An update regarding implementation of DEG and EG testing for all lots of glycerin.\n\n• A detailed risk assessment for drug products distributed by your firm that contain glycerin and are within expiry in the U.S. market.\n\n• Test reserve samples of all lots of glycerin for DEG and EG with the test method and provide test results.\n\nMisbranding Due to False or Misleading Labeling of Drug Products\n\nUnder section 502(a) of the FD&C Act, a drug is misbranded if its label is “false or misleading in any particular.” Further, 21 CFR 201.1(h)(2) specifies that “The appearance on a drug product label of a person's name without qualification is a representation that the named person is the sole manufacturer of the product. That representation is false and misleading, and the drug product is misbranded under section 502(a) of the [FD&C] act, if the person is not the manufacturer of the product in accordance with this section.”\n\nThe labels your firm affixed to the following repackaged\u002Frelabeled API identify PCCA, but do not designate your firm’s role:\n\n• tramadol HCl (lot # C191954);\n\n• fentanyl citrate (lot # C189348);\n\n• buprenorphine HCl (lot # C191213); and,\n\n• morphine sulfate (lot # C192769).\n\nEvidence collected during the inspection of your facility establishes that other firms were involved in the manufacturing of these API. Because these API labels bear only the PCCA name without further qualifications, the labels falsely represent that PCCA is the sole drug manufacturer. Therefore, these repackaged\u002Frelabeled API are misbranded under section 502(a) of the FD&C Act because the labels are false and misleading.\n\nRegulatory Meeting\n\nUpon submission of your response to this letter, email CDR John W. Diehl, Director, Compliance Branch, FDA\u002FORA\u002FOPQO Division II, at John.Diehl@fda.hhs.gov to schedule a meeting to discuss the adequacy of the corrective actions you proposed to prevent the continued introduction of adulterated and misbranded goods into interstate commerce. Topics of the regulatory meeting will also include supply chain controls and compliance with CGMP.\n\nConclusion\n\nThe deviations and violations cited in this letter are not intended to be an all-inclusive list of deviations and violations that exist at your facility. You are responsible for investigating and determining the causes of any deviations and violations and for preventing their recurrence or the occurrence of other violations and deviations.\n\nIf you are considering an action that is likely to lead to a disruption in the supply of drugs produced at your facility, FDA requests that you contact CDER’s Drug Shortages Staff immediately, at drugshortages@fda.hhs.gov, so that FDA can work with you on the most effective way to bring your operations into compliance with the law. Contacting the Drug Shortages Staff also allows you to meet any obligations you may have to report discontinuances or interruptions in your drug manufacture under 21 U.S.C. 356C(b). This also allows FDA to consider, as soon as possible, what actions, if any, may be needed to avoid shortages and protect the health of patients who depend on your products.\n\nProfessional Compounding Centers of America, Inc., Houston FEI: 1629694 Page 9\n\nFailure to promptly address these deviations and violations may result in legal action without further notice including, without limitation, seizure and injunction. Other Federal agencies may take your compliance history into account when awarding contracts.\n\nFailure to address violations of FD&C Act sections may be cause for FDA to withhold issuance of Export Certificates and may be cause for FDA to withhold approval of new applications or supplements listing your firm as a drug manufacturer. We may re-inspect to verify that you have completed your corrective actions.\n\nThis letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done since our inspection to address any deviations and violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot completely address deviations and violations within 15 working days, state your reasons for delay and your schedule for completion.\n\nPlease identify your response with FEI 1629694 and Case # 597638. Send your electronic reply to Monica R. Maxwell, Program Division Director, FDA\u002FORA\u002FOPQO Division II at ORAPharm2_Responses@fda.hhs.gov.\n\nIf you have any questions concerning the letter, please direct those to CDR Diehl at (214) 253-5288 or john.diehl@fda.hhs.gov.\n\nSincerely,\n\n\u002FS\u002F\n\nAlonza Cruse\n\nDirector\n\nOffice of Pharmaceutical Quality Operations\n\nOffice of Medical Products and Tobacco Operations\n\nOffice of Regulatory Affairs\n\n\u002FS\u002F\n\nFrancis Godwin\n\nDirector\n\nOffice of Manufacturing Quality\n\nOffice of Compliance\n\nCenter for Drug Evaluation and Research\n\n___________________________\n\n1 Products from (b)(4), FEI (b)(4), have also been placed on IA 66-40 because that facility ships products manufactured at FEI (b)(4).\n\n2 Certain drugs were carved out due to shortage concerns.\n\n3 Throughout this letter, where applicable, we have provided the date of the memorandum documenting FDA’s internal determination that a firm’s deviations were adequately addressed prior to the final removal of the firm’s products from import alert.\n\n4 USP Glycerin monograph, Document ID: GUID-6A5A5AD2-0762-4830-8E99-D593E5400FF0_4_en-US\n\n5 See the identity test for glycerin included in the USP Monograph for glycerin, supra note 1","Professional Compounding Centers of America dba PCCA","professional-compounding-centers-america-dba-pcca-597638-01272021","2026-08-18T06:42:29.460824+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fprofessional-compounding-centers-america-dba-pcca-597638-01272021","2026-10-26T08:09:44.708578+00:00","2021-01-27","597638","2023-12-01","Mr. Fabian V. Zaccardo","2026-08-20T03:26:25.345+00:00",{"id":101,"raw":102,"subject":106,"body_html":107,"body_text":108,"firm_name":109,"letter_id":110,"created_at":111,"fei_number":19,"letter_url":112,"updated_at":113,"action_type":22,"case_status":23,"posted_date":114,"marcs_cms_no":115,"product_type":116,"closeout_date":19,"issuing_office":11,"recipient_name":117,"body_fetched_at":118,"delivery_method":119,"recipient_title":19,"reference_number":120,"action_taken_date":121,"medical_device_id":19,"response_letter_date":19},686,[103,104,105,11,106,13,13,13],"\u003Ctime datetime=\"2025-09-02T04:00:00Z\">09\u002F02\u002F2025\u003C\u002Ftime>\n","\u003Ctime datetime=\"2025-08-20T04:00:00Z\">08\u002F20\u002F2025\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fchromatography-institute-america-dba-compounders-international-analytical-laboratory-708944-08202025\">Chromatography Institute of America dba Compounder’s International Analytical Laboratory \u003C\u002Fa>","CGMP\u002FFinished Pharmaceutical\u002FAPI\u002FAdulterated","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Email\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>320-25-101\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Animal &amp; Veterinary\u003Cbr>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Ronald E. Sutton\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>President &amp; Owner\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Chromatography Institute of America dba Compounder’s International Analytical Laboratory \u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>4760 Castleton Way, Suite A\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Castle Rock\u003C\u002Fspan>, \u003Cspan>CO\u003C\u002Fspan> \u003Cspan>80109\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:rsutton@compounderslab.com\"> rsutton@compounderslab.com  \u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n  \u003Cdiv>\n    \u003Cdiv>Secondary Issuing Offices\u003C\u002Fdiv>\n          \u003Cdiv>\n              \u003Cdiv>    \u003Cbr>\n     \n        \u003Cdd>Center for Veterinary Medicine\u003C\u002Fdd>\n    \n     \n        \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n    \n    \n    \n    \n\u003C\u002Fdiv>\n              \u003C\u002Fdiv>\n      \u003C\u002Fdiv>\n\n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>Warning Letter\u003C\u002Fstrong> 320-25-101\u003C\u002Fp>\u003Cp>August 20, 2025\u003C\u002Fp>\u003Cp>Dear Mr. Sutton:\u003C\u002Fp>\u003Cp>The United States Food and Drug Administration (FDA) inspected your contract testing laboratory, Chromatography Institute of America dba Compounder’s International Analytical Laboratory, FEI 3012069146, at 4760 Castleton Way, Suite A, Castle Rock, Colorado, from February 24 to March 5, 2025.\u003C\u002Fp>\u003Cp>This warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) requirements for finished pharmaceuticals and significant deviations from CGMP for active pharmaceutical ingredients (APIs).\u003C\u002Fp>\u003Cp>Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drugs are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\u003Cp>We reviewed your March 21, 2025, response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence.\u003C\u002Fp>\u003Cp>During our inspection, our investigators observed specific violations and deviations including but not limited to the following:\u003C\u002Fp>\u003Cp>\u003Cstrong>1. Lack of adequate laboratory control mechanisms\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your firm conducts chemical and microbiological testing of APIs, drug products compounded by outsourcing facilities registered under section 503B of the FD&amp;C Act, and finished drug products for human and animal use. Records and information collected during the inspection demonstrate that you use the same methods and procedures whether you are testing APIs, drug products compounded by outsourcing facilities registered under section 503B of the FD&amp;C Act, or finished drug products for human and animal use.\u003C\u002Fp>\u003Cp>You lacked adequate controls to ensure the reliability of your microbiological testing results. For example, you documented sterility failures for several samples prepared in a \u003Cstrong>(b)(4)\u003C\u002Fstrong> media lot, but you were unable to show that you performed growth promotion testing on this lot before use. In your investigations into these sterility failures, you noted “false positives” with this lot, but you did not include appropriate negative controls corresponding to this lot in your tests and lacked sufficient evidence to support your “false positives” statement. Moreover, after obtaining a failing sterility test result, you repeated the test on a fraction of the original sample amount, which is not in accordance with USP &lt;71&gt; and is an unacceptable practice.\u003C\u002Fp>\u003Cp>In your response, you state that you rely on your manufacturer’s certificates of analysis to establish media suitability. You indicate that you perform growth promotion testing \u003Cstrong>(b)(4)\u003C\u002Fstrong> and that moving forward, you commit to performing growth promotion testing on \u003Cstrong>(b)(4)\u003C\u002Fstrong> media lot. Additionally, you assert that you will revise your procedures to note that you will perform retesting of a failed sample, provided that sufficient sample quantity remains after initial testing. You also assert that you follow all aspects of USP &lt;71&gt; “as best as is possible.”\u003C\u002Fp>\u003Cp>Your response is inadequate because you did not include a comparability analysis of your sterility test method and USP &lt;71&gt; method, to show that your method is equivalent despite the deviations from USP &lt;71&gt; requirements, such as growth promotion testing, negative controls, and sterility retest sample amounts. You also did not include any documentary evidence to support your assertions about random testing and updated procedures.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>A comprehensive independent assessment of your laboratory practices, procedures, methods, equipment, documentation, and analyst competencies. Based on this review, provide a detailed plan to evaluate and remediate the effectiveness of your laboratory system.\u003C\u002Fli>\u003Cli>A comprehensive assessment and remediation plan for your sterility testing procedure to ensure that it satisfies all requirements specified in USP &lt;71&gt;. Include:\u003Cbr>o Instructions for how you determine which of your method kits (\u003Cstrong>(b)(4)\u003C\u002Fstrong>) purchased from third-party suppliers are suitable for sterility testing of your laboratory samples.\u003Cbr>o A requirement that each media lot used in the preparation of sterility samples on a given day will include an appropriate negative control.\u003Cbr>o Requirements for appropriate sample amounts needed for a sterility retest.\u003C\u002Fli>\u003Cli>A remediation plan for qualification of your suppliers of growth media. Include a commitment to perform growth promotion testing on all incoming media lots used for microbial and sterility testing, to verify their suitability for use.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>2. Lack of adequate investigations\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your investigations into multiple failed sterility test results were inadequate. In 2024, you had nine drug product sterility test failures, for which your investigation concluded that the probable root cause was “technician error – environmental contamination.” However, your root cause was not supported by the environmental monitoring data on the dates when the failing sterility samples were prepared. You did not recover any microorganisms on settle plates from your ISO 7 sterility suite, on ISO 5 “compounding aseptic isolators” where your sterility samples are prepared, or on contact plates used for monitoring of personnel who prepared the sterility samples. You subsequently performed a new analysis on the drug product samples, and you recorded the passing results.\u003C\u002Fp>\u003Cp>In your response, you indicate that you initiated corrective and preventive actions (CAPA), which included the retraining of technicians and their dismissal upon repeated infractions, review of your sterility procedures and cleaning agents, and the frequency of cleaning the sterility suite.\u003C\u002Fp>\u003Cp>Your response is inadequate. You initially identified the potential root cause “technician error – environmental contamination” in 2024, and you continued to note this root cause in several subsequent sterility out-of-specification (OOS) investigations, without identifying and implementing the appropriate CAPA from these investigations to prevent similar future errors.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>A retrospective, independent review of all invalidated OOS (including in-process and release\u002Fstability testing) results for U.S. products for the last three years from the initial date of inspection, and a report summarizing the findings of the analysis, including the following for each OOS:\u003Cbr>o Determine whether the scientific justification and the evidence relating to the invalidated OOS result conclusively or inconclusively demonstrate causative laboratory error.\u003Cbr>o For investigations that conclusively establish laboratory root cause, provide the rationale, and ensure that all other laboratory methods vulnerable to the same or similar root cause are identified for remediation.\u003C\u002Fli>\u003Cli>A comprehensive review and remediation plan for your OOS result investigation systems. The CAPA should include but should not be limited to addressing the following:\u003Cbr>o Quality unit oversight of laboratory investigations\u003Cbr>o Identification of adverse laboratory control trends\u003Cbr>o Resolution of causes of laboratory variation\u003Cbr>o Initiation of thorough investigations of potential manufacturing causes whenever a laboratory cause cannot be conclusively identified\u003Cbr>o Adequate scoping of each investigation and its CAPA\u003Cbr>o Revised OOS investigation procedures with these and other remediations\u003C\u002Fli>\u003Cli>A comprehensive assessment of your overall system for investigating deviations, discrepancies, complaints, OOS results, and failures. Provide a detailed action plan to remediate this system. Your action plan should include but should not be limited to significant improvements in investigation competencies, scope determination, root cause evaluation, CAPA effectiveness, quality unit oversight, and written procedures. Address how your firm will ensure that all phases of investigations are appropriately conducted.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>3. Lack of adequate Quality Unit oversight\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your Quality Unit (QU) failed to exercise adequate oversight over your contract testing operations. For example, your QU failed to ensure:\u003C\u002Fp>\u003Cul>\u003Cli>Establishment of restricted access and appropriate controls on computerized systems to prevent any potential alteration or deletion of laboratory data.\u003C\u002Fli>\u003Cli>Implementation of an effective document control system for issuance, tracking, and reconciliation of CGMP documents used for laboratory testing and analysis.\u003C\u002Fli>\u003Cli>Review and approval of an uncontrolled document, “Sample Prep Tips and Tricks,” used by laboratory staff for preparation of analytical samples.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>In your response you state that moving forward, you will create individual logins on your computers, and you are looking into installing technology with audit trail capability. Further, you state that you will create templates for your forms and bind them into a book. You also commit to placing the unapproved sample preparation document, “Sample Prep Tips and Tricks,” into your controlled document system.\u003C\u002Fp>\u003Cp>Your response is inadequate because it does not include a comprehensive assessment into the vulnerabilities in your computerized systems that may have affected data integrity, nor do you explain how binding the templates into a book will remedy the deficiencies in your documentation control practices. Your response does not indicate whether your sample preparation protocols have been validated, to ensure that sample preparation is consistent and suitable for analysis. Finally, your response lacks details on how your QU will oversee CAPA implementation and evaluate their effectiveness.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>A comprehensive assessment and remediation plan to ensure that your QU is given the authority and resources to function effectively. The assessment should also include but should not be limited to:\u003Cbr>o A determination of whether procedures used by your firm are robust and appropriate.\u003Cbr>o Provisions for QU oversight throughout your operations, to evaluate adherence to appropriate practices.\u003Cbr>o A complete and final review of each batch and its related information before the QU makes a decision concerning its disposition.\u003Cbr>o Oversight and approval of investigations and discharging of all other QU duties to ensure identity, strength, quality, and purity of all products.\u003C\u002Fli>\u003Cli>A comprehensive, independent assessment and CAPA plan for computer system security and integrity. Include a report that identifies design and control vulnerabilities and provides appropriate remediations for each of your laboratory and manufacturing computer systems. This should include but should not be limited to:\u003Cbr>Compounder’s International Analytical Laboratory, Castle Rock 3012069146 page 5\u003Cbr>o A list of all hardware that includes all equipment, both stand-alone and network, in your laboratory.\u003Cbr>o A list of all software configurations (both equipment software and \u003Cstrong>(b)(4)\u003C\u002Fstrong>) and versions, details concerning all user privileges, and oversight responsibilities for your computerized systems. Regarding user privileges, specify user roles and associated user privileges (including the specific permissions allowed for anyone who has administrative rights) for all staff who have access to the laboratory and manufacturing computer systems, with their organizational affiliation and title. Also describe how you will ensure that staff are not given administrative rights or other permissions that may compromise data retention or reliability.\u003Cbr>o System security provisions, including but not limited to whether unique usernames\u002Fpasswords are always used and their confidentiality is safeguarded.\u003Cbr>o Detailed procedures for robust use and review of audit trail data, and the current status of audit trail implementation for each of your systems.\u003Cbr>o Technological improvements to increase the integration of data generated through electronic systems from stand-alone equipment (for example, balances, pH meters, water-content testing equipment) into the \u003Cstrong>(b)(4)\u003C\u002Fstrong> network.\u003Cbr>o A detailed summary of your procedural updates and associated training, including but not limited to system security control to prevent unauthorized access, and to ensure appropriate user role assignments, secondary review of all analyses, and other system controls.\u003C\u002Fli>\u003Cli>A comprehensive evaluation of your document “Sample Prep Tips and Tricks” and how it is used to determine the preparation method for analytical samples. Describe how you verify the suitability of the sample preparation method, and if you document the method in a sample preparation protocol that is reviewed and approved by the QU.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>Ineffective Quality System\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Significant findings in this letter demonstrate that your firm does not operate an effective quality system in accordance with CGMP. In addition to the lack of effective management oversight of your laboratory operations, we found that your quality unit is not enabled to exercise proper authority and\u002For has insufficiently implemented its responsibilities. Executive management should immediately and comprehensively assess your company’s global manufacturing operations to ensure that your systems, processes, and products conform to FDA requirements.\u003C\u002Fp>\u003Cp>See FDA’s guidance for industry \u003Cem>Quality Systems Approach to Pharmaceutical CGMP Regulations\u003C\u002Fem> at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71023\u002Fdownload for help in implementing an adequate Quality Unit (QU) in your laboratory operations to meet the requirements of CGMP.\u003C\u002Fp>\u003Cp>\u003Cstrong>Responsibilities of a Contract Testing Lab\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>FDA considers contractors as extensions of the manufacturer’s own facility. Your failure to comply with CGMP may affect the quality, safety, and efficacy of the drugs you test for your clients. It is essential that you understand your responsibility to operate in full compliance with CGMP, and that you inform all your customers of any OOS results or significant problems encountered during the testing of these drugs.\u003C\u002Fp>\u003Cp>We also have concerns about the validity and integrity of the data you provided to outsourcing facilities registered under section 503B of the FD&amp;C Act.\u003C\u002Fp>\u003Cp>\u003Cstrong>Drug Testing Ceased\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>During the FDA inspection, you communicated your intention to shut down your contract testing laboratory and to cease operations. However, several statements made in your responses to the FDA Form 483 observations conflict with this declaration.\u003C\u002Fp>\u003Cp>In response to this letter, clarify the current operational status of your contract testing laboratory. If you plan to sell your laboratory, provide the name and address of the acquiring party.\u003C\u002Fp>\u003Cp>If you plan to resume contract laboratory testing operations regulated under the FD&amp;C Act, notify this office before resuming your drug testing operations. You are responsible for resolving all deficiencies and systemic flaws to ensure that your firm can comply with ongoing CGMP. In your notification to the Agency, provide a summary of your remediations to demonstrate that you have appropriately completed all CAPA.\u003C\u002Fp>\u003Cp>Note that remediating these CGMP violations will be necessary if Compounder’s International Analytical Laboratory, a successor, or an acquirer resumes drug testing operations at this site.\u003C\u002Fp>\u003Cp>\u003Cstrong>CGMP Consultant Recommended\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>If your firm intends to resume testing drugs for the U.S. market, you should engage a consultant qualified to evaluate your operations to assist your firm in meeting CGMP requirements. Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP.\u003C\u002Fp>\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>The violations and deviations cited in this letter are not intended to be an all-inclusive list of violations and deviations that exist at your facility. You are responsible for investigating and determining the causes of any violations and deviations and for preventing their recurrence or the occurrence of other violations and deviations.\u003C\u002Fp>\u003Cp>Correct any violations and deviations promptly. Failure to address this matter promptly and adequately may result in regulatory or legal action without further notice including, without limitation, seizure and injunction. Unresolved violations and deviations may also prevent other federal agencies from awarding contracts.\u003C\u002Fp>\u003Cp>Failure to address violations may also cause FDA to withhold issuance of Export Certificates. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations and deviations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to address any violations and deviations.\u003C\u002Fp>\u003Cp>This letter notifies you of our findings and provides you with an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and deviations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration while we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\u003C\u002Fp>\u003Cp>Send your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 3012069146 and address it “ATTN: Christopher Keating.”\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Francis Godwin\u003Cbr>Director\u003Cbr>Office of Manufacturing Quality\u003Cbr>Office of Compliance\u003Cbr>Center for Drug Evaluation and Research\u003C\u002Fp>\u003Cp>\u002FS\u002F\u003C\u002Fp>\u003Cp>Johnetta Walters, Ph.D.\u003Cbr>Acting Director\u003Cbr>Division of Drug Compliance\u003Cbr>Office of Surveillance and Compliance\u003Cbr>Center for Veterinary Medicine\u003C\u002Fp>\u003Cp>Cc:&nbsp;\u003C\u002Fp>\u003Cp>Nancy G. Sutton\u003Cbr>Vice President &amp; Owner\u003Cbr>Email: nsutton@compounderslab.com\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Email\n\nReference #:\n\n320-25-101\n\nProduct:\n\nAnimal & Veterinary\nDrugs\n\nRecipient:\n\nRecipient Name\n\nMr. Ronald E. Sutton\n\nRecipient Title\n\nPresident & Owner\n\nChromatography Institute of America dba Compounder’s International Analytical Laboratory\n\n4760 Castleton Way, Suite A\n\nCastle Rock, CO 80109\n\nUnited States\n\nrsutton@compounderslab.com\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nSecondary Issuing Offices\n\nCenter for Veterinary Medicine\n\nUnited States\n\nWarning Letter 320-25-101\nAugust 20, 2025\nDear Mr. Sutton:\nThe United States Food and Drug Administration (FDA) inspected your contract testing laboratory, Chromatography Institute of America dba Compounder’s International Analytical Laboratory, FEI 3012069146, at 4760 Castleton Way, Suite A, Castle Rock, Colorado, from February 24 to March 5, 2025.\nThis warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) requirements for finished pharmaceuticals and significant deviations from CGMP for active pharmaceutical ingredients (APIs).\nBecause your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drugs are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 351(a)(2)(B).\nWe reviewed your March 21, 2025, response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence.\nDuring our inspection, our investigators observed specific violations and deviations including but not limited to the following:\n1. Lack of adequate laboratory control mechanisms\nYour firm conducts chemical and microbiological testing of APIs, drug products compounded by outsourcing facilities registered under section 503B of the FD&C Act, and finished drug products for human and animal use. Records and information collected during the inspection demonstrate that you use the same methods and procedures whether you are testing APIs, drug products compounded by outsourcing facilities registered under section 503B of the FD&C Act, or finished drug products for human and animal use.\nYou lacked adequate controls to ensure the reliability of your microbiological testing results. For example, you documented sterility failures for several samples prepared in a (b)(4) media lot, but you were unable to show that you performed growth promotion testing on this lot before use. In your investigations into these sterility failures, you noted “false positives” with this lot, but you did not include appropriate negative controls corresponding to this lot in your tests and lacked sufficient evidence to support your “false positives” statement. Moreover, after obtaining a failing sterility test result, you repeated the test on a fraction of the original sample amount, which is not in accordance with USP \u003C71> and is an unacceptable practice.\nIn your response, you state that you rely on your manufacturer’s certificates of analysis to establish media suitability. You indicate that you perform growth promotion testing (b)(4) and that moving forward, you commit to performing growth promotion testing on (b)(4) media lot. Additionally, you assert that you will revise your procedures to note that you will perform retesting of a failed sample, provided that sufficient sample quantity remains after initial testing. You also assert that you follow all aspects of USP \u003C71> “as best as is possible.”\nYour response is inadequate because you did not include a comparability analysis of your sterility test method and USP \u003C71> method, to show that your method is equivalent despite the deviations from USP \u003C71> requirements, such as growth promotion testing, negative controls, and sterility retest sample amounts. You also did not include any documentary evidence to support your assertions about random testing and updated procedures.\nIn response to this letter, provide:\nA comprehensive independent assessment of your laboratory practices, procedures, methods, equipment, documentation, and analyst competencies. Based on this review, provide a detailed plan to evaluate and remediate the effectiveness of your laboratory system.\nA comprehensive assessment and remediation plan for your sterility testing procedure to ensure that it satisfies all requirements specified in USP \u003C71>. Include:\no Instructions for how you determine which of your method kits ((b)(4)) purchased from third-party suppliers are suitable for sterility testing of your laboratory samples.\no A requirement that each media lot used in the preparation of sterility samples on a given day will include an appropriate negative control.\no Requirements for appropriate sample amounts needed for a sterility retest.\nA remediation plan for qualification of your suppliers of growth media. Include a commitment to perform growth promotion testing on all incoming media lots used for microbial and sterility testing, to verify their suitability for use.\n2. Lack of adequate investigations\nYour investigations into multiple failed sterility test results were inadequate. In 2024, you had nine drug product sterility test failures, for which your investigation concluded that the probable root cause was “technician error – environmental contamination.” However, your root cause was not supported by the environmental monitoring data on the dates when the failing sterility samples were prepared. You did not recover any microorganisms on settle plates from your ISO 7 sterility suite, on ISO 5 “compounding aseptic isolators” where your sterility samples are prepared, or on contact plates used for monitoring of personnel who prepared the sterility samples. You subsequently performed a new analysis on the drug product samples, and you recorded the passing results.\nIn your response, you indicate that you initiated corrective and preventive actions (CAPA), which included the retraining of technicians and their dismissal upon repeated infractions, review of your sterility procedures and cleaning agents, and the frequency of cleaning the sterility suite.\nYour response is inadequate. You initially identified the potential root cause “technician error – environmental contamination” in 2024, and you continued to note this root cause in several subsequent sterility out-of-specification (OOS) investigations, without identifying and implementing the appropriate CAPA from these investigations to prevent similar future errors.\nIn response to this letter, provide:\nA retrospective, independent review of all invalidated OOS (including in-process and release\u002Fstability testing) results for U.S. products for the last three years from the initial date of inspection, and a report summarizing the findings of the analysis, including the following for each OOS:\no Determine whether the scientific justification and the evidence relating to the invalidated OOS result conclusively or inconclusively demonstrate causative laboratory error.\no For investigations that conclusively establish laboratory root cause, provide the rationale, and ensure that all other laboratory methods vulnerable to the same or similar root cause are identified for remediation.\nA comprehensive review and remediation plan for your OOS result investigation systems. The CAPA should include but should not be limited to addressing the following:\no Quality unit oversight of laboratory investigations\no Identification of adverse laboratory control trends\no Resolution of causes of laboratory variation\no Initiation of thorough investigations of potential manufacturing causes whenever a laboratory cause cannot be conclusively identified\no Adequate scoping of each investigation and its CAPA\no Revised OOS investigation procedures with these and other remediations\nA comprehensive assessment of your overall system for investigating deviations, discrepancies, complaints, OOS results, and failures. Provide a detailed action plan to remediate this system. Your action plan should include but should not be limited to significant improvements in investigation competencies, scope determination, root cause evaluation, CAPA effectiveness, quality unit oversight, and written procedures. Address how your firm will ensure that all phases of investigations are appropriately conducted.\n3. Lack of adequate Quality Unit oversight\nYour Quality Unit (QU) failed to exercise adequate oversight over your contract testing operations. For example, your QU failed to ensure:\nEstablishment of restricted access and appropriate controls on computerized systems to prevent any potential alteration or deletion of laboratory data.\nImplementation of an effective document control system for issuance, tracking, and reconciliation of CGMP documents used for laboratory testing and analysis.\nReview and approval of an uncontrolled document, “Sample Prep Tips and Tricks,” used by laboratory staff for preparation of analytical samples.\nIn your response you state that moving forward, you will create individual logins on your computers, and you are looking into installing technology with audit trail capability. Further, you state that you will create templates for your forms and bind them into a book. You also commit to placing the unapproved sample preparation document, “Sample Prep Tips and Tricks,” into your controlled document system.\nYour response is inadequate because it does not include a comprehensive assessment into the vulnerabilities in your computerized systems that may have affected data integrity, nor do you explain how binding the templates into a book will remedy the deficiencies in your documentation control practices. Your response does not indicate whether your sample preparation protocols have been validated, to ensure that sample preparation is consistent and suitable for analysis. Finally, your response lacks details on how your QU will oversee CAPA implementation and evaluate their effectiveness.\nIn response to this letter, provide:\nA comprehensive assessment and remediation plan to ensure that your QU is given the authority and resources to function effectively. The assessment should also include but should not be limited to:\no A determination of whether procedures used by your firm are robust and appropriate.\no Provisions for QU oversight throughout your operations, to evaluate adherence to appropriate practices.\no A complete and final review of each batch and its related information before the QU makes a decision concerning its disposition.\no Oversight and approval of investigations and discharging of all other QU duties to ensure identity, strength, quality, and purity of all products.\nA comprehensive, independent assessment and CAPA plan for computer system security and integrity. Include a report that identifies design and control vulnerabilities and provides appropriate remediations for each of your laboratory and manufacturing computer systems. This should include but should not be limited to:\nCompounder’s International Analytical Laboratory, Castle Rock 3012069146 page 5\no A list of all hardware that includes all equipment, both stand-alone and network, in your laboratory.\no A list of all software configurations (both equipment software and (b)(4)) and versions, details concerning all user privileges, and oversight responsibilities for your computerized systems. Regarding user privileges, specify user roles and associated user privileges (including the specific permissions allowed for anyone who has administrative rights) for all staff who have access to the laboratory and manufacturing computer systems, with their organizational affiliation and title. Also describe how you will ensure that staff are not given administrative rights or other permissions that may compromise data retention or reliability.\no System security provisions, including but not limited to whether unique usernames\u002Fpasswords are always used and their confidentiality is safeguarded.\no Detailed procedures for robust use and review of audit trail data, and the current status of audit trail implementation for each of your systems.\no Technological improvements to increase the integration of data generated through electronic systems from stand-alone equipment (for example, balances, pH meters, water-content testing equipment) into the (b)(4) network.\no A detailed summary of your procedural updates and associated training, including but not limited to system security control to prevent unauthorized access, and to ensure appropriate user role assignments, secondary review of all analyses, and other system controls.\nA comprehensive evaluation of your document “Sample Prep Tips and Tricks” and how it is used to determine the preparation method for analytical samples. Describe how you verify the suitability of the sample preparation method, and if you document the method in a sample preparation protocol that is reviewed and approved by the QU.\nIneffective Quality System\nSignificant findings in this letter demonstrate that your firm does not operate an effective quality system in accordance with CGMP. In addition to the lack of effective management oversight of your laboratory operations, we found that your quality unit is not enabled to exercise proper authority and\u002For has insufficiently implemented its responsibilities. Executive management should immediately and comprehensively assess your company’s global manufacturing operations to ensure that your systems, processes, and products conform to FDA requirements.\nSee FDA’s guidance for industry Quality Systems Approach to Pharmaceutical CGMP Regulations at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71023\u002Fdownload for help in implementing an adequate Quality Unit (QU) in your laboratory operations to meet the requirements of CGMP.\nResponsibilities of a Contract Testing Lab\nFDA considers contractors as extensions of the manufacturer’s own facility. Your failure to comply with CGMP may affect the quality, safety, and efficacy of the drugs you test for your clients. It is essential that you understand your responsibility to operate in full compliance with CGMP, and that you inform all your customers of any OOS results or significant problems encountered during the testing of these drugs.\nWe also have concerns about the validity and integrity of the data you provided to outsourcing facilities registered under section 503B of the FD&C Act.\nDrug Testing Ceased\nDuring the FDA inspection, you communicated your intention to shut down your contract testing laboratory and to cease operations. However, several statements made in your responses to the FDA Form 483 observations conflict with this declaration.\nIn response to this letter, clarify the current operational status of your contract testing laboratory. If you plan to sell your laboratory, provide the name and address of the acquiring party.\nIf you plan to resume contract laboratory testing operations regulated under the FD&C Act, notify this office before resuming your drug testing operations. You are responsible for resolving all deficiencies and systemic flaws to ensure that your firm can comply with ongoing CGMP. In your notification to the Agency, provide a summary of your remediations to demonstrate that you have appropriately completed all CAPA.\nNote that remediating these CGMP violations will be necessary if Compounder’s International Analytical Laboratory, a successor, or an acquirer resumes drug testing operations at this site.\nCGMP Consultant Recommended\nIf your firm intends to resume testing drugs for the U.S. market, you should engage a consultant qualified to evaluate your operations to assist your firm in meeting CGMP requirements. Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP.\nConclusion\nThe violations and deviations cited in this letter are not intended to be an all-inclusive list of violations and deviations that exist at your facility. You are responsible for investigating and determining the causes of any violations and deviations and for preventing their recurrence or the occurrence of other violations and deviations.\nCorrect any violations and deviations promptly. Failure to address this matter promptly and adequately may result in regulatory or legal action without further notice including, without limitation, seizure and injunction. Unresolved violations and deviations may also prevent other federal agencies from awarding contracts.\nFailure to address violations may also cause FDA to withhold issuance of Export Certificates. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations and deviations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to address any violations and deviations.\nThis letter notifies you of our findings and provides you with an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and deviations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration while we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\nSend your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 3012069146 and address it “ATTN: Christopher Keating.”\nSincerely,\n\u002FS\u002F\nFrancis Godwin\nDirector\nOffice of Manufacturing Quality\nOffice of Compliance\nCenter for Drug Evaluation and Research\n\u002FS\u002F\nJohnetta Walters, Ph.D.\nActing Director\nDivision of Drug Compliance\nOffice of Surveillance and Compliance\nCenter for Veterinary Medicine\nCc:\nNancy G. Sutton\nVice President & Owner\nEmail: nsutton@compounderslab.com","Chromatography Institute of America dba Compounder’s International Analytical Laboratory","chromatography-institute-america-dba-compounders-international-analytical-laboratory-708944-08202025","2026-08-18T06:42:28.676509+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fchromatography-institute-america-dba-compounders-international-analytical-laboratory-708944-08202025","2026-10-26T08:08:15.132992+00:00","2025-09-02","708944","Animal & VeterinaryDrugs","Mr. Ronald E. Sutton","2026-08-19T16:26:38.524+00:00","Via Email","320-25-101","2025-08-20",5,{"510k":124,"classification":125,"enforcement":126,"event":127,"event_backfill":128,"pma":129,"warning_letter":130},"2026-11-16T02:00:55.89+00:00","2026-11-16T02:00:41.999+00:00","2026-11-16T02:00:49.415+00:00","2026-11-17T04:00:34.414+00:00","2026-09-07T05:17:28.839+00:00","2026-11-16T02:01:03.155+00:00","2026-11-17T01:02:55.859+00:00"]